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 The research herein outlines the development of flavonol-based 
compounds that when triggered, release carbon monoxide using visible light. Use 
of 1) microenvironment effects; 2) modifications to the core structure of 3-
hydroxyflavone; and 3), zinc stabilization of the anionic form of flavonols, enabled 
the development of a family of novel compounds that exhibit a wide array of CO 
release reactivity 
An initial study of zinc 3-hydroxyflavone compounds provided evidence 
that modulation of the microenvironment surrounding the 3-hydroxyflavonolato 
moiety influences the quantum yield for light-induced CO release. A hydrophobic 
microenvironment gives the highest quantum yield for CO release whereas a 
hydrophilic microenvironment slows light-induced CO release. These properties 
mimic those found for light-induced CO-release from free flavonols in organic 




 A new family of extended flavonols containing an additional fused 
aromatic ring were prepared, characterized and evaluated for CO release 
reactivity. Members of this family of compounds were tuned to absorb light from 
400-600 nm using substituent and heavy atom effects.  Notable attributes of this 
family of compounds include: 1) ease and high yield of synthesis; 2) solubility in 
aqueous dimethyl sulfoxide (DMSO); 3) thermal stability in aqueous, aerobic 
media in the absence of light; 4) quantitative CO release reactivity upon 
exposure to visible light in air; 5) low toxicity, including for the CO release 
product; and 5) fluorescence prior to CO release, which enables tracking of the 
compounds within cells. Anaerobic CO release reactivity was also discovered for 
the derivative that absorbs lowest energy visible light.  Overall, this family of 
compound has many properties that make them desirable for use in biological 
applications. 
Stabilization of the monoanionic form of the extended flavonols via zinc 
coordination results in compounds that exhibit red-shifted absorption spectra, 
enhanced quantum yields for quantitative CO release, and most notably, solid 
state CO release reactivity. Notably, zinc complexes containing two deprotonated 
extended flavonols exhibit visible-light induced release of two equivalents of CO 
in the presence of air as either solutions in pyridine or as solids. A compound of 
this type can be used as an in-situ solid-state source for CO in a palladium-





Carbon Monoxide on Demand: Light-Induced CO Release of Flavonols 
Stacey N. Anderson
Carbon monoxide (CO) is an extremely useful molecule with applications 
in industrial manufacturing, synthetic procedures as a C1 building block, and as a 
potential pharmaceutical to produce anti-inflammatory effects and vasodilation. 
However, the toxicity associated with CO has prevented its full utilization. In 
order to safely handle CO, compounds and molecules have been developed that 
act as storage materials for the gas. Ideal storage platforms only release CO 
upon stimulation via a trigger. Light activation is the most desirable trigger as it 
can be regulated in terms of the intensity and the wavelength of light used. The 
majority of light-induced CO-storage platforms that have been reported to date 
consist of metal carbonyl compounds where CO is bound directly to a metal 
center. However, disadvantages inherent to this motif, such as potential toxicity 
associated with the metal and lack of characterization of CO release remnant(s), 
has pushed the research community to search for alternative CO storage 
structures. 
The research presented in this dissertation outlines our approach toward 
the development of safe-to-handle, light-induced CO release platforms. We use a 
flavonol structure similar to those found in fruits and vegetables, such as 
quercetin, as a light-induced CO release unit. Through changes in the structure 
of the flavonol and its surrounding environment in chemical compounds, we have 
found ways to strategically control the light-induced CO release reactivity of the 
flavonol.  Chemical compounds developed in this project are of interest for 
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Carbon Monoxide – Overview 
Carbon monoxide (CO) (Figure 1-1) is a colorless, odorless, diatomic gas 
with a molecular weight of 28.0 g/mol, making it slightly lighter than the average 
molecular weight of air (28.8 g/mol). The boiling point of CO is 82 K and the 
melting point is 68 K. The bond dissociation energy of this diatomic molecule is 




The History of Carbon Monoxide 
The toxic properties of carbon monoxide have been known for centuries. 
Aristotle (384-322 BC) was the first to record that burning coals produced a toxic 
gas. It wasn’t until 1800 that the Scottish chemist William Cumberland 
Cruikshank, collecting gases produced by burning charcoal over red-hot metal 
oxides, identified an inflammable gas containing carbon and oxygen, CO.2 
Exploitation of the poisonous effect of this gas has occurred from antiquity, when 
convicts were enclosed in rooms with burning coals to modern times where it 
 
 





was used in large scale at Nazi extermination camps.3 While CO is no longer 
utilized as a means of execution, CO poisoning is the most common type of fatal 
poisoning in many countries.4 From 1999-2010, there were 5,149 fatalities in the 
United States resulting from unintentional CO inhalation.5 The commonality in 
everyday life of processes that produce CO, such as the incomplete combustion 
of fossil fuels used to heat homes and power automobiles, has caused CO 
poisoning to remain relevant.  
It is the chemical properties of CO that make it a potent poison. It is 
colorless, odorless, and tasteless, earning it the moniker of “silent killer.” 
However, its toxicity truly arises from the ability of this gas to irreversibly bind to 
metal centers. CO binds to metal centers through σ donation from the highest 
occupied molecular orbital (HOMO) on CO (σ*) to an empty d orbital of a metal 
and through π back-bonding from a filled d orbital on a metal to the lowest 
occupied molecular orbital (LUMO) on CO (π*) (Figure 1-2). For example, this 
strong binding of CO to a metal center results in a 230-times stronger affinity for 
CO than molecular oxygen (O2) in hemoglobin, the iron-containing metalloprotein 
responsible for oxygen-transport.7-9 Since 1921, it has been thought that the 
irreversibility of the binding between CO and the iron-center in hemoglobin, which 
disrupts O2 delivery to tissues, causes the toxicity of CO. While the binding of CO 
to hemoglobin has long been touted as the root of its harmfulness, a subsequent 
study reported in 1976 has cast some doubt onto this theory. In this study, dogs 
were administered similar concentrations of carbon monoxide through inhalation 






Unfortunately, all of the dogs from the inhalation trials died, while none of the 
dogs with carboxyhemoglobin saturated blood passed away.6 These results 
indicate that the harmfulness of CO is not entrenched in its ability to bind 
hemoglobin.  
 
Figure 1-2.  (top) Bonding scheme of carbon monoxide to a metal center; 







Beneficial Biology of Carbon Monoxide 
 Compared to the long known history of carbon monoxide as a lethal gas, 
its beneficial effects were only recently discovered in the 20th century. Seminal 
work by Swedish physician Torgny Sjöstrand demonstrated that not only is CO 
endogenously produced in humans, but that the oxidative decomposition of heme 
was the source.7 Additional work by Coburn and associates demonstrated that 
the concentration of CO exhaled was greater than the concentration inhaled, 
particularly under physiologically stressful conditions.8 These initial findings 
indicated that CO might serve in a beneficial capacity. 
 
Heme Oxygenase 
 The oxidation catalyzed by the enzyme heme oxygenase (HO) is the rate-
limiting step in the degradation of heme in mammals.9 HO catalyzes the oxidation 
of the ɑ-meso carbon of the protoporphyrin ring leading to the formation of 
carbon monoxide, free iron in the +2 oxidation state, and biliverdin, which is 
rapidly converted to bilirubin by biliverdin reductase (Figure 1-3).9-10 Originally 
characterized in 1969, this enzyme has two isoforms.11 The isoform constitutively 
expressed in tissues, heme oxygenase-2 (HO-2; ~36 kDa, enzyme classification 
(EC) 1.14.99.39) functions mainly to regulate necessary levels of free heme.12 
The other isoform, heme oxygenase-1 (HO-1; ~32 kDa, EC 1.14.99.3), is 
inducible and its regulation and expression is modulated in response to oxidative 





Figure 1-3. Proposed mechanism of COrelease from heme via heme 






expressed in a variety of diverse disease states such as cardiovascular, 
neurodegenerative, and immune diseases.12-13 The over-expression of HO-1 in a 
number of disease states led to the hypothesis that instead of heme being merely 
catabolized, that there exists a dynamic equilibrium between destructive and 
constructive metabolism of heme.14 In destructive metabolism, the end products 
of heme degradation are simply eliminated from the organism, whereas in 
constructive metabolism, CO and bilirubin are purposely produced to modulate 
vital biological activities.14 This hypothesis is supported by multiple reports of 
bilirubin acting as an antioxidant and antinitrosative agent and the ever 
increasing body of literature demonstrating the efficacy of CO in the treatment of 
numerous disease states in animal models (Table 1.1).15  
 
Cellular Targets of Carbon Monoxide 
 Carbon monoxide, as a small, gaseous molecule, is freely diffusible 
across membranes and does not require transporters.25 Therefore, CO can 
rapidly facilitate transformations in the cell. Due to the ease with which CO can 
move across membranes, multiple targets both on or near the cellular surface 
and within cells have been proposed. The targets proximal to the cellular surface 
include heme-containing potassium channels, caveolar nitric oxide synthase 
(NOS; the endothelial isoform of NO synthase), surface NADPH oxidase, and 
soluble guanylyl cyclase (sGC).26 Distal cellular targets are thought to include 
heme-containing transcription factors such as BACH1 and NPAS2 and 




Table 1-1. Preclinical efficacy of inhaled carbon monoxide. Reprinted by 
permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery (Ref 
16), copyright 2010. 
Models of disease CO gas effect 
Bacterial infection in 
mice 
250 ppm improves survival and prevents multiple-
organ failure when administered after gram-positive or 
gram-negative bacterial infection.16 
Sepsis and 
endotoxemia in mice, 
rats, and pigs 
50-250 ppm has anti-inflammatory effects; 250 ppm 
improved lung derangement by endotoxin; 10-250 
ppm as a pretreatment or as a post-treatment 
improves survival, and lung and liver injury in 
response to lipopolysaccharides.17 
Pulmonary hypertension 
in rats and mice 
250 ppm for 1 hour per day beginning at peak 
hypertension reverses right heart size and pulmonary 
arterial pressure; 50 ppm for 21 days prevents 
pulmonary hypertension.18 
Cardiac graft rejection in 
mice and rats; mouse to 
rat xenografts 
20 ppm prolongs survival; 250-400 ppm for 5-6 days 
prevents rejection.19 
Myocardial infarction in 
mice; cardiac ischemia-
reperfusion injury in rats 
250-1,000 ppm after injury prevents infarct mass 
induced by left anterior descending artery ligation.20 
Hemorrhagic shock in 
mice 
250 ppm after resuscitation prevents organ failure.21 
Model of acute 
inflammation in mice; 
acute lung injury 
250 ppm prevents hypoxia-induced lung inflammation 
and injury.22 
Aortic allograft rejection 
in mice and rats 
250-400 ppm prevents transplant vascular stenosis.23 
Lung allograft rejection 
in mice and rats 
250 ppm prevents chronic rejection, ischemia 




metals and while it has been postulated that CO binds to many targets, direct 
evidence of CO interaction with cellular components that do not contain transition 
metals is lacking.17a, 28 It has been demonstrated that the binding of CO to heme 
in proteins alters their conformation and thereby controls activity. In the case of 
sGC and NOS, the interaction of CO with the heme moiety leads to an increased 
production of cyclic guanosine monophosphate (cGMP) and nitric oxide (NO), 
respectively. cGMP and NO are both potent regulators of vascular tone and 
neurotransmission.26 CO can also have an inhibitory effect such as with NADPH 
oxidase where it interferes with the production of superoxide and in cytochrome c 
oxidase in mitochondria, where it is thought to interfere with electron transport 
and oxidative phosphorylation thus increasing the production of reactive oxygen 
species (ROS).29 While there is a significant amount of evidence implicating 
potential cellular targets of carbon monoxide, a clear understanding of the 
molecular mechanisms by which CO imparts its biological effects is lacking. 
Compounds capable of releasing discrete quantities of CO in a directed manner 
have the potential to expand the current working knowledge of this potentially 
therapeutic molecule. 
 
Carbon Monoxide-Releasing Molecules (CORMS) 
The numerous health benefits observed for administration of low doses of 
carbon monoxide, coupled with the dangers of exposure to large amounts of 
carbon monoxide, led researchers to develop safe-to-handle storage platforms 




with CO as ligands) have been utilized in synthetic organic chemistry as CO 
sources, such as in palladium-catalyzed carbonylation reactions.30 For this 
reason and the commercial availability of metal carbonyls, the first reported 
CORMs belong to this class of compounds. CORM-1 (Mn2(CO)10) (Figure 1-4 
(left)) and CORM-2 ([Ru(CO)3Cl]2) (Figure 1-4 (middle)) were the first reported 
metal carbonyl compounds that exhibited biological effects similar to gaseous 
CO.31 Both of these highly lipophilic compounds exhibit CO release upon 
dissolution in dimethylsulfoxide (DMSO) albeit through different mechanisms. 
CORM-1 was observed to liberate CO only upon illumination while CO was 
displaced from CORM-2 through ligand exchange with DMSO and the formation 
of tricarbonyl and dicarbonyl monomers. Due to the poor solubility of CORM-1 
and CORM-2 in aqueous media, for initial biological studies a cell line was 
chosen that displayed resistance to toxic insult, bovine vascular smooth muscle 
cells (2% DMSO had no effect on cell viability).32 While the originally reported 
IC50 values for CORM-1 and CORM-2 were > 100 μM and > 400 μM respectively, 
in subsequent studies, CORM-2 induced cell death at concentrations as low as 
10 nM in HL-1 heart cells.33 The CO released from CORM-1 and CORM-2 
produced a vasodilatory effect (CORM-2; using isolated aortic ring model; 
CORM-1; using isolated rat heart) and the ability to modulate mean arterial 
carbonyl compound could deliver CO in vivo and evoke biological responses 
spurred the further development of metal carbonyl CORMs by derivatization of 





Compounds need to be able to move across lipid bilayers of cell 
membranes before entering the blood stream and distributing throughout the 
body. Lipophilic compounds, such as CORM-2, are generally able to diffuse 
across cell membranes whereas hydrophilic compounds are usually unable to 
penetrate the lipid bilayer.34 A method used to overcome the potential toxicity 
associated with lipophilic CORM-2, was to increase the hydrophilicity of the 
compound through the introduction of a supporting ligand. A little more than a 
year after the initial report of CORM-2 was published, the same authors 
described a tricarbonylchloro(glycinato)ruthenium(II) compound, CORM-3 (Figure 
1-4 (right)).35 The use of deprotonated glycine as a supporting ligand imparted 










the cell viability of porcine aortic endothelial cells or primate peripheral blood 
mononuclear cells in vitro at concentrations up to 500 μM.36 CORM-3 releases 
approximately one equivalent of carbon monoxide per equivalent of compound. 
In vitro and in vivo experiments using CORM-3 have revealed a host of beneficial 
health effects, such as the protection of cardiac cells against oxidative stress, 
cardioprotective effects against myocardial ischemia-reperfusion injury, and the 
prevention of allograft rejection.35, 37 These findings propelled CORM-3 into use 
to probe the biological effects of CO.38 The excellent biological properties 
coupled with the low toxicity of CORM-3 indicated that this compound had 
potential to enter clinical trials; however, complicated aqueous chemistry in both 
the synthesis and its CO release mechanism limited its potential (Figure 1-5(a)). 
While the synthesis of CORM-3 is straight forward, with [Ru(CO)3Cl2]2 (CORM-2) 
and glycine combined with sodium ethoxide in methanol under nitrogen, the 
purification is problematic.39 The IR spectrum of each preparation of CORM-3 
displayed stretches at 2137, 2072, and 2058 cm-1, consistent for a fac-Ru(CO)3 
group lacking C3 symmetry.39 However, another IR stretch at 1985 cm-1 was 
observed consistent with a cis- Ru(CO)2 impurity.39 It was initially assumed that 
this impurity was a result of CO loss, until it was realized that 
[Ru(CO)3Cl(glycinato)] was reacting with water in the solvent to form 
[Ru(CO)2(CO2H)Cl(glycinato)]-.39 This was additionally confirmed through the 
observation that CORM-3, upon dissolution in neutral water, lowered the pH to 
approximately 3.40 The original report of CORM-3 indicated that despite the 




equivalent of compound.35 Subsequent studies demonstrated that in addition to 
the formation of CO, CORM-3 also released carbon dioxide (CO2), indicating the 
presence of other isomer(s) at physiological pH (Figure 1-5(a)).40 It was 
subsequently determined that in the pH range of 6-10 one of the carbonyl ligands 







Figure 1-5. Aqueous reactivity of CORM-3: (a) The most probable species 
formed at equilibrium at different pHs involving CORM-3, and (b) Water-gas 
shift reaction of CORM-3 in solution to rapidly release CO2, creating an open 
site at the ruthenium center which enables coordination to histidine residues. 
Adapted with permission from Mann, B. E. Organometallics 2012, 31, 5728-




The formation of a metal coordinated CO2 and subsequent loss had an 
unintended side-effect for the biological reactivity of this compound. As CO2 has 
a much lower affinity towards metal centers as compared to CO, this ligand was 
readily lost leaving an open coordination site that was readily filled by binding 
with protein residues. In biological environments, the protein bound ruthenium 
carbonyl is the actual CO-releasing molecule.38e While CORM-3 remains the 
compound of choice for elucidating the biological effects of CO, the complicated 
aqueous chemistry has hindered further development as a pharmaceutical. 
Ruthenium complexes, in addition to being utilized as CORMs, have been 
widely explored as anticancer agents.41 Due to potential of biological activity of 
the metal remnants left after CO release occurs from CORM-2 and CORM-3, 
various other metal centers have been explored. The majority of CORMs 
reported thus far contain iron or manganese, with a few featuring chromium, 
rhenium, iridium, tungsten, cobalt, molybdenum, or rhodium.42 However, none of 
these compounds have achieved the same level of widespread application as 
CORM-2 or CORM-3. These subsequent CORMs all display disadvantages that 
have hampered continued development. Metal carbonyl CORMs have two 
potential environments that can be tuned for the effective development of a 
pharmaceutical candidate; the “CORM sphere,” defined by the number of 
carbonyl ligands and the “drug sphere,” defined by the supporting ligands which 
can modulate the pharmacological profiles of the compounds (Figure 1-6).43 Key 
parameters of the “CORM sphere” are the number of CO molecules that can be 






that leads to CO release. It is important to note that there is no current 
consensus in the scientific community as to whether a large or small number of 
carbonyl ligands is desirable and whether the CO release rate should be slow or 
fast. Rather, it is likely that there is no single answer to these questions and 
instead a variety of CORMs should be developed to address specific 
pharmacological applications. However, the majority of CORMs reported have 
focused almost exclusively on the development of the “CORM sphere” with the 
“drug sphere” largely neglected. The development of the “drug sphere” is vital to 
the progression of CORMs beyond simply compounds capable of studying the 
biological effects of CO to the end goal of real pharmaceuticals. The lack of 
 
 
Figure 1-6. The ligand environment surrounding the metal center in a metal-
carbonyl CORM is divided into the “drug sphere” and the “CORM sphere”. The 
“drug sphere” is defined by the supporting ligands which can be modulated for 
pharmacokinetics. The “CORM sphere” is defined by the stoichiometry and 
kinetics of CO release from the metal center. Adapted by permission from 






progress on the “drug sphere” of CORMs is likely due to other undesirable 
characteristics present in metal carbonyl CORMs. These complexes release CO 
through ligand exchange (Figure 1-7). Most have been tested for CO release in 




what is known as the myoglobin assay. This assay relies on the different 
absorption features of deoxymyoglobin and dicarboxymyoglobin and the reported 
 
Figure 1-7. Metal carbonyl carbon monoxide-releasing molecules (CORMs). 
(a) CO release from metal carbonyl CORMs through ligand exchange, where 
L’ is either solvent or a biologically relevant coordinating species such as a 
histidine residue, and (b) selected examples of metal carbonyl CORMs that 





CO release from CORMs using this method was reproducible. However, using 
alternative methods to test for CO release, such as gas chromatography or CO-
specific electrodes, it has been determined that CORMs release very little CO in 
solution and it was the presence of an additional component in the myoglobin 
assay solution, sodium dithionite, that induced CO release.44 The small amount 
of CO release detected for CORMs using gas chromatography or CO-specific 
electrodes is thought to be due to the reversibility of the ligand exchange reaction 
liberating CO from the metal center.45 The reversibility of the CO release reaction 
is an undesirable characteristic of metal carbonyl compounds and has hindered 
their further development as CORMs.  
While CO release from CORMs in solution via ligand exchange is slow it is 
not controllable in terms of location and timing. The spontaneity of the CO 
release calls into question the numerous reports of the biological activity of CO 
derived from CORMs as the response could have been due to the presence of 
CO, the CORM, the metal-containing fragment remaining after CO release, or a 
combination of all of these things. Additionally, for the majority of CORMs 
reported no information regarding the product(s) remaining after CO release is 
available. The majority of CORMs contain redox active metal centers. Once CO 
has been fully liberated, an open coordination site at the metal center is formed. 
These remnants have the potential to be extremely toxic via the formation of 
reactive radical species from components common to biological environments, 
such as O2. However, as the metal-containing compound(s) formed post CO 




reactions can only be estimated at this point. The numerous disadvantages 
associated with metal carbonyl CORMs have hindered their development as 
pharmaceutical pro-drugs.  
 
Triggered Carbon Monoxide-Releasing Molecules 
 Since CORMs serve as a storage platform for the biologically active agent 
CO, the trigger mechanism is a fundamental aspect of the compounds. As noted 
above, CORMs, such as CORM-3, liberate CO through ligand exchange, which 
imparts the disadvantage of the lack of temporal control and site-specific delivery 
of CO. In order to side-step this problem, CORMs have been developed that are 
stable in solution and only release CO upon stimulation via either an internal 
(enzyme triggered; ET-CORMs) or external source (magnetic heating or 
photoexcitation; photoCORM). The CORMs reported to date that are able to 
release CO when supplied with certain triggers are still almost exclusively metal 
carbonyl compounds.  
 
Enzyme Triggered Carbon Monoxide-Releasing Molecules (ET-CORMs) 
ET-CORMs (Figure 1-8) were developed as a means of slowing down the 
rate of CO release from metal carbonyl CORMs.46 The ET-CORMs developed to 
date utilize supporting ligands susceptible to enzymatic degradation and an 
Fe(CO)3 “CORM sphere”.46-47 Prior to incubation in the presence of appropriate 







The enzymes transform the compounds into highly unstable intermediates that 
readily decompose and release CO.48 While it is known that these compounds 
release CO, the other products of the reaction are less well defined. The 
proposed reaction mechanism involves release of the transformed supporting 
ligand as well as Fe3+.46 The potential release of Fe3+ is problematic for the 
development of these compounds into pharmaceuticals in that while iron is 
essential to life, the storage and regulation is tightly controlled due to its redox 
capabilities. Additionally, the classes of enzymes used for these transformations 
tend to be ubiquitous and therefore targeting to specific biological sites is 
currently unavailable.  
 
Figure 1-8. Enzyme triggered CO-releasing molecules (ET-CORMs). (A) The 
ET-CORMs reported to date, and (B) Proposed CO release mechanism from 
ET-CORMs. Adapted by permission from John Wiley and Sons: British Journal 





Magnetic Heat Triggered Carbon Monoxide-Releasing Molecules 
An alternative and interesting approach to triggering CO release from 
CORMs is the use of magnetic heating. Ruthenium carbonyl compounds were 




compounds seem promising in that magnetic nanoparticles would allow the 
compounds to be directed to specific physiological locations by magnetic control. 
CO release from the CORM-appended nanoparticle increased two-fold upon 
magnetic heating.49 Unfortunately, due to the type of CORM used in this report 
(CORM-3 derivative), magnetic heating of the nanoparticle was not necessary for 





Figure 1-9. Magnetic heat triggered carbon monoxide-releasing molecule. CO 
release from ruthenium carbonyl moieties appended to iron oxide 
nanoparticles. CO release is triggered using an alternating current magnetic 









Photoinduced Carbon Monoxide-Releasing Molecules (photoCORMs) 
The most popular type of trigger used to initiate CO release from CORMs 
is light. The use of light as a trigger is popular because it would allow for site 
directed CO release. While the photoCORM itself would be systemic, CO release 
has the potential to be confined simply by limiting illumination to certain areas of 
the body. The earliest CORMs tested, Fe(CO)5 and Mn2(CO)10, fall into this 
category, now known as photoCORMs, with CO release occurring only upon 
illumination. Due to the strength of the CO-metal bonding interaction, these 
photoCORMs required UV-light to initiate CO liberation. The requirement of UV-
light is problematic not only due to the harmful nature of UV-light on living 
organisms, but also due to its inability to penetrate tissues. The penetration depth 
of light is wavelength dependent with visible light having greater penetration 
depth as well as being less harmful than UV-light. However, compounds capable 
of undergoing photoinduced CO release upon illumination with red light would be 
the most desirable as wavelengths in the range of 620 - 910 nm have the 
greatest penetration depth due to the lack of biologically relevant species 
absorbing in this window (Figure 1-10). Utilizing supporting ligands with specific 
properties, metal carbonyl photoCORMs have been developed that are capable 
of undergoing photoinduced CO release at wavelengths ≥ 520 nm.51 The design 
strategy for the supporting ligands in these compounds employs a combination of  
a strong σ-donating ligand like Br-, to destabilize occupied orbitals, and a highly 
conjugated ligand with low-lying π* molecular orbitals to further destabilize the 






these compounds release CO upon illumination with low energy light, as a 
consequence of destabilizing the metal carbonyl bonds enough to allow for the 
use of red light, they are not entirely stable in solution and will also release CO 




Figure 1-10. The absorption spectrum of a human hand. The best 
transmission through a hand is between approximately 670 nm and 910 
nm and from approximately 1050 nm and higher.50 Optical density is 
abbreviated O.D. unpublished data of Karl H. Norris, from The Science of 










Upconverting Nanoparticles (UCNP) 
 A different method to obtaining compounds capable of using low energy 
red light for CO release is the use of an upconverting nanoparticle (UCNP) 
together with a photoCORM that requires high-energy visible light (i.e. blue-light). 
UCNPs are NaGdF4 nanoparticles doped with ytterbium (20%) as the red-light 




Figure 1-11. Photoinduced carbon monoxide-releasing molecules 
(photoCORMs). (a) CO release from metal carbonyl photoCORMs via 
illumination where L’ is proposed to be solvent, and (b) selected examples of 







generate high-energy visible light when multiple Yb3+ ions absorb low energy red 
light or near infrared light and transfer energy to Tm3+ thereby populating excited 
states that emit higher energy light. The high energy emitted light can then be 
absorbed by a photoCORM tethered to the nanoparticle and undergo CO 
liberation. UNCPs offer an exciting alternative to achieve CO release from 
photoCORMs using low energy light without compromising the stability of the 
photoCORM itself, although the biological compatibility of UCNPs has yet to be 
determined. 
 
Figure 1-12. Electronic absorption spectrum (yellow) of a Mn(I) carbonyl 
photoCORM and emission spectrum (blue) of an upconverting nanoparticle. 
Reproduced (Ref. 54) with permission of The Royal Society of Chemistry 
(RSC) on behalf of the European Society for Photobiology, the European 







 PhotoCORMs offer a distinct advantage over traditional CORMs in that 
CO release can be controlled with the use of photoexcitation. However, in 
retaining the metal carbonyl framework as the CORM sphere, photoCORMs 
retain the same disadvantage as their earlier predecessors in the potentially toxic 
and often uncharacterized metal containing fragments left after CO release. In 
reaction to the perceived toxicity of metal carbonyl photoCORMs, CORMs, 
and/or the metal-containing byproduct(s) of the photoreaction, several purely 
organic compounds capable of undergoing CO release either through 
photoreaction or some other mechanism have been recently reported (Figure 1-
13).55 These compounds represent a significant divergence from traditional metal 
carbonyl CORMs. Wowever, fundamental disadvantages have hampered their 
significant development as well.  
The diketone compound (Figure 1-13(a)) exhibits photoinduced CO-
release using visible light (λirr = 470 nm) with two equivalents of CO liberated per 
equivalent of compound and the production of a fluorescent photoproduct which 
could enable tracking of CO liberation in cellular environments.55b However, the 
synthesis of the compound requires multiple steps with an overall yield of 19%. 
Additionally, the toxicity of the photoCORM and the organic photoproduct has not 
been evaluated, and importantly, the diketone moiety, necessary for CO release, 
has been shown to hydrate in aqueous media thereby deactivating the CO-







The carboxylate compound (Figure 1-13(b)) undergoes photoreaction to 
liberate one mole of CO per mole of molecule and is fluorescent.55a While the 
toxicity of neither the photoCORM nor the photoproduct has been determined, 
 
Figure 1-13. Proposed mechanism for CO release from the four reported 
organic CORMs. (a) photoinduced CO release from a diketonate moiety, (b) 
photoinduced CO release from a carboxylate, (c) photoinduced CO release 
from a carboxylate BODIPY compound, and (d) the formation of an unstable 





the main disadvantage to this compound is the synthesis needed to produce the 
photoCORM. It is generated using a photoreaction; therefore, isolating the 
photoCORM before it can undergo further reaction to release CO is problematic 
and results in an extremely low yield.  
A third organic photoCORM has recently been reported that relies on a 
boron dipyrromethene (BODIPY; Figure 1-13(c)) framework.56 Derivatives using 
this framework undergo photoinduced CO-release at wavelengths greater than 
500 nm with an extended conjugation derivative capable of CO release upon 
activation with near-IR light. Additionally, this compound is fluorescent whereas 
the photoproduct(s) are not allowing for the potential to track CO release in a 
cellular environment. Minimal toxicity was observed for cells (cell viability did not 
drop below 50%; neuroblastoma and SH-SY5Y cell lines) at all concentrations 
tested (up to 100 μM). An almost quantitative amount of CO was produced from 
the photoreaction of the BODIPY carboxylate under anaerobic conditions (87% 
yield). However, in aerated solution, the quantity of CO produced decreases 
dramatically (44% yield). This is thought to be due to the formation of 1O2, which 
then reacts with the starting material, forming a heretofore unidentified species 
that is unable to undergo CO release. The efficacy of the lead compound was 
also tested on hairless mice which displayed increased carboxyhemoglin levels, 
particularly in the liver and kidneys. Unfortunately, the toxicity of the organic 
photoproducts was not tested. This was probably due to the fact that a mixture of 
products is generated, only two of which have been identified as 2-methylpyrrole 




A fourth compound that doesn’t require an external trigger to release CO 
has also been reported (Figure 1-13(d)). This organic CORM is produced in situ 
via a Diels-Alder reaction and subsequently decomposes to produce CO and an 
aromatic organic product.55c Cytotoxicity assays of the reactants necessary to 
form the CORM and the CO release product were examined and one of the 
reactants displayed a relatively high toxicity (IC50 12.5 μM) while the other 
reactant was minimally toxic (IC50 1 mM). The organic CO release product was 
non-toxic at all concentrations tested (0.78 - 100 μM). Unfortunately, this CO 
release system utilizes an in situ bimolecular process that could be severely 
hampered in the complex environments of biological organisms. While organic 
compounds may represent the future of CO-releasing materials for use as 
possible therapeutics, those described above have limitations that hamper their 
continued development.  
 
Alternative Platforms for Carbon Monoxide Release 
A notable alternative to metal carbonyl or organic compounds capable of 
undergoing CO release reactions either triggered or through ligand exchange is 
CORM-A1 and derivatives thereof (Figure 1-14(a)).57 CORM-A1 is a water 
soluble sodium boranocarbonate compound (Na2[H3BCO2]) that decomposes to 
release CO upon interaction with protons. The slow, pH-dependent liberation of 
CO (t½ 27.06 min. at pH 7.4, 37 °C) has been considered key for the therapeutic 
effects observed in a variety of in vitro tests and in vivo animal disease models.58 







IsoLink kit that in situ, reduces [99mTc(O4)]- to [99mTc(CO)3]+ for use in 
radiopharmaceutical diagnostics.59 Additionally, the first biological studies of this 
compound were performed in the 1990s well before the beneficial health effects 
Figure 1-14. Alternative CO release platforms to metal carbonyl complexes 
and organic compounds. (a) pH-dependent CO release from sodium 
boranocarbonate (CORM-A1), and (b) Iron(III) terephthalate metal organic 
framework (MOF) utilized for CO storage; viewed along the a axis (left), c axis 
(middle), and one of the μ3-oxo-bridged timeric unit made of iron octahedrons 
and terephthalate linkers (right). Empty circles represent terminal ligands, iron 
atoms are displayed as light gray spheres, oxygen atoms as gray spheres and 
carbon atoms as black spheres. Reproduced by permission from John Wiley 





of CO were recognized.60 While the CO release from CORM-A1 cannot be 
controlled in terms of location and timing, the main disadvantage of this 
compound likely comes from its hydride donor character, with a reducing 
capability equivalent to that of sodium borohydride (Na[BH4]).61  
An additional alternative to traditional CORMs has been reported in the 
form of two metal organic frameworks (MOFs). MOFs are porous coordination 
polymers constructed from metal nodes and organic linkers. The MOFs reported 
as CO storage and release platforms are comprised of iron in the +3 oxidation 
state and dicarboxylate, terephthalate linkers (Figure 1-14b).62 In order to load 
CO into the MOF, an activation process is required to remove non-bridging 
ligands, such as water and chloride, from the iron centers. This process involves 
heating the MOF above 100 °C in a CO gas stream. CO is released from the 
platforms via decomposition of the MOF in physiological media. Neither the 
toxicity of the MOFs nor the decomposition products were reported. However, it 
is particularly troubling that the decomposition products were not characterized at 
all. While iron is a biologically required metal ion, its storage is highly controlled 
as free iron ions are capable of undergoing reactions to produce compounds that 
are extremely damaging, such as through Fenton reactions. Additionally, the 
amount of CO loaded and released from the MOFs is unknown, which is 
extremely problematic for a compound that is therapeutic in low doses and 





The Future of CORMs 
 Since discovering the potential health benefits of low doses of CO, a 
considerable number of storage and release platforms for this small gaseous 
molecule have been developed. However, none of the compounds or materials 
developed to date represents viable constructs for further development into 
pharmaceuticals. It is clear that the field of CORMs needs a revolutionary future 
direction verses a continued investment in the evolutionary development of the 
previously described CORMs. Nature has the potential to serve as inspiration for 
a new direction. In higher organisms, the enzyme heme oxygenase 
endogenously produces CO through the breakdown of hemoglobin. This process 
can be visually monitored through bruise healing. The utilization of hemoglobin or 
hemoglobin-like compounds as CORMs could be problematic as it would rely on 
pre-existing enzymes for CO release and could potentially lead to the destruction 
of naturally occurring hemoglobin to restore homeostasis. Bacteria and fungi 
utilize enzymes known as quercetin dioxygenases (QDOs) to produce CO 
(Figure 1-15). QDOs make use of a class of naturally occurring compounds 
called flavonols to yield CO. Flavonols are potent antioxidants found in a variety 
of fruits and vegetables and can serve as inspiration for a revolutionary new 






Industrial Significance of Carbon Monoxide 
Carbon monoxide is used in the production of a wide variety of products 
from the purification of metals to the synthesis of chemicals.65 Well known 
compounds manufactured using CO include drugs, such as ibuprofen, and 
familiar household products such as vinegar, detergents, and plastics.66 It is also 
routinely used by workers in small-scale drug discovery companies and in 
academic laboratories. Additionally, CO is utilized in atmospheric packaging 
systems for meats in order to lower microbial load and extend shelf life.67 The 
use of CO gas in industrial processes have become incredibly pervasive to its 
low cost and excellent atom economy and is produced (Figure 1-16) by the 
megaton (Mt) each year for its multiple applications. The dangers of carbon 
 
Figure 1-15. Proposed mechanism of CO release from a flavonol in copper 





monoxide are well documented and can result in fatal poisoning. The symptoms 
of CO poisoning - headache, nausea, vomiting, and dizziness - can be difficult to 




poisoning). In large-scale industrial environments, elaborate and expensive gas 
handling systems are incorporated to minimize the risk of workers being exposed 
to CO. However, smaller scale facilities and academic environments lack the 
resources to invest in such an infrastructure and as such the gas is used under 
much less rigorous safety conditions. Recognition by the chemical community 
 






that this is a severe hazard has led to the consideration of alternative means of 
delivering CO into chemical reactions. A general approach has been to develop 
molecules that will release CO when triggered.68 To date, the majority of these 
compounds are used in an ex situ fashion, meaning that gaseous CO is 
produced and then transferred into the reaction chamber.  
 The most commercially significant CO-release system for use in chemical  




This approach involves using chemical compounds to generate CO ex situ and 
deliver the gas via diffusion into the catalytic reaction using a two chambered 
 
Figure 1-17. “COgen”/”COware”. Listed on the right are compounds that are 
also patented for use as CO-release agents using COware.  
 
“COgen”/”COware”
• Special two-chamber system 
required (non-standard 
glassware)
• CO generated via palladium 
catalysis in one side; 
palladium-catalyzed 
carbonylation in other side
COware
COgen




system. The utility of this system has been examined on palladium-catalyzed 
carbonylation reactions. Reactions of this type were first discovered by Richard 




Using a palladium catalyst, two molecules are joined via the formation of two new 
bonds on either side of an inserted C=O unit. The broad generality of this 
reaction in terms of the compounds that can be coupled make this synthetic 
approach incredibly powerful. For example, a palladium-catalyzed carbonylation 
reaction is used in the synthesis of ibuprofen.66 However, due to size limitations 
with the required glassware, the primary users of “COgen”/”COware” are likely 
 
 
Figure 1-18. Proposed catalytic cycle of a carbonylative Heck reaction 




small-scale synthetic laboratories (academic and industrial). Notably, this system 
is able to deliver stoichiometric quantities of CO and has the ability to incorporate 
carbon isotopes in the CO unit.68a-ab, 69  
“COgen”/ ”COware” has also demonstrated some drawbacks. These 
include: (1) the requirement of the two-chamber glassware that is not common in 
most synthetic organic laboratories and must be specially purchased; (2) both 
sides of the chamber are heated at the same temperature; and (3) the use of 
expensive palladium catalysts in both chambers as both the release of CO from 
COgen and the incorporation of CO into the product require palladium catalysts. 
A few other compounds have been reported to date that can be used as in situ 
CO-release agents (formamides68ai-ap, CHCl3/CsOH68aq, 68as, 70, Mo(CO)668ar, 68at-
ba), however all require the presence of additional reagents or heat to induce CO 
release, which can be problematic with regard to reactivity of substrates. For 
example, Mo(CO)6 acts as a reducing agent toward nitro-substituted substrates 
and thus limits the substrate scope that can be examined using this CO-release 
agent in situ.71  
A significant advance for the use of carbon monoxide for the production of 
value added compounds would be the development of a safe-to-handle, 
heterogeneous, triggered CO-release material that could be used in situ in a 
broad array of reactions under a variety of reaction conditions. The importance of 
a material that is safe-to-handle cannot be understated as it could expand the 




environments that may not have the capital to invest in the expensive and 
elaborate infrastructure to use CO safely. The heterogeneous nature would 
differentiate such a material from CO release agents currently employed and 
would be especially advantageous as reaction work-up would only involve 
separation of the CO release material via simple filtration. If such a material could 
be prepared at low cost and used in standard laboratory glassware, it would be 
uniquely useful relative to all other reported CO release compounds.  
 
Conclusions 
 Carbon monoxide is a small gaseous molecule with a long history of 
toxicity. More recently, the importance of CO in human health as well as in a 
wide variety of chemical processes has been demonstrated. Due to the ever-
increasing significance of this small molecule, the development of safe-to-handle, 
storage platforms that have properties desirable to the specific application is vital 
to the continued advancement of CO both as a pharmaceutical and in the 
production of value-added compounds. In the Berreau group, we are interested 
in the development and evaluation of novel compounds capable of undergoing 
photoinduced CO-release based on the framework of naturally occurring 
flavonols. We hypothesized that flavonols could be developed into a new family 
of tunable visible light-triggered photoCORMs. In the subsequent chapters of this 
dissertation, the following topics will be presented: (1) the effect of 
microenvironment on the photoinduced CO release reactivity of zinc-bound 3-




family of flavonols capable of CO release upon illumination with visible light; (3) 
the optimization of photochemical efficiency and solid state photoreactivity of zinc 
bound flavonolato compounds utilizing a hydrophobic microenvironment; and (4) 
the development of zinc bis-flavonolato compounds for use as heterogeneous in 
situ CO sources in oxidative palladium catalyzed carbonylation reactions. 
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INFLUENCE OF SUPPORTING LIGAND MICROENVIRONMENT ON THE 
AQUEOUS STABILITY AND VISIBLE LIGHT INDUCED CO RELEASE 
REACTIVITY OF ZINC FLAVONOLATO SPECIES‡ 
 
Abstract 
 The visible light induced CO release reactivity of the zinc flavonolato 
complex [(6-Ph2TPA)Zn(3-Hfl)]ClO4 (1) has been investigated in 1:1 H2O:DMSO. 
Additionally, the effect of ligand secondary microenvironment on the aqueous 
stability and visible light-induced CO release reactivity of zinc flavonolato species 
has been evaluated through the preparation, characterization, and examination 
of the photochemistry of compounds supported by chelate ligands with differing 
secondary appendages, [(TPA)Zn(3-Hfl)]ClO4 (3; TPA = tris-2-
(pyridylmethyl)amine) and [(bnpapa)Zn(3-Hfl)]ClO4 (4; bnpapa = N,N-bis((6-
neopentylamino-2-pyridyl)methyl)-N-((2-pyridyl)methyl)amine)).  Compound 3 
undergoes reaction in 1:1 H2O:DMSO resulting in the release of the free neutral 
flavonol. Irradiation of acetonitrile solutions of 3 and 4 at 419 nm under aerobic 
conditions results in quantitative, photoinduced CO release. However, the 
reaction quantum yields under these conditions are lower than that exhibited by 
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1, with 4 exhibiting an especially low quantum yield.  Overall, the results of this 
study indicate that positioning a zinc flavonolato moiety within a hydrophobic 
microenvironment is an important design strategy toward further developing such 
compounds as CO release agents for use in biological systems.  
 
Introduction 
 The development of carbon monoxide releasing molecules (CORMs) for 
use in biological systems is of significant current interest.[1-7]  This is due to the 
identification of several beneficial health effects associated with the controlled 
administration of small amounts of CO. These include anti-inflammatory and 
antiapoptotic effects, as well as the promotion of vasodilation and protection of 
tissues against reperfusion injury.[4] To date, the vast majority of CORMs 
reported are low-valent metal carbonyl compounds. These compounds, while 
exhibiting a number of favorable properties for biological use, also have 
limitations, including the fact that many cannot be controlled in terms of the 
location and timing of the CO release. In this regard, metal-carbonyl based 
CORMs that exhibit photoinduced CO release reactivity (photoCORMs) using low 
energy visible light are of particular current interest.[1, 2, 8-13] However, an 
important unresolved issue for these compounds is the potential for toxicity 
resulting from the remaining metal/ligand fragment following CO release.  




molecules that are not based on the metal-carbonyl unit. In this regard, it is 
known that metalloenzymes termed quercetin dioxygenases (QDOs) catalyze the 
oxidative breakdown of flavonols to give CO and an O-benzoylsalicylic acid (O-
bs) derivative as products.[14] In studies of synthetic complexes of relevance to 
the enzyme/substrate (ES) adducts of QDOs, we discovered stoichiometric, UV-
light induced CO-release reactivity for a family of divalent metal complexes ([(6-
Ph2TPA)M(3-Hfl)]X,  M = Zn(II), Co(II) Cu(II), Ni(II), Mn(II); X = ClO4- or OTf-) 
containing a deprotonated 3-hydroxy-4-flavonolato ligand (3-Hfl) and supported 
by a tetradentate N4-donor chelate ligand (6-Ph2TPA, N,N-bis((6-phenyl-2-
pyridyl)methyl)-N-((2-pyridyl)methyl)amine).[15,16] For these complexes, CO 
release occurs via a photoinduced, dioxygenase-type reaction akin to the thermal 
reaction catalyzed by QDOs. The reaction observed for [(6-Ph2TPA)Zn(3-
Hfl)]ClO4 (1) in CH3CN under O2 is shown in Scheme 2-1. The quantum yield for 
this reaction with irradiation at 300 nm (ɸ = 0.09(1)) [16] is an order of magnitude 
higher than that exhibited by structurally similar Mn(II), Co(II), Ni(II), Cu(II) 
complexes (ɸ = 0.005-0.008).[16] This is the result of quenching of the excited 
state in the complexes containing an open-shell dn metal ion. The photoinduced 
reaction pathway for O2-dependent CO-release from [(6-Ph2TPA)Zn(3-Hfl)]ClO4 
(1) likely involves either the coordinated flavonolato ligand acting as a 
photosensitizer to generate singlet oxygen (1O2), which can then react with 
ground-state 1, or an excited state singlet to triplet conversion of the zinc-bound 





Scheme 2-1. Photoinduced CO release from zinc-bound flavonolato.  
 
The initial studies outlined above have led us to further examine the 
chemistry of zinc flavonolato species. In the results described herein, we have 
evaluated the visible light induced CO release reactivity of 1 in 1:1 H2O:DMSO. 
Additionally, we have evaluated how the nature of the supporting chelate ligand, 
particularly with respect to the secondary microenvironment surrounding the zinc 
flavonolato moiety, influences the aqueous stability and visible light induced CO-
release reactivity of this unit. These combined results provide evidence that 
maintaining a hydrophobic microenvironment surrounding the zincflavonolato 










Chemicals and reagents 
 All chemicals and reagents were obtained from commercial sources and 
used as received unless otherwise noted. Anaerobic procedures were performed 
under N2 in either a VAC Atmospheres or an MBRAUN Unilab glovebox. 
Solvents for glovebox use were dried according to published methods and 
distilled under N2.[17] The preparation of the chelate ligands tris(2-
pyridylmethyl)amine (TPA) [18] and N,N-bis((6-neopentylamino-2-pyridyl)methyl)-
N-((2-pyridyl)methyl)amine (bnpapa) [19] was accomplished as previously 
reported. [(6-Ph2TPA)Zn(3-Hfl)]ClO4 (1) was prepared as previously described.[20] 
 
Physical methods  
 1H NMR spectra were collected using a JEOL ECX-300 or Bruker ARX-
400 spectrometer. Chemical shifts (in ppm) are referenced to the residual solvent 
peaks in CD2HCN (1H: 1.94 (quintet) ppm; 13C: 1.39 (quintet) ppm). J values are 
given in Hz. IR spectra were recorded on a Shimadzu FTIR-8400 spectrometer 
as KBr pellets. UV-vis spectra were recorded at ambient temperature using a 
Hewlett-Packard 8453A diode array spectrophotometer. Emission spectra were 
collected using a Shimadzu RF-5301PC spectrofluorophotometer using a slit 




maximum of the complex above 400 nm. A Rayonet photoreactor equipped with 
RPR-4190A lamps was used for all photochemical reactions. Quantum yields 
were determined using potassium ferrioxalate actinometry as a standard to 
measure photon flux.[21-23] Carbon monoxide was quantified as previously 
described.[16] Mass spectral data was collected at the Mass Spectrometry 
Facility, University of California, Riverside. Elemental analyses were performed 
by Atlantic Microlab, Inc., Norcross, GA using a PE2400 automatic analyzer.  
Caution! Perchlorate salts of metal complexes with organic ligands are 
potentially explosive. Only small amounts should be prepared and these should 
be handled with great care.[24] 
 
Photoreactivity of 1 in 1 : 1 H2O : DMSO using visible light 
 A solution of 1 (0.1 mmol in 10 mL 1:1 H2O:DMSO) was placed in a 100 
mL round bottom flask under air. This solution was irradiated at 419 nm until the 
reaction was determined to be complete as evidenced by loss of the 420 nm 
absorption band. CO release was determined to be quantitative by GC. 
Performing the same reaction in 1:1 D2O:d6-DMSO confirmed the formation of 2 






Preparation of zinc flavonolato complexes 
[(TPA)Zn(3-Hfl)]ClO4 (3). Under a N2 atmosphere, a methanol solution (2 
mL) of Zn(ClO4)2×6H2O (40 mg, 0.11 mmol) was added to solid TPA (39 mg, 0.13 
mmol) and the solution was stirred until the chelate ligand had dissolved. The 
resulting mixture was combined with a methanol solution (2 mL) containing 3-
hydroxyflavone (32 mg, 0.13 mmol) and Me4NOH×5H2O (24 mg, 0.13 mmol). This 
mixture was stirred for 4 hours at ambient temperature. The solvent was then 
removed under reduced pressure and the residual solid dissolved in CH2Cl2. The 
CH2Cl2 solution was filtered through a Celite/glasswool plug and the product was 
precipitated via the addition of excess hexanes (40 mL). The isolated solid was 
dried under reduced pressure. Recrystallization via Et2O diffusion into CH3CN 
yielded yellow crystals suitable for X-ray crystallography (74 mg, 80%). Anal. 
Calcd. for C33H27ClN4O7Zn (%): C, 57.24; H, 3.93; N, 8.09. Found: C, 57.55; H, 
4.00; N, 7.84. 1H NMR (CD3CN, 300 MHz) δ 8.9 (br, 2H), 8.80-8.45 (br, 4H), 
8.03-7.77 (br, 3H) 7.76-7.59 (m, 4H), 7.58-7.20 (m, 8H), 4.79-4.02 (bs, 6H) ppm; 
UV-vis (CH3CN), nm (ε, M-1cm-1) 415 (19000), 313 (7600); FTIR (KBr, cm-1) 1558 
(nC=O), 1088 (νClO4), 619 (νClO4); MALDI-MS, m/z (relative intensity) 
C33H27N4O3Zn: Calcd: 591.1369; Found: 591.1385 ([M-ClO4]+, 100). 
[(bnpapa)Zn(3-Hfl)]ClO4 (4). Prepared using a synthetic procedure similar 
to that employed for the preparation of [(6-Ph2TPA)Zn(3-Hfl)]ClO4.[20] 
Recrystallization of the crude product via slow Et2O diffusion into CHCl3 yielded 




Anal. Calcd. for C43H49ClN6O7Zn(%): C, 59.86; H, 5.72; N, 9.74. Found: C, 60.05; 
H, 6.02; N, 9.38. 1H NMR (CD3CN, 300 mHz) δ 8.87 (br, 2H, N-H), 8.73 (d, J = 
7.9 Hz, 1H), 8.10 (d, J = 7.9 Hz, 1H), 7.82-7.63 (m, 5H), 7.61-7.52 (m, 2H), 7.50-
7.32 (m, 4H), 7.30-7.18 (m, 2H), 6.49 (d, J = 7.2 Hz, 2H), 6.36 (d, J = 8.6 Hz, 
2H), 4.52 (d, J = 14.3 Hz, 2H), 4.31 (s, 2H), 4.23 (d, J = 14.3 Hz, 2H), 2.87 (d, J = 
7.2 Hz, 1H), 2.83 (d, J = 7.5 Hz, 1H), 2.62 - 2.48 (m, 2H), 0.63 (s, 18H) ppm; UV-
vis (CH3CN), nm (ε, M-1cm-1) 401 (16500), 321 (18400); FTIR (KBr, cm-1) 3307 
(br, νN-H), 1560 (nC=O), 1085 (νClO4), 620 (νClO4); MALDI-MS, m/z (relative 
intensity) C43H49N6O3Zn: Calcd: 761.3152; Found: 761.3120 ([M-ClO4]+, 100). 
 
Photoreactivity of [(L)Zn(3-Hfl)]ClO4 (L = TPA (3) or bnpapa (4)) 
 
Identification of [(L)Zn(O-bs)]ClO4 products (O-bs = O-benzoylsalicylato) 
A solution of each complex ([(L)Zn(3-Hfl)]ClO4 (L = TPA (3) or bnpapa (4); 
0.1 mmol in 10 mL CH3CN) was placed in a 100 mL round bottom flask under air. 
Each solution was irradiated at 419 nm until the reaction was determined to be 
complete as evidenced by loss of the ~400-415 nm absorption band. The solvent 
was then removed under reduced pressure and the residual solid was 
redissolved in a minimal amount of CH3CN (ca. 2 mL). Addition of excess Et2O 
(~20 mL) resulted in the deposition of a beige solid that was dried in vacuo to 




(6). 18O2-labeled samples were prepared by transferring aliquots of 18O2 into 
frozen CH3CN solutions of 3 and 4 in 100 mL solvent transfer flasks, followed by 
irradiation and work-up as described above.   
[(TPA)Zn(O-bs)]ClO4 (5). Yield: 91%. 1H NMR (CD3CN, 300 MHz) δ 8.74 
(s, 3H), 8.02 (td, J1= 7.8, J2 = 1.5, 4H), 7.73-7.23 (m, 14 H), 4.13 (s, 6H); FTIR 
(KBr, cm-1) 1761 (νC=O); 18O2 sample: MALDI-MS, m/z (relative intensity); 
C32H27N416O218O2Zn: Calcd. 599.1403. Found: 599.1407 ([M-ClO4]+; 27). 
[(bnpapa)Zn(O-bs)]ClO4 (6). Yield: 88%. 1H NMR (CD3CN, 300 MHz) δ 
8.57 (s, 1H), 8.19 - 7.00 (m, 14H), 6.65 (s, 2H), 6.47 (d, J = 6.4 Hz, 2H), 4.06 (s, 
2H), 3.81-3.62 (m, 4H), 3.12-2.87 (m, 6H), 0.85 (s, 18H); FTIR (KBr, cm-1) 1743 
(νC=O); MALDI, m/z (relative intensity); C42H49N616O4Zn: Calcd: 765.3101. 
Found:  765.3124 ([M-ClO4]+, 30). 18O2 sample: MALDI-MS, m/z (relative 
intensity); C42H49N616O218O2Zn: Calcd. 769.3186. Found: 769.3196 ([M-ClO4]+, 
58). 
 
Dark control reactions 
 Solutions of 3 and 4 in CD3CN (~0.02 M) were prepared in air under 
minimal red light and placed in NMR tubes. Each NMR tube was then covered 
with foil and irradiated at 419 nm for a specific amount of time (3: 24 h; 4: 96 h)). 
For both, evaluation of the solution by 1H NMR indicated that no reaction had 




photoinduced and not thermal processes. 
 
Anaerobic control reactions 
 Solutions of 3 and 4 in CD3CN (~0.02 M) were prepared under N2 in a 
glove box and placed in NMR tubes. Each NMR tube was then irradiated at 419 
nm for a specific amount of time (3: 24 h; 4: 96 h)). For both, evaluation of the 
solution by 1H NMR indicated that no reaction had occurred. These results 




Data collection and refinement 
 Single crystals of 3×CH3CN and 4×CHCl3 were each mounted on a glass 
fiber using viscous oil and then transferred to a Nonius Kappa CCD 
diffractometer for data collection using Mo Ka radiation (l = 0.71073 Å). Methods 
of unit cell refinement and determination of final cell constants have been 
previously reported.[25] The data collected for each compound was corrected for 




SCALEPAC.[26] Each structure was solved using a combination of direct methods 
and heavy atoms using SIR 97.  
 
Structure solution  
 Complexes 3×CH3CN and 4×CHCl3 crystallize in the space groups P21/n 
and P-1, respectively. All non-hydrogen atoms were refined with anisotropic 
displacement coefficients. All hydrogen atoms were assigned isotropic 
displacement coefficients (U(H) = 1.2U(C) or = 1.5U(Cmethyl)) and their 
coordinates were allowed to ride using SHELXL97.[27] In 3×CH3CN the 
perchlorate anion exhibits disorder of three of the oxygen atoms. In 4×CHCl3, 
hydrogen bonding interactions are found between the secondary amine NH units 
of O(1) of the coordinated flavonolato ligand.  
 
Results and discussion 
 
Spectroscopic features and photoinduced CO-release reactivity of 1 in 1:1 
H2O:DMSO 
 




Compound 1 is not soluble in water, but exhibits good solubility in 1:1 
H2O:DMSO. As shown in Figure 2-1(a), 1 exhibits a ~420 nm absorption band in 
this solvent mixture which is similar to the spectrum produced in CH3CN. 
Evaluation of this solution after 24 h of storage at ambient temperature in the 
dark revealed no spectral changes. Hence, the compound is stable in an 
aqueous environment under dark, aerobic conditions.   
 
 
Figure 2-1. (a) Absorption spectra of 1 in CH3CN and 1:1 DMSO:H2O. (b) 
Fluorescence emission spectra of 1 in CH3CN and 1:1 DMSO:H2O generated 





Photoinduced CO-release reactivity of 1 using visible light 
 Irradation of 1 in 1:1 H2O:DMSO using visible light (419 nm) under air 
results in the release of one equivalent of CO (Table 2-1) and the formation of 
[(6-Ph2TPA)Zn(O-bs)]ClO4 (2). The quantum yield for this reaction (ɸ = 0.006) is 
only two-fold lower than that observed in acetonitrile under similar conditions. 
 
Table 2-1. Reaction quantum yields and CO quantification for the visible light  
induced aerobic CO release reactions of 1, 3, and 4. 
Compound Solvent ɸa,b Eq. COb 
1 CH3CN 0.012(2) 0.99(2) 
1:1 H2O/DMSO 0.006(1) 0.977(6) 
3 CH3CN 0.0060(9) 0.99(1) 
4 CH3CN 0.000269(8) 1.00(4) 
alirr = 419 nm; bAverage of three independent determinations. 
 
Synthesis and characterization of 3 and 4 
 To investigate the influence of the chelate ligand on the aqueous stability 
and photoinduced CO release reactivity of 1, analogs were prepared and 
characterized using tetradentate chelate ligands that either lacked secondary 







Synthesis of 3 and 4. 
Admixture of the appropriate chelate ligand (TPA or bnpapa) with 
Zn(ClO4)2×6H2O, followed by treatment with a solution containing a mixture of 3-
hydroxyflavone (3-HflH) and Me4NOH×5H2O, respectively, produced yellow 
reaction mixtures. After workup, each complex was isolated as a crystalline solid 
(Scheme 2-2) in 75-80% yield. The zinc flavonolato complexes [(TPA)Zn(3-
Hfl)]ClO4 (3) and [(bnpapa)Zn(3-Hfl)]ClO4 (4) were characterized by elemental 
analysis, X-ray crystallography, absorption and emission spectroscopy, IR, 1H 
NMR, and mass spectrometry.  
 
 





 The elemental analysis data for bulk samples of 3 and 4 is consistent with 
the dried powder form of each complex having an analytical formulation that 
lacks the CH3CN and CHCl3 solvate molecules, respectively, that are found in the 
X-ray structures of these complexes (vide infra). 
 
X-ray crystallography 
 Representations of the cationic portions of 3·CH3CN and 4·CHCl3 are 
shown in Figure 2-2. Details of the X-ray data collection and refinement are 
givenin Table A-1. Bond distances and angles within the cationic portions of 
these structures are given in Table A-2. The Zn(II) centers in the cationic portions 
of 3·CH3CN and 4·CHCl3 have a coordination number of six and exhibit a 
distorted psuedoctahedral geometry. This differentiates the solid-state structures 
of these cations from that found for 1×2CH2Cl2, which exhibits an overall 
coordination number of five, a distorted square pyramidal geometry (t = 0.35) [28], 
and a dissociated phenyl-appended pyridyl donor. All three complexes exhibit 
bidentate coordination of the flavonolato ligand, with the shorter zinc-oxygen 
distance in each involving the deprotonated hydroxyl donor  (1×2CH2Cl2: 1.951(2) 





Figure 2-2. Thermal ellipsoid (50%) representations of the cationic portions of (a) 
3 and (b) 4. Hydrogen atoms except those of the N-H units have been omitted for 
clarity. 
 
oxygen (1×2CH2Cl2: 2.1175(19) Å; 3·CH3CN: 2.1373(17) Å; 4·CHCl3: 2.159(2) Å). 
The DZn-O value is similar in this family of compounds, with all being found in the 
range of 0.14-0.17 Å. Generally, the observed bond lengths and DZn-O values for 
the complexes described herein fall within the ranges of other previously reported 




Zn-O distances elongate across the supporting chelate ligand series in the order 
6-Ph2TPA < TPA < bnpapa. The same trend is found in the average Zn-Npy 
distance, which increases from 2.11 Å in the 6-Ph2TPA-ligated complex to 2.16 
and 2.17 Å in the TPA- and bnpapa-ligated complexes, respectively. This latter 
trend is likely due to the effect of overall coordination number, as well as the 
presence of the secondary amine donor appendages in the bnpapa-ligated 
system, which introduces additional steric hindrance.  
Examination of the bond lengths within the coordinated flavonolato ligand 
shows that all three complexes exhibit a similar slight elongation (~0.02 Å) of the 
ketone carbonyl C-O bond and a slight contraction (~0.02-0.04 Å) of the C-O 
bond of the hydroxyl donor relative the distances found in the free flavonol 
(1.232(3) and 1.357(3) Å, respectively).[32] The C=C bond distance within the 
flavonolato chelate ring is similar in all three complexes (1×2CH2Cl2: 1.458(4) Å; 
3·CH3CN: 1.439(3) Å; 4·CHCl3; 1.460(4) Å) and is elongated relative to that 
found in the free flavonol (1.363(4) Å).[32] Overall, the bond lengths within the 
flavonolato ligands of this series of complexes are only minimally affected by the 
nature of the supporting chelate ligand.   
In 4·CHCl3, hydrogen bonds are found between the two secondary amine 
NH units of the bnpapa chelate ligand and O(1) of the coordinated flavonolato 
ligand. The heteroatom distances (2.93 and 3.01 Å) and corresponding N-H…O 
angles (136.5° and 155.2°) associated with these interactions suggest that these 





Powdered samples of 3 and 4 were characterized by solid state IR 
spectroscopy, and solutions of these complexes were examined using 1H NMR, 
mass spectrometry, and absorption and emission spectroscopy. 
 
Infrared spectra 
The solid-state FTIR spectra of 1, 3 and 4 contain a nC=O vibration at 
~1550-1560 cm-1 for the coordinated ketone moiety, as well as vibrations for the 
perchlorate counterion. For 4, a broad vibration at ~3300 cm-1 is consistent with 
the presence of the secondary amine appendages and their involvement in 
hydrogen bonding interactions with the coordinated flavonolato ligand. 
 
1H NMR 
 Complex 1 exhibits a 1H NMR spectrum with the appropriate number of 
signals for Cs symmetry in CD3CN (Figure A-1). This is consistent with 
coordination of all of the nitrogen donors of the 6-Ph2TPA ligand in the solution 
structure of the complex. Complex 3 exhibits broadened 1H NMR signals 
suggestive of fluxional behavior when dissolved in CD3CN (Figure A-2) or CD2Cl2 
(Figure A-3(a)) at 25 oC. The broadened benzylic methylene resonance at ~4.4 




pyridyl donors (Figure A-3). This type of behavior has been previously identified 
in d10 Cu(I) complexes of TPA.[34] Cooling of a CD2Cl2 solution of 3 from 25 oC to -
53.5 oC (Figure A-3(a-h)) produced a sharpening of some of the resonances that 
was reversible upon returning the sample to room temperature. Further 
evaluation of the 1H NMR properties of 3 are underway. Complex 4 exhibits 1H 
NMR features (Figure A-4) consistent with the cationic portion having Cs 
symmetry. 1H NMR spectra of photoproducts 5 (Figure A-5) and 6 (Figure A-6) 
were as expected. 
 
Mass spectrometry 
 Complexes 3 and 4 as well as their photoproducts, 5 and 6, respectively, 
were evaluated by MALDI mass spectrometry (Figures A-7 – A-12). Each 
exhibits an isotopic cluster molecular ion that is consistent with the proposed 
cationic formulation. 18O2 incorporation into 5 and 6 was evaluated by MALDI 
mass spectrometry. Each exhibits an isotopic cluster molecular ion consistent 
with the incorporation of both atoms of 18O2 into the compounds. 
 
Absorption and emission spectra in CH3CN and 1:1 H2O:DMSO   
Free 3-hydroxyflavone (3-HflH) exhibits absorption bands at 304 and 343 nm, 




is assigned to a π®π* HOMO to LUMO transition, while the higher energy Band 
II corresponds to a HOMO-1 to LUMO transition. The absorption spectra of 3 and 
4 in CH3CN are shown in Figure 2-3. The Band I absorption feature for 1, 3 and 4 
is red-shifted relative to the neutral flavonol, with the degree of shift depending  
 
 
Figure 2-3. (a) Absorption spectra of 3 in CH3CN and 1:1 DMSO:H2O and the 
absorption spectrum of 3-hydroxyflavone in 1:1 DMSO:H2O. (b) Absorption 
spectra of 4 in CH3CN and 1:1 DMSO:H2O.  
 
on the nature of the supporting chelate ligand. Specifically, the most red-shifted 
Band I absorption is found for the 6-Ph2TPA-ligated complex 1 (lmax = 420 nm 




and 4 (lmax = 401 nm (16,500 M-1cm-1)). In 1:1 DMSO:H2O, the TPA-supported 
complex 3 exhibits spectral changes consistent with protonation of the 
coordinated flavonolato ligand and displacement from the Zn(II) center (Figure 2-
3(a)). A new absorption feature at ~350 nm is consistent with the presence of 
free 3-hydroxyflavone (Figure 2-3(a)). The UV-vis absorption spectrum of 4 in 1:1 
DMSO:H2O is similar to that found in CH3CN (Figure 2-3(b)) albeit with 
significantly lower molar absorptivity values. Excitation into the ~400-415 nm 
absorption maximum of 3 and 4 dissolved in anaerobic CH3CN (5 x 10-5 M) 
produced the emission spectra shown in Figure 2-4. Compound 3 exhibits a 
similar Stokes shift (~72 nm) to that found for 1, but with an overall lower intensity 
fluorescent emission. Essentially no fluorescent emission is observed for 4 upon 
excitation at its absorption maximum (401 nm). Thus, the fluorescence intensity 
decreases in the order of 1 > 3 > 4 in CH3CN. We propose that this difference 
relates to the microenvironment in the 6-Ph2TPA chelate in 1, resulting in the 
phenyl appendages surrounding the coordinated flavonolato ligand. Specifically, 
the presence of the phenyl appendages in the 6-Ph2TPA chelate in 1 result in the 
flavonolato ligand being positioned in a hydrophobic microenvironment. This 
motif more limits solvent access to the flavonolato ligand relative to that in 3 
thereby reducing collisional quenching.  That being said, in 1:1 H2O:DMSO, the 
emission of 1 decreases in intensity relative to that found in CH3CN (Figure 2-





Figure 2-4. Fluorescence emission spectra of 1, 3, and 4 in CH3CN. All spectra 
were obtained with λex at the absorption maximum at ~400-420 nm. 
 
complex 4, the presence of the rigid intramolecular hydrogen bond donors, which 
may undergo excited state lengthening or shortening, results in significant 







Visible light induced reactivity of 3 and 4 
 As 3 undergoes reaction in 1:1 H2O:DMSO to produce free 3-
hydroxyflavone, we have only examined the visible light induced CO release 
reactivity of this compound in aerobic CH3CN using 419 nm irradiation. Complex 
4 was also examined in aerobic CH3CN and was found to exhibit such low 
photochemical efficiency (vide infra) that further studies in 1:1 H2O:DMSO were 
not performed. Each reaction was irradiated until judged to be complete by the 
disappearance of the ~400-415 nm absorption band.  
 
Product Identification 
 GC headspace gas analysis, 1H NMR, IR, and mass spectrometry were 
used to characterize the products generated upon photoirradiation of 3 and 4 in 
CH3CN at 419 nm. For each complex, the photoreaction resulted in the formation 
of one equivalent of CO (Table 2-1) as well as a [(L)Zn(O-bs)]ClO4 complex 
(TPA: 5; bnpapa: 6). The latter complexes were identified by their 1H NMR 
spectral features (Figures 2-7 and 2-8), molecular ions in MALDI mass spectral 
experiments (Figures 2-11, 2-12, 2-13 and 2-14), and by their characteristic nC=O 
ester vibration at 1740-1770 cm-1 for the O-benzoysalicylate ligand. Quantitative 
18O incorporation from 18O2 for the reactions of 3 and 4 provides conclusive 




control reactions demonstrate that the observed reactions for 3 and 4 are O2 
dependent photoinduced processes.  
 
Reaction Quantum Yields 
 The quantum yields for the visible light induced CO release reactions of 3 
and 4 in CH3CN are shown in Table 2-1. The structure of the supporting chelate 
ligand has a significant effect on the photochemical efficiency of the CO release 
reactions, with the quantum yield for 1 being two-fold higher than that of 3, and 
both of these values being >20 fold higher than the quantum yield for the reaction 
of 4. These results demonstrate that positioning a zinc flavonolato moiety within a 
rigid hydrogen bond donor environment significantly stabilizes the compound with 
respect to light induced reactivity.  
 
Conclusions 
In the studies outlined herein, we have examined the aqueous, visible light 
induced CO release reactivity properties of 1. The results indicate that this 
complex is stable in an aqueous, aerobic environment in the dark, but will exhibit 
quantitative, visible light induced CO release to generate a single zinc-containing 
product. The quantum yield for CO release in 1:1 H2O:DMSO is only of factor of 




We have also examined how the supporting chelate ligand influences the 
aqueous stability and visible light induced CO-release reactivity of zinc 
flavonolato species. We were particularly interested in examining the influence of 
the aryl appendages of the 6-Ph2TPA ligand in 1 as it is well known that the 
photochemical reactivity of organic and inorganic molecules can be modulated 
via encapsulation within a confined microenvironment such as a cyclodextrin 
cavity, hydrogen-bonded capsules, or hollow molecular structure [38,39]. Our 
results demonstrate that the secondary environment introduced by the 
tetradentate chelate ligand influences the chemistry of zinc flavonolato 
complexes in multiple ways. First, the presence of the hydrophobic 
microenvironment in 1 stabilizes the zinc flavonolato moiety with respect to water 
and differentiates the chemistry of 1 from that of 3 in aqueous DMSO solution. 
The observation of flavonol displacement from 3 in water is noteworthy not only 
to this study, but also to investigations being performed in other laboratories 
wherein simple zinc flavonolato species such as [Zn(3-Hfl)(acetate)] are being 
evaluated in aqueous media for their antidiabetic and DNA binding properties 
[40-42]. Second, the lower quantum yields observed for photoinduced CO 
release from 3 and 4 in CH3CN relative to 1 is likely a consequence of the 
enhanced accessibility of solvent to the flavonolato moiety and/or secondary 
hydrogen bonding. These interactions offer additional pathways for non-radiative 
decay thus leading to the observed excited state quenching and less efficient 




Overall, these investigations revealed that the presence of a hydrophobic 
microenvironment is important toward providing aqueous stability and maximizing 
the photochemical efficiency of the CO-release reaction of a zinc flavonolato 
moiety. Therefore, if zinc flavonolato species are to be advanced for use as 
photoinduced CO release agents in biological systems, careful consideration will 
need to be given to the supporting microenvironment within the compound.  
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A STRUCTURALLY-TUNABLE 3-HYDROXYFLAVONE MOTIF FOR VISIBLE 
LIGHT-INDUCED CO-RELEASING MOLECULES (CORMS)‡ 
 
Abstract 
 Molecules that can be used to deliver a controlled amount of CO have the 
potential to facilitate investigations of the roles of this gaseous molecule in 
biology and advance therapeutic treatments. This has led to the development of 
light-induced carbon monoxide-releasing molecules (photoCORMs). A goal in 
this field is the development of molecules that exhibit a combination of controlled 
CO release, favorable biological properties (e.g. low toxicity and trackability in 
cells), and structural tenability to affect CO release. Herein we report a new 
biologically-inspired organic photoCORM motif that exhibits several features that 
are desirable in a next generation photoCORM. We show that 3-hydroxyflavone-
based compounds are easily synthesized and modified to impart changes in 
absorption features and quantum yield for CO release, exhibit low toxicity, are 
trackable in cells, and can exhibit both O2-dependent and –independent CO 
release reactivity.  
                                                        
‡ Coauthored by Jason M. Richards, Hector J. Esquer, Abby D. Benninghoff, 
Prof., Atta M. Arif, Dr., and Lisa M. Berreau, Prof. Reproduced in a modified 





 Carbon monoxide-releasing molecules (CORMs) are of significant current 
interest due to the potential of CO as a therapeutic molecule.[1] The vast majority 
of CORMs developed to date are based on a metal-carbonyl unit as the CO-
releasing moiety.[2] Many molecules of this type, including protein-bound  
derivatives of [RuCl(glycinato)(CO)3] (CORM-3, Figure 3-1) and analogs,  
 
release CO spontaneously through ligand exchange in an aqueous 
environment.[3] The lack of temporal control for CO release in such systems has 
led to the use of metal carbonyl complexes that release CO only when 
triggered.[4,5] Examples of such complexes include photoCORMs, which release 
CO from a metal carbonyl unit upon illumination with UV or visible light.[4] Recent 
advances in the field of metal carbonyl photoCORMs demonstrate that CO 
 







release can be tuned to occur upon illumination with low-energy red or NIR light 
through modification of supporting ligands or through approaches using 
nanoparticles.[4] However, a concern associated with some metal-carbonyl based 
photoCORMs are side effects related to the metal-containing photoproducts.[6] A 
limited number of organic photoCORMs (1-3, Figure 3-1) have also been recently 
reported.[7] However, these molecules also have limitations. For example, 1 and 
2 are derived from relatively low-yield, multistep synthetic routes that have not 
been shown to be amenable to structural modification for the tuning of physical 
properties or biological targeting. The Diels-Alder product 3 can be generated in 
good yield and subsequently undergoes CO release. However, this compound 
cannot be isolated and stored.  
 Desirable features in a next generation organic photoCORM motif include: 
(1) a high-yield synthesis that enables the preparation of gram quantities of 
analytically pure compound; (2) solubility in water or aqueous DMSO; (3) thermal 
stability in aerobic, aqueous environments; (4) controllable, triggered CO release, 
preferably using light at wavelengths that do not have the potential to impart 
cellular damage; (5) low toxicity of the photoCORM and its post-CO-release 
byproducts; (6) ease of structural modification to modulate aqueous solubility, 
photochemical properties (e.g. light absorption properties), and biocompatibility, 
and (7) exhibits fluorescence so as to enable tracking of the localization and CO 
release reactivity of the molecule within cells.[8] In the results reported herein, we 
describe a new class of biologically-inspired photoCORMs that exhibit all of the 




hydroxyflavone motif, which is found in naturally-occurring molecules that are 
already known to exhibit several types of biological activity, including antioxidant, 
anti-inflammatory, and anti-cancer activity, as well as protection against 
cardiovascular disease.[9] The new flavones reported herein all exhibit visible 
light-induced CO-release in O2-containing environments, with one derivative also 
exhibiting O2-independent CO release reactivity.  
 
Discussion 
Naturally-occurring 3-hydroxyflavone derivatives, such as quercetin 
(Scheme 3-1(top)), are known to undergo O2-dependent, enzyme-catalyzed 
degradation to produce CO in bacteria and fungi.[10] In the absence of enzyme, 
quercetin is known to undergo various types of oxidative reactions, including UV 
light-induced reactions, which can result in CO release.[11] It is known that 
unsubstituted 3-hydroxyflavone (3-HflH) will undergo incorporation of both atoms 
of O2 and expulsion of CO in the presence of a photosensitizer, or via direct 
illumination using UV light (Scheme 3.1(middle)).[12] These reactions are 
proposed to proceed from the normal and tautomeric excited state forms of 3-
HlfH, respectively. We have reexamined the photoinduced (l = 300 nm) reactivity 
of 3-HflH under O2 and found that while a nearly quantitative amount of CO is 
generated (0.95 eq), multiple organic products are detected by GC-MS. Finally, 
3-HflH is also known to undergo UV light-induced rearrangement resulting in CO 





Scheme 3-1. Top) O2-dependent CO release reactivity of quercetin and 3-HflH. 
Bottom) O2-independent, UV-light induced isomerization reactivity of 3-HflH.  
 
results indicate that 3-hydroxyflavone derivatives have multiple reaction 
pathways by which light-induced CO-release reactivity can occur.  
We hypothesized that the 3-hydroxyflavone structural motif could be tuned 
to undergo visible light-induced CO release. With this strategy in mind, the new 
3-hydroxyflavone 4 was designed and prepared using Alger-Flynn-Oyamada 
methodology (Figure 3-2(top)).[14] X-ray quality crystals of 4 were obtained via 




characterized by elemental analysis, spectroscopic methods (Figures B-1 and B-
3 – B-5), and mass spectrometry (Figure B-2). Compound 4 is readily soluble in  
organic solvents and is also soluble in aqueous DMSO at concentrations suitable 
for spectroscopic measurements (1:1 H2O:DMSO)  and biological experiments 
(1% DMSO). Compound 4 crystallizes in the monoclinic space group C2/c.[15] A 




In the solid state, the 3-hydroxy-4-pyrone units from two molecules form 
centrosymmetric hydrogen bonded dimers with two identical intermolecular O-
H..O hydrogen bonds (O…O 2.69 Å; 145.3°).[16] The naphthyl-fused 3-hydroxy-4-
pyrone ring structure is nearly planar, and the phenyl appendage twists only 
 
Figure 3-2. Top) Synthetic route for the preparation of 4. Bottom left) A 
representation of the molecular structure of 4 as determined by X-ray 






slightly out of this plane. This overall structure favors conjugation of the two 
electronic systems. Compound 4 has bond lengths and angles very similar to 
those of 3-hydroxyflavone (3-HflH).[16]  
The extended conjugation in 4 produces a red-shift of the absorption 
features relative to those found for 3-HflH in CH3CN (Figure B-3).[13] The lowest 
energy band for 4 is found in the visible region with maximum intensity at 409 nm  
(e = 16,600 M-1cm-1) in CH3CN, whereas there is no absorption feature above  
400 nm for 3-HflH. In 1:1 H2O:DMSO, 4 exhibits similar absorption features but 
with overall lower intensity (Figure B-3). Excitation into any of the absorption 
features exhibited by 4 in CH3CN produces a single broad emission feature 
centered at 582 nm (Figure B-4). Based on literature precedent for 3-HflH, the 
large Stokes shift (³ 177 nm) suggests the formation of an excited state 
tautomeric form wherein intramolecular proton transfer has occurred to give a 
zwitterionic species. [17] When dissolved in 1:1 H2O:DMSO and excited in the 
lowest energy absorption band, 4 exhibits two emission bands at 475 and 582 
nm, respectively (Figure B-5). The former is of relatively low intensity and likely 
represents emission from an excited state normal form of the molecule, whereas  
the latter matches the emission feature produced in organic solvent.[17]  
Solutions of 4 in acetonitrile, 1:1 H2O:DMSO, or cell culture media (RPMI-
1640; pH = 7.4) are stable in the presence of ambient O2 for >2 weeks when 
protected from light. Exposure of an aerobic CH3CN solution of 4 to visible light 




headspace analysis and the formation of 3-(benzoyloxy)-2-naphthoic acid (5, 




does not exhibit any emission features in the visible region (Figure B-10). The 
quantum yield for the CO-release reaction of 4 is 0.007(3). The same reaction 
occurs in methanol (Figure B-8) and 1:1 H2O:DMSO as determined by 1H NMR 
and GC head space gas analysis. Control reactions indicate that both O2 and 
visible light are needed for the CO release reaction of 4. An 18O2 labeling 
experiment demonstrates that both oxygen atoms from O2 are incorporated into 
the organic photoproduct. Compound 4 exhibits several features that suggest 
that it could be a useful CO release agent in biological systems. First, it exhibits 
minimal toxicity, as determined by MTT cell viability assays using A549 cells (IC50 
= 41.5 μM; Figure B-11), and the organic product remaining following CO release 












prior to CO release. The cellular uptake properties of 4 were evaluated in A549 
cells, which were exposed to Hoechst stain for 10 minutes (to enable 
visualization of nuclei), followed by incubation with 4 for 1 hour in the dark. 
Fluorescence microscopy images (Figure 3-3; Figure B-12) of the cells were 
collected after 30 seconds, 3 minutes, and 10 minutes of visible light exposure.[18]  
The observed green emission at the first two time points provides 
evidence that 4 is taken up by almost all cells. The compound is not associated 
with the plasma membrane, but is distributed throughout the cytoplasm and 
appears to concentrate around the nucleus. Importantly, continued exposure of 
the cells to visible light results in a decrease in the observed green fluorescence 
of the compound after three minutes, with complete loss after ten minutes. This 
observation provides strong evidence for the photoinduced cleavage of the 3-
hydroxy-4-pyrone ring and CO release reactivity within the cells as the 
photoproduct does not display any emission. It should be noted that use of the 
intracellular CO probe COP-1 is not feasible in this system because the emission 
of 4, which disappears upon CO release, overlaps with the emission feature of 
CO-incorporated COP-1. [19]  
A key feature of the structural motif of 4 that distinguishes it from all 
previously described organic photoCORMs is the ease with which structural 
modifications can be introduced to tune its physical properties. For example, a 
dialkylamino substituent can be incorporated on the phenyl ring or the carbonyl 




the therapeutic window. Dialkylamino-substituted flavonols have been previously 
used as 
 
Figure 3-3. Fluorescence microscopy images of human lung cancer (A549) cells 
treated with 4 for 1 hr, then exposed to visible light (X-Cite 120 LED light source 
(Lumen Dynamics) with a 120-watt lamp used at 18% power (~4 x 1016 
photons/sec) and 38HE filter) for a) 30 sec, b) 3 min, and c) 10 min.[18] Pictures 
represent overlay images for fluorescence detection of 4 (green) and the nuclear 
Hoechst stain (blue). Loss of fluorescence with increasing length of exposure to 




for separate images of each detection channel and the complete field of view 
observed. 
environment-sensitive probes in biological systems.[20] However, neutral flavonols 
of this type have not been previously shown to exhibit photoinduced CO-
releasing reactivity. Flavothiones, have been reported to undergo O2-dependent 
photodegradation to give non-toxic byproducts, but these reactions have not 
been fully explored in terms of product identification.[21] Molecules 6-8 (Figure 3-
4) were easily prepared using standard synthetic methods and were isolated in 
analytically pure forms via precipitation. Each compound was characterized by 
elemental analysis, UV-vis, fluorescence, IR, and mass spectrometry (Figure B-
13 – B-21). These molecules exhibit red-shifted absorption features and higher 
molar absorptivity values than were observed for 4 (Figure 3-4). Quantitative CO 
release occurs when aerobic CH3CN solutions of 6-8 are exposed to visible light 
(6,7: 419 nm; 8: >546 nm) (Table 3-1). For 6 and 7, O2-incorporated organic 
products akin to that found in the reaction of 4 were identified by 1H NMR, IR, 
and mass spectral analysis (Figures B-22 – B-26). The quantum yield associated 
with the reaction of 7 is significantly enhanced relative to that found for 4. The 
reaction involving 8 is noteworthy in that, while a full equivalent of CO is released 
under aerobic conditions, significant light-induced CO release reactivity (0.32(7) 
eq) also occurs under anaerobic conditions. Both the aerobic and anaerobic 
pathways for CO release from 8 result in the production of a mixture of products, 




B-27 – B28). Photoinduced CO-release also occurs when 6-8 are dissolved in 
other solvents, including DMSO and 1:1 H2O:DMSO. 
 
Figure 3-4. (top) Synthetic procedures for 6-8. (bottom) Absorption spectra of 4 








The use of a 3-hydroxyflavone-based structural motif offers many 
advantages in terms of photoCORM design. Compounds of this type can be 
prepared and isolated in analytically pure form using simple organic chemistry. 
Compounds 4 and 6-8 are soluble in organic solvents as well as aqueous DMSO. 
Solutions of these compounds are stable with respect to O2 for weeks when 
protected from light. CO release is triggered under aerobic conditions by the 
introduction of visible light, the wavelength of which can be tuned through 
structural modification of the molecule. A representative example of this family of 
compounds (4) exhibits minimal toxicity and its organic byproduct following CO 
release is non-toxic. The fluorescent nature of 4 and analogs makes these 
molecules trackable in cells up to the point of CO-release. The observed 
Table 3-1. CO quantification and quantum yields for the reactions of 4 and 6-8 
with O2 upon illumination with visible light in CH3CN.   
Compound eq. CO[c] F[c] 
4[a] 0.96(2) 0.007(3) 
6[a] 0.99(1) 0.006(1) 
7[a] 1.00(1) 0.426(3) 
8[b] 1.00(1) [d] 
8[b] 0.32(7)[e] [d] 
[a] Measured using 419 nm light. [b] Measured using >546 nm light. [c]Reported 
values are the average of three independent trials. [d]Not reported due to 





photoinduced reactivity of 6-8 demonstrates that structural modifications can be 
made without loss of the CO-release reactivity, and that both aerobic and 
anaerobic CO-release reaction pathways can be accessed. Overall, this family of 
compounds thus meets key criteria set forth for next generation photoCORMs. 
Further evaluation of the applications of these novel molecules and analogs for 




Chemicals and Reagents 
All chemicals and reagents were obtained from commercial sources and 
used as received unless otherwise noted. Anaerobic procedures were performed 
under N2 in a VAC Atmosphere glovebox. Solvents for glovebox use were dried 
according to published methods and distilled under N2.[22]  
 
Physical Methods 
1H and 13C{1H} NMR spectra (in ppm) were collected using JEOL ECX-
300 MHz spectrometer and are referenced to the residual solvent peak in CDCl3 
(1H: 7.26 (singlet) ppm; 13C 77.16 (singlet) ppm). J values are given in Hz. IR 
spectra were collected using a Shimadzu FTIR-8400 spectrometer. UV-vis 




diode array spectrophotometer. Fluorescence emission spectra were collected 
using a Shimadzu RF-530XPC spectrometer in the range of 400-800 nm, with 
the excitation wavelength corresponding to the absorption maxima of the 
molecules. The excitation and emission slit widths were set at 1.5 nm for all 
molecules. Mass spectral data was collected at the Mass Spectrometry Facility, 
University of California, Riverside. ESI/APCI mass spectra were recorded on an 
Agilent LCTOF (2006) with a Windows XP based operating system. Elemental 
analyses were performed by Atlantic Microlab, Inc., Norcross, GA, using a 
PE2400 automatic analyzer. A Rayonett photoreactor equipped with either RPR-
4190A or white light lamps with 546 nm cutoff filters were used for all 
photochemical reactions. Quantum yields were determined using potassium 
ferrioxalate or potassium reinekate as standards to measure photon flux.[23] 
Carbon monoxide was quantified as previously described.[24]  
1-(3-hydroxynaphthalen-2-yl)ethenone. 2-hydroxynaphthoic acid 
(1.8818 g, 10 mmol) was dissolved in dry, freshly distilled THF (40 mL). This 
solution was purged with N2 and subsequently cooled to 0 °C using an ice bath. 
Methyllithium (30 mmol, 18.7 mL, 1.6 M in hexanes) was then slowly added in 
aliquots via air-tight syringe. The reaction was allowed to stir at 0 °C for 3 hours 
and then quenched with 0.5 M HCl dropwise until any frothing ceased. The THF 
was then removed under reduced pressure and 0.5 M HCl (60 mL) was added to 
the residue. The acidic aqueous solution was then extracted using 




sodium sulfate, filtered, and the solvent was then removed under reduced 
pressure yielding the product as a bright yellow solid (1.84 g, 99%). 1H NMR 
(CDCl3, 300 MHz) δ 11.54 (s, 1H), 8.35 (s, 1H), 7.79 (d, J = 6.0 Hz, 1H), 7.65 (d, 
J = 6.0 Hz, 1H), 7.50 (t, J = 5.1 Hz, 1H), 7.32 (t, J = 5.1 Hz, 1H), 7.24 (s, 1H), 
2.78 (s, 3H) ppm. 13C NMR (CDCl3, 100 MHz) 204.9, 157.3, 138.4, 133.7, 129.8, 
129.5, 127.0, 126.4, 124.2, 121.5, 112.4, 27.1 ppm (12 signals expected and 
observed). Melting point 111-113 °C. The 13C NMR and melting point data are 
consistent with reported literature values.[25]  
3-Hydroxy-2-phenyl-benzo[g]chromen-4-one (4). Sodium hydroxide (21 
mL. 5M, 104 mmol) was added to a suspension of 1-(3-hydroxynaphthalen-2-
yl)ethanone (3.90 g, 21 mmol) in ethanol (60 mL) and allowed to stir for 30 
minutes at room temperature. Benzaldehyde (2.14 mL, 21 mmol) was added to 
the reaction and the resulting mixture was stirred for 5 hours resulting in the 
formation of a dark red solution. The reaction was then cooled to 0 °C in an ice 
bath, hydrogen peroxide (7.6 mL, 30%) was added drop-wise, and the resulting 
mixture was stirred overnight while warming to room temperature. Acidification of 
the solution to pH = 6.5 with 0.5 M HCl resulted in the formation of a bright yellow 
precipitate which was isolated by filtration and washed with ethanol (3.74 g, 
62%). 1H NMR (CDCl3, 300 MHz) δ 8.88 (s, 1H), 8.35 (d, J = 5.4 Hz, 2H), 8.08 (t, 
J = 3.6 Hz, 2H), 7.95 (d, J = 6.3 Hz, 1H), 7.67 – 7.45 (m, 5H), 6.93 (s, 1H) ppm. 
13C NMR (CDCl3, 100 MHz) 174.6, 151.7, 145.8, 137.3, 136.1, 131.4, 130.5, 




signals expected and observed). FTIR (KBr, cm-1) 3290 (νO-H), 1596 (νC=O). UV-
vis (CH3CN, nm) (ε, M-1cm-1) 409 (16,600), 392 (15,900), 345 (22,800). Melting 
point 208-210 °C.  Anal. Calc. C19H12O3: C, 79.16; H, 4.20. Found: C, 78.96; H, 
4.23. ESI/APCI-MS (relative intensity) calcd. for C19H13O3 [MH]+: 289.0859; 
found: 289.0866 (100%).  
Photoreactivity of 4 in the presence of O2. Production of 3-
(benzoyloxy)-2-naphthoic acid (5). A solution of 4 (~0.05 mmol) in 5.0 mL 
CH3CN was placed in a 50 mL round bottom flask under air. The solution was 
then placed in a Rayonette photoreactor equipped with 419 nm lamps and was 
irradiated until the reaction was determined complete as evidenced by the 
disappearance of the lowest energy absorption band. The solvent was then 
removed under reduced pressure yielding an off-white solid (100%). 1H NMR 
(CDCl3, 300 MHz) δ 8.73 (s, 1H), 8.25 (d, J = 7.5, 2H), 7.98 (d, J = 7.8, 1H), 7.86 
(d, J = 7.8, 1H), 7.72 - 7.46 (m, 6H) ppm. FT-IR (KBr, cm-1) 1743 (νC=O). 
ESI/APCI-MS (relative intensity) calcd. for C18H13O4 [MH]+: 293.0808; found: 
293.0811 (83%). 
18O-labeling studies. Aliquots of 18O2 were transferred into a frozen 
CH3CN solution of 4 in a 100 mL solvent transfer flask followed by irradiation at 
419 nm and removal of the solvent under reduced pressure. ESI/APCI-MS 





Dark Control Reaction. A solution of 4 in CD3CN (~3 mM) was prepared 
in air under minimal red light and placed in an NMR tube. The NMR tube was 
then covered with foil, placed in a photo reactor, and irradiated using 419 nm 
lamps for 24 hours. Evaluation of the solution by 1H NMR indicated that no 
reaction had occurred.  
Anaerobic Control Reaction. A solution of 4 in CD3CN (~3 mM) was 
prepared under N2 in a glove box and placed in an NMR tube. The NMR tube 
was then placed in a photo reactor and irradiated using 419 nm lamps for 24 
hours. Evaluation of the solution by 1H NMR indicated that no reaction had 
occurred.  
Cell Culture and Viability Assays. Jurkat (JM) cells were maintained as 
previously described by Shorey et al.[26] A549 human adenocarcinoma cells 
(ATCC, Manassas, VA) cells were grown in DMEM/Ham’s F-12 1:1 mixture 
medium supplemented with 10% charcoal-stripped, heat-inactivated fetal bovine 
serum (FBS; Caisson Laboratories, Logan, UT) in a humidified incubator at 37°C 
with 5% CO2.  Cytotoxicity was determined by the colorimetric MTT [3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazoluim bromide] assay as previously 
described.[26] Briefly, 2.1 x 103 cells/ml for A549 cells or 1 x 105 cells/ml for Jurkat 
cells.  Test compounds were prepared in DMSO, then added to culture media for 
a maximum final DMSO concentration not greater than 0.1% (v/v).  After addition 
of test compounds at concentrations ranging from 80 nM to 100 μM, cells were 




outlined previously.[26] All experiments were independently replicated three times, 
and each experimental treatment was performed in triplicate.   
Fluorescence microscopy. A549 cells were maintained in culture as 
described above, then seeded into Millicell E-Z-Slide culture chambers (EMD 
Millipore, Billerica, MA) at an initial density of 7.5 × 104 cells/cm3 and allowed to 
adhere to the chamber slides for 24 hr. The cells were then treated for 1 hr with 
the nuclear dye Hoechst 33342 (0.5% v/v) for 10 min, followed by three washes 
with plain culture media to remove residual dye. All of incubation and wash steps 
described below were performed under minimal red light. A 100 mM stock 
solution of compound 4 was prepared in DMSO and then diluted to a working 
concentration of 2 mM in culture media (DMEM/Ham’s F-12).  The compound 4 
working stock was diluted again to a final concentration of 50 μM in the culture 
chamber media, and the cells were incubated for 1 hr. The culture chamber was 
then gently washed thrice with plain culture media.  Cells were fixed with a 1:10 
(v/v) solution of formaldehyde fixative (Immunochemistry Technologies, 
Bloomington, MN) and culture media for 5 min, then washed twice with plain 
culture media.  Finally, cells were imaged using a Zeiss Axio Observer inverted 
microscope (Carl Zeiss Microscopy, Thornwood, NY) equipped with fluorescence 
detection.  Images were acquired using a 10x objective with excitation λ of 450-
490 nm (BP 470/40 filter) and emission λ of 500-550 nm (BP 525/50 filter) for 
detection of compound 4 in A549 cells following 30 sec, 3 min or 10 min 




fluorescence image was acquired at excitation λ at 365 nm; emission λ of 420-
470nm (BP 445/50 filter).  Acquired images were universally adjusted to enhance 
contrast levels (same settings for all acquired images for each detection channel) 
using Adobe Photoshop CS6 (Adobe, San Jose, CA).   
2-(4-(diethylamino)phenyl)-3-hydroxy-4H-benzo[g]chromen-4-one (6). 
Sodium hydroxide (4.0 mL, 5M, 20 mmol) was added to a suspension of 1-(3-
hydroxynaphthalen-2-yl)ethanone (0.931 g, 5 mmol) in ethanol (14 mL) and the 
resulting mixture was allowed to stir for 30 minutes at room temperature. 4-
diethylaminobenzaldehyde (0.886 g, 5 mmol) was added to the mixture and the 
solution stirred for 24 hours. The reaction mixture was then cooled to 0 °C in an 
ice bath, hydrogen peroxide (3 mL, 30%) added drop-wise, and the solution was 
stirred overnight. Acidification of the solution to pH = 6.5 with 0.5 M HCl caused 
the formation of an orange precipitate. The solid was filtered from solution and 
washed with ethanol   (0.754 g, 42% yield). 1H NMR (CDCl3, 300 MHz) δ 8.83 (s, 
1H), 8.27 (d, J = 9.27 Hz, 2H), 8.06 (d, J = 8.22 Hz, 1H), 8.02 (s, 1H), 7.93(d, J = 
8.22 Hz, 1H), 7.60 (t, J = 7.89 Hz, 1H), 7.51 (t, J = 7.89 Hz, 1H), 6.9 – 6.76 (m, 
3H), 3.48 (q, J = 7.2 Hz, 4H), 1.26 (t, J = 7.2 Hz, 6H) ppm. 13C NMR (CDCl3, 100 
MHz) 173.2, 151.7, 149.4, 147.9, 135.8, 135.7, 130.1, 129.6, 128.6, 127.4, 
126.2, 125.8, 120.6, 117.6, 114.1, 111.2, 44.7, 12.8 ppm (19 signals expected 
and observed). FT-IR (KBr, cm-1) 3270 (νO-H), 1588 (νC=O). UV-vis (CH3CN), nm 
(ε, M-1cm-1) 442 (51,000), 301 (22,100). Melting point 191-192 °C. Anal. Calc. 




ESI/APCI-MS (relative intensity) calcd. for C23H22NO3 [MH]+: 360.1594; found: 
360.1594 (100%). 
Synthesis of 7 and 8. Lawsson’s Reagent (1.01 g, 2.5 mmol) was added 
to a solution of 4 or 6 in toluene (120 mL), thoroughly purged with N2, and 
refluxed for 4 hours producing a dark red solution. The solution was cooled to 
room temperature, filtered, and the solvent removed under reduced. The residual 
solid was washed with methanol and hexanes yielding 7 (61% yield) or 8 (60% 
yield) as a dark orange and dark purple solid respectively.  
3-Hydroxy-2-phenyl-4H-benzo[g]chromene-4-thione (7). 1H NMR 
(CDCl3, 300 MHz) δ 9.15 (s, 1H), 8.61 (bs, 1H), 8.49 (d, J = 8.1 Hz, 2H), 8.17-
8.07 (m, 2H), 7.94 (d, J = 8.4 Hz, 1H), 7.70-7.45 (m, 5H) ppm. 13C NMR (CDCl3, 
100 MHz) δ 189.7, 147.5, 145.4, 142.1, 135.8, 131.4, 131.2, 129.8, 129.6, 129.3, 
129.1, 129.0, 127.3, 126.7, 126.4, 114.8 ppm (17 signals expected, 16 
observed). UV-vis (CH3CN), nm (ε, M-1cm-1) 478 (36,700), 456 (29,600), 376 
(40,300). Melting Point 151-152 °C. Anal. Calc. C19H12O2S·0.1H2O: C, 74.54; H, 
4.02. Found: C, 74.42; H, 4.09. The presence of 0.1 eq H2O was confirmed by 
integration of the peak at 1.56 ppm in the 1H NMR spectrum. ESI/APCI-MS 
(relative intensity) calcd. for C19H13O2S [MH]+: 305.0631; found: 305.0638 
(100%). 
2-(4-(diethylamino)phenyl)-3-hydroxy-4H-benzo[g]chromene-4-thione 




2H), 8.08 (d, J = 8.1 Hz, 1H), 8.03 (s, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.57 (t, J = 
7.5 Hz, 1H), 7.49 (t, J = 7.5 Hz, 1H), 6.82 (d, J = 9.0, 2H), 3.49 (q, J = 7.2 Hz, 
4H), 1.27 (t, J = 7.2 Hz, 6H) ppm. 13C NMR (CDCl3, 100 MHz) 182.6, 150.3, 
147.4, 145.0, 134.9, 131.8, 131.0, 129.6, 129.0, 128.3, 127.2, 126.4, 125.9, 
116.8, 114.0, 111.5, 44.9, 12.8 ppm (19 signals expected, 18 observed). UV-vis 
(CH3CN), nm (ε, M-1cm-1) 544 (85,800), 400 (19,500), 320 (22,800). Melting 
point:  176-177 oC. Anal. Calc. C23H21NO2S: C, 73.57; H, 5.64; N, 3.73. Found: 
C, 73.30; H, 5.79; N, 3.70. ESI/APCI-MS (relative intensity) calcd. for 
C23H22NO2S [MH]+: 376.1366; found: 376.1364 (100%). 
Photoreactivity of 6-8. Identification of 9-11. A solution of each 
molecule 6, 7 and 8 (~0.05 mmol) in 5.0 mL CH3CN was placed in a 50 mL round 
bottom flask under air. The solution was then placed in a Rayonette photoreactor 
equipped with lamps of appropriate wavelength (6,7: 419 nm lamps; 8: white light 
lamps with 546 nm cutoff filters) and irradiated until the reaction was determined 
complete as evidenced by the loss of the lowest energy absorption band (409 - 
544 nm). The solvent was then removed under reduced pressure yielding 
molecules 9-11.  
3-((4-(diethylamino)benzoyl)oxy)-2-naphthoic acid (9). 1H NMR 
(CDCl3, 300 MHz) 8.69 (s, 1H), 8.07 (d, J = 9.0 Hz, 2H), 7.96 (d, J = 8.4 Hz, 1H); 
7.84 (d, J = 8.1 Hz, 1H), 7.68 (s, 1H), 7.61 (t, J = 8.4 Hz, 1H), 7.53 (t, J = 8.1 Hz, 




(t, J = 6.9 Hz, 6H) ppm. FT-IR (KBr, cm-1) 1716 (νC=O). ESI/APCI-MS (relative 
intensity) calcd. for C22H22NO4 [MH]+: 364.1543; found: 364.1544 (100%). 
3-(benzoyloxy)naphthalene-2-carbothioic-O-acid (10). 1H NMR (CDCl3, 
300 MHz) 8.67 (s, 1H), 8.24 (d, J = 7.8 Hz, 2H), 7.99 (d, J = 8.7 Hz, 1H), 7.85 (d, 
J = 7.8 Hz, 1H), 7.76 (s, 1H), 7.72 - 7.39 (m, 5H) ppm. FT-IR (KBr, cm-1) 1704 
(νC=O). ESI/APCI-MS (relative intensity) calcd. for C36H22O6S2Na [2M+Na]+: 
637.0750; found: 637.0757 (37%).  
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SOLUTION OR SOLID - IT DOESN’T MATTER: DIOXYGENASE-TYPE VISIBLE 




A family of zinc flavonolato complexes, [(6-Ph2TPA)Zn(flavonolato)]X, of 
four extended flavonols has been prepared, characterized, and evaluated for 
visible light-induced CO release reactivity. Zinc coordination of each flavonolato 
anion results in a red-shift of the lowest energy absorption feature and in some 
cases enhanced molar absoptivity. The zinc-coordinated flavonolato ligands 
undergo visible light-induced CO release with enhanced reaction quantum yields 
relative to the neutral flavonols. Most notable is the disovery that zinc flavonolato 
derivatives undergo similar visible light-induced CO release reactivity in solution 
and in the solid state. This discovery suggests the possible application of solid 
zinc flavonolato species in applications requiring controlled, light-triggered CO 
release in biological and synthetic applications. 
 
Introduction 
Delivery of controlled amounts of carbon monoxide (CO) is of significant 
current interest both in biology and synthetic chemistry. In humans, CO is 




of the effects of CO have demonstrated its potential to produce a variety of 
beneficial health effects including anti-inflammatory, anti-apoptotic, vasodilation, 
and anti-bacterial effects.2,3 To explore the biology of CO and its possible uses 
as a therapeutic, CO-releasing molecules (CORMs) have been developed for the 
delivery of controlled amounts of CO.4 To date, the majority of CORMs 
investigated have been metal carbonyl compounds (MCCs), with the most 
extensively studied being [Ru(CO)3(glycinate)Cl] (CORM-3).5 This compound 
coordinates to histidine residues of proteins and spontaneously releases CO via 
ligand exchange.6-8 Other MCC CORMs release CO via enzyme-induced 
reactivity9,10, magnetic heating11, or via visible light-induced reactivity 
(photoCORMs).12-14 CORMs that can be controlled in terms of their CO release 
reactivity are especially attractive as they offer the opportunity for localized 
release of CO at specific sites for biological studies or therapeutic purposes. 
To address issues of solubility and concerns regarding the use of redox-
active and heavy metals in MCCs, efforts to encapsulate these compounds in 
micelles, dendrimers, and solid supports have been reported.11,15-19 Efforts to 
develop metal-free organic photoCORMs have also advanced.20-23 The 
development of organic photoCORMs holds significant promise as standard 
approaches employed in medicinal chemistry for tuning and targeting could be 
possible.24-26  
CO-releasing molecules are also of significant current interest for 
applications in synthetic organic chemistry. For example, because of the health 




development of molecules that release CO on demand for synthetic applications, 
such as palladium-catalyzed carbonylation reactions.27-32 The majority of the CO-
release compounds currently being used in synthetic organic applications either 
are used in an ex situ fashion or are used in situ but require the introduction of 
additional reagents, microwave irradiation, or heating to induce CO release. 
An area that has seen little development is that of solid-state coordination 
compounds capable of visible light-induced CO release. Such compounds offer 
the possibility of CO release materials with no soluble byproducts, which could 
have tremendous advantages for both biological and synthetic applications. 
Mascharak recently reported two visible light induced MCC photoCORMs that 
are reported to undergo solid-state CO release.33 However, the quantity of CO 
released and the other products of this reactivity have not been reported.   
 Our laboratory is developing CO release compounds based on the 3-
hydroxy-4-flavone moiety found in naturally occurring flavonols. We recently 
reported a new family of flavonol derivatives (1-4, Figure 4-1) that undergo visible 
light-induced quantitative CO release when dissolved in organic solvents or 
organic/aqueous mixtures in the presence of O2.34 As shown in Table 4-1, this 
class of compounds can be structurally tuned to undergo quantitative CO release 
under aerobic or anaerobic conditions. These flavonol derivatives are fluorescent 
and therefore are trackable in cells. Compound 1 has been demonstrated to 
penetrate cells and then undergo CO release upon exposure to visible light. The 





 Fig 4-1 Structures of flavonol-based CO releasing molecules.  
 














Yes 0.007(3) No 
2 442 
(51,000) 
Yes 0.006(1) No 
3 478 
(36,700) 
Yes 0.426(3) No 
4 544 
(85,500) 
Yes d Yes 
aMost red-shifted absorption feature. bMeasured in acetonitrile in the presence of 
air. cAverage of three independent trials; values in parenthesis represent 
standard error. dQuantum yield for CO release not reported due to concurrent 





center as a means of tuning the reactivity of the CO-releasing moiety. In the 
studies reported herein, we have used a structural template from our laboratory 
that has been employed in studies of other metal flavonolato compounds35-37 to 
evaluate how zinc stabilization of 1-4 affects their CO-release reactivity. Key 
findings include that zinc coordination: (1) red shifts the absorption spectral 
features of the compounds, with some being in the therapeutic window (>650 
nm), (2) significantly enhances the quantum yield for visible-light induced CO 
release, and (3) enables solid-state CO release activity that is identical to the 
reactivity seen in solution. The discovery of light-induced solid-state release 
reactivity is particularly significant as it suggests that solid-state CO-release 
materials based on a zinc flavonolato motif can be developed. Overall, our 
results suggest that the structural motif in 1-4 is a highly versatile CO release unit 






Chemicals and reagents. All chemicals and reagents were obtained from 
commercial sources and used as received unless otherwise noted. The synthesis 
of the extended flavonols 1-4 proceeded as previously reported.34 The 6-Ph2TPA 
(N,N-bis(((6-phenyl-2-pyridyl)methyl)-N-((2-pyridyl)methyl)amine) ligand was 




Physical Methods. Anaerobic procedures were performed in a Vacuum 
Atmospheres glovebox under N2. Solvents for glovebox use were dried according 
to published methods and distilled under N2.36 UV-vis spectra were recorded at 
room temperature using a Hewlett-Packard 8453A diode array 
spectrophotometer. Fluorescence emission spectra were collected using a 
Shimadzu RF-530XPC spectrometer in the range of 400-800 nm with the 
excitation wavelength corresponding to the most red-shifted absorption maximum 
of the compound. Infrared spectra were recorded using a Shimadzu FTIR-8400 
as KBr pellets. 1H NMR spectra (in ppm) are referenced to the residual solvent 
peaks in acetonitrile-d3 (1H: 1.94 (quintet) ppm). J values are given in Hz. Mass 
spectral data was collected at the Mass Spectrometry Facility, University of 
California, Riverside. Elemental analyses were performed by Atlantic Microlab, 
Inc., Norcross, GA, or by Robertson Microlit Laboratories, Ledgewood, NJ. 
Photochemical experiments were performed using a Luzchem photoreactor 
equipped with either RPR-4190A, RPR-5750A, or Sylvania cool white lamps. 
Carbon monoxide quantification was performed by gas chromatography as 
previously described.37 Quantum yields were determined by ferrioxalate or 
potassium reineckate actinometry using an integrative analysis method.38-40 The 
output measured during the quantum yield determination for 5 was 1.46091 x 
1017 photons/sec when illuminated with RPR-4190A lamps and for 6, 7, and 8 
was 6.87824 x 1015 photons/sec when illuminated with white light lamps 




Caution! Perchlorate salts of metal complexes with organic ligands are 
potentially explosive. Only small amounts of material should be prepared, and 
these should be handled with great care.42 
Synthesis of 5-8. In a N2-filled glovebox, a methanolic solution (2 mL) of 
Zn(ClO4)2.6H2O (0.0500 g, 0.134 mmol) was added to solid 6-Ph2TPA (0.0594 g, 
0.134 mmol) and the resulting mixture was stirred until all of the chelate ligand 
dissolved. The solution was then added to a methanolic solution (2 mL) 
containing 1, 2, 3, or 4 (0.134 mmol) and Me4NOH.5H2O (0.0243 g, 0.134 mmol). 
The mixture was allowed to stir for 4 hours at ambient temperature. The solvent 
was then removed under reduced pressure and the residual solid was dissolved 
in CH2Cl2. The solution was then filtered through a Celite/glasswool plug and the 
final product was precipitated by the addition of excess hexanes. Each solid 
product was dried under reduced pressure. 
[(6-PhTPA)Zn(1-)]ClO4 (5). Orange solid (89%). 1H NMR (CD3CN, 300 
MHz) δ 8.62 (d, J = 5.1, 1H), 8.27 (t, J = 1.5, 1H), 8.25 (t, J = 1.5, 1H), 8.21 (d, J 
= 21.6, 2H), 8.03 (m, 2H), 7.96 (t, J = 7.5, 1H), 7.78 (t, J = 7.8, 2H), 7.66 - 7.37 
(m, 9H), 7.33 (d, J = 7.8, 2H), 7.16 - 6.88 (m, 10H), 4.92 (d, J = 14.7, 2H), 4.57 
(d, J = 14.7, 2H), 4.43 (s, 2H) ppm. FTIR (KBr, cm-1) 1094 (νClO4), 622 (νClO4). 
UV-vis (CH3CN) nm (ε, M-1cm-1) 480 (6300), 384 (1700). ESI/APCI-MS, m/z 
(relative intensity) 793.2152, calc. 793.2157 ([M-ClO4]+, 34%). Anal Calc. 
C49H37N4O7ClZn·0.7CH2Cl2: C, 62.56; H, 4.06; N, 5.87. Found: C, 62.62; H, 4.26; 
N, 6.16. The presence and quantity of dichloromethane in the solid sample was 




[(6-Ph2TPA)Zn(2-)]ClO4 (6).Orange-red solid (93%). 1H NMR (CD3CN, 
300 MHz) δ 8.50 (d, J = 4.8 Hz, 1H), 8.31 (d, J = 9.3 Hz, 2H), 8.22 (s, 1H), 8.09 
(s, 1H), 8.05 - 7.93 (m, 2H), 7.85 (t, J = 7.8 Hz, 1H), 7.78 (t, J = 7.5 Hz, 2H), 7.64 
- 7.45 (m, 4H), 7.44 - 7.34 (m, 3H), 7.31 - 7.21 (m, 5H), 7.11 (t, J = 7.5 Hz, 2H), 
7.01 (t J = 7.5 Hz, 4H), 6.80 (d, J = 9.0 Hz, 2H), 4.93 (d, J = 14.4 Hz, 2H), 4.54 
(d, J = 14.4 Hz, 2H), 4.37 (s, 2H), 3.51 (q, J = 7.2 Hz, 4H), 1.24 (t, J = 7.2 Hz, 
6H) ppm. FT-IR (KBr, cm-1) 1088 (νClO4), 618 (νClO4). UV-vis (CH3CN) nm (ε, M-
1cm-1) 524 (80,000). ESI/APCI-MS, m/z (relative intensity) 864.2887, calc. 
864.2882 ([M-ClO4]+, 7%). Anal Calc. C53H46N5O7ClZn.H2O: C, 64.70; H, 4.92; N, 
7.12. Found: C, 64.84; H, 4.63; N, 6.52. The presence and quantity of water in 
the elemental analysis sample was confirmed through integration of the H2O 
resonance in the 1H NMR spectrum. 
[(6-Ph2TPA)Zn(3-)]ClO4 (7).Dark red solid (93%). 1H NMR (CD3CN, 300 
MHz) δ 8.80 (s, 1H), 8.47 - 8.39 (m, 2H), 8.38 - 8.30 (m, 2H), 8.13 (d, J = 9.0 Hz, 
1H), 8.05 (d, J = 9.0 Hz, 1H), 7.85 (t J = 7.8 Hz, 1H), 7.79 (t, J = 7.8 Hz, 2H), 
7.64 (t, J = 6.6 Hz, 1H), 7.60 - 7.52 (m, 4H), 7.43 (t, J = 6.6 Hz, 5H), 7.28 (d, J = 
6.9 Hz, 5H), 7.08 (t, J = 7.2 Hz, 2H), 6.99 (t, J = 7.2 Hz, 4H), 4.82 (bd, J = 14.4 
Hz, 2H), 4.49 (bd, J = 14.4 Hz, 2H), 4.41 (s, 2H) ppm. FT-IR (KBr, cm-1) 1086 
(νClO4), 619 (νClO4). UV-vis (CH3CN) nm (ε, M-1cm-1) 550 (9,300), 396 (7,200). 
ESI/APCI-MS, m/z (relative intensity) 809.1930, calc. 809.1923 ([M-ClO4]+, 25%). 
Anal Calc. C49H37N4O6ClSZn . 0.5H2O . 1CH2Cl2: C, 59.77; H, 4.01; N, 5.58. 




dichloromethane in the elemental analysis sample was confirmed through 
integration of the respective resonances in the 1H NMR spectrum.  
[(6-Ph2TPA)Zn(4-)]ClO4 (8).Dark blue solid (91%). 1H NMR (CD3CN, 300 
MHz) δ 8.69 (s, 1H), 8.58 (d, J = 9.3 Hz, 2H), 8.43 (d, J = 5.4 Hz, 1H), 8.21 (s, 
1H), 8.10 (d, J = 8.1 Hz, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.89 - 7.77 (m, 3H), 7.64 - 
7.42 (m, 10H), 7.38 (t, J = 7.2 Hz, 1H), 7.29 (d, J = 7.8 Hz, 1H), 7.24 - 7.17 (m, 
2H), 7.16 - 7.07 (m, 4H), 6.86 (d, J = 9.3 Hz, 2H), 4.83 (d, J = 13.8 Hz, 2H), 4.49 
(d, J = 13.8 Hz, 2H), 4.41 (s, 2H), 3.54 (q, J = 7.2 Hz, 4H), 1.23 (t, J = 7.2 Hz, 
6H) ppm. FT-IR (KBr, cm-1) 1084 (νClO4), 622 (νClO4). UV-vis (CH3CN) nm (ε, M-
1cm-1) 600 (111,700). ESI/APCI-MS, m/z (relative intensity) 880.2659, calc. 
880.2658 ([M-ClO4]+, 15%). Anal Calc. C53H46N5O6ClSZn.H2O: C, 63.67; H, 4.84; 
N, 7.00. Found: C, 63.37; H, 4.57; N, 6.75. The presence and quantity of water in 
the elemental analysis sample was confirmed through integration of the H2O 
resonance in the 1H NMR spectrum. 
Photoinduced Reactivity of 5-8 in CH3CN. Illumination of aerobic 
CH3CN solutions of 5-8 using visible light (5: 419 nm; 6, 7, 8: >546 nm) results in 
the release of one equivalent of CO (Table 4-2) and the formation of the 
carboxylate derivatives [(6-Ph2TPA)Zn(carboxylate)]ClO4 (9-12) which were 
characterized by 1H NMR, IR, and ESI/MS. 
[(6-Ph2TPA)Zn(((3-benzoyl)oxy)-2-naphthanoate)]ClO4. (9). 1H NMR 
(CD3CN, 300 MHz) δ 8.22 (d, J = 4.5 Hz, 1H), 8.14-7.99 (m, 3H), 7.93-7.78 (m, 
4H), 7.66 (d, J = 7.5 Hz, 2H), 7.64-7.51 (m, 6H), 7.50 - 7.37 (m, 5H), 7.34-7.23 




(nC=O). ESI/APCI-MS, m/z (relative intensity), 797.2113, calc. 797.2201 ([M-
ClO4]+, 35%).  
 
Table 4-2 Properties of 5-8.  





Fc Solid-state CO 
release (eq CO)f 
5 480 
(6300) 
0.94(4) 0.651(2)d 0.96(3) 
6 524 
(80,000) 
0.98(1) 0.583(4)e 0.93(2) 
7 550 
(9300) 
0.92(3) 0.951(4)e 0.97(1) 
8 600 
(111,700) 




(10). 1H NMR (CD3CN, 300 MHz) δ 8.24 (d, J = 5.4 Hz, 1H), 8.15-7.97 (m, 3H), 
7.88-7.77 (m, 2H), 7.68 (t, J = 9.0 Hz, 4H), 7.61-7.50 (m, 4H), 7.49-7.39 (m, 3H), 
7.34-7.24 (m, 2H), 7.21 - 6.84 (m, 9H), 6.60 (d, J = 9.0 Hz, 2H), 4.65-4.27 (m, 
6H), 3.41 (q, J = 7.2 Hz, 4H), 1.15 (t, J = 7.2 Hz, 6H) ppm. FT-IR (KBr, cm-1) 
1722 (νC=O). ESI/APCI-MS, m/z (relative intensity), 868.2870, calc. 868.2836 ([M-
ClO4]+, 3%). 
[(6-Ph2TPA)Zn(3-((benzoyloxy)naphthalene-2-carbothiolate)]ClO4 (11). 
1H NMR (CD3CN, 300 MHz) 8.46 (d, J = 5.4 Hz, 1H), 8.15-7.84 (m, 6H), 7.83-




4H), 7.09 (d, J = 7.8 Hz, 3H), 4.60-4.16 (m, 6H) ppm. FT-IR (KBr, cm-1) 1742 
(νC=O). ESI/APCI-MS, m/z (relative intensity), 813.1889, calc. 813.1872 ([M-
ClO4]+, 100%). 
[(6-Ph2TPA)Zn(3-((4-diethylamino)benoyl)oxy)naphthalene-2-
carbothiolate)]ClO4 (12). 1H NMR (CD3CN, 300 MHz) 8.46 (d, J = 5.1 Hz, 1H), 
8.00 - 7.88 (m, 4H), 7.85 - 7.75 (m, 2H), 7.65 (d, J = 9.3 Hz, 2H), 7.61 - 7.52 (m, 
4H), 7.48 - 7.35 (m, 7H), 7.25 (t, J = 7.8 Hz, 4H), 7.10 (d, J = 7.5 Hz, 4H), 6.68 
(d, J = 9.3 Hz, 2H), 4.62 - 4.28 (m, 6H), 3.51 (q, J = 6.9 Hz, 4H), 1.25 (t, J = 6.9 
Hz, 6H) ppm. FT-IR (KBr, cm-1) 1739 (nC=O). ESI/APCI-MS, m/z (relative 
intensity), 884.2641, calc. 884.2607 ([M-ClO4]+, 50%). 
Control reactions. Solutions of 5-8 (~10 mM) in d3-acetontirile were 
prepared in air under minimal red light and placed in NMR tubes. The tubes were 
then covered with foil and illuminated with white light for 24 hours. Evaluation of 
each solution by 1H NMR indicated that no reaction had occurred. 
Anaerobic control reactions. Solutions of 5-8 (~10 mM) in d3-acetontrile 
were prepared in a Vacuum Atmospheres glovebox under N2 and placed in NMR 
tubes. The caps of the NMR tubes were wrapped securely with Parafilm and the 
tubes were illuminated with white light lamps for 24 hours. Evaluation of the 
samples by 1H NMR indicated that no reaction had occurred. 
CO release quantification of 5-8 in acetonitrile. 50 mL round bottom 
flasks were loaded with 5-8 (ca. 10 mg) dissolved in acetonitrile (5.0 mL). The 




illuminated with white light for 24 hours resulting in bleaching of each solution to 
colorless. A sample (10 mL) of the headspace gas was then analyzed by gas 
chromatography and the area of the peak associated with CO applied to a 
calibration curve created specifically for reactions done in acetonitrile. The 
solvent was then removed under reduced pressure and the residual solid 
analyzed by 1H NMR for completeness of reaction. 
Photoinduced Reactivity of 5-8 as Solids. Compounds 5-8 (ca. 10 mg) 
were loaded into 50 mL round bottom flasks under O2. Exposure of solid 5-8 to 
white light for 48 hours results in clean conversion to 9-12 as determined by 1H 
NMR of the final product. Additionally, the color of the solid compounds changed 
to beige. 
Results 
The development of CO-releasing structural motifs that can be easily 
prepared and tuned via multiple strategies (e.g. organic synthesis and/or metal 
coordination) offers advantages toward the development of compounds that can 
be applied in biology and synthesis. Our approach focuses on the use of 
extended 3-hydroxy-4-pyrone based frameworks which are easily structurally 
modified to modulate spectroscopic and CO release properties. The presence of 
the 3-hydroxy-4-pyrone unit also offers the possibility of metal coordination. 
Compounds 5-8 were prepared via the approach shown in Scheme 4-1. Each 
was obtained in high yield as an analytically pure solid following precipitation 






member of this family of compounds, the 1H NMR spectral features of 5-8 
(Figures C-1, C-6, C-11, and C-16) suggest a mononuclear pseudo-octahedral 
Zn(II) center with the flavonolato ligand positioned between the phenyl-appended 
pyridyl donors of the 6-Ph2TPA ligand. Evidence for this type of structure is the 
1H NMR features of the benzylic hydrogens which are consistent with Cs (mirror 
plane) symmetry in the cation. When dissolved in CH3CN, each compound 
exhibits a molecular ion consistent with the proposed mononuclear formulation 
(Figures C-5, C-10, C-15, and C-20). The outer sphere ClO4- is evidenced in the 
solid state IR spectra of the compounds (Figures C-2, C-7, C-12, and C-17).  
Each compound 5-8 exhibits a ~60-90 nm red-shift for the lowest energy 
absorption feature relative to neutral 1-4 (Tables 4-1 and 4-2; Figures C-3, C-8, 












energy absorption band than the neutral flavonols, those of the NEt2-substituted 
6 and 8 are enhanced relative to the neutral flavonols. In terms of previously 
reported photoCORMs, the molar absorptivity values of 6-8 at >500 nm exceed 
those exhibited by molecular metal carbonyl photoCORMs that absorb above 
500 nm.12 aMost red-shifted absorption feature.b Compound dissolved in 
acetonitrile in the presence of O2. CO quantification performed by GC after 
illumination with 419 nm lamps (5) or white light lamps equipped with 546 nm cut 
off filters (6, 7, 8) for 24 h. Average CO release of three independent samples; 
values in parentheses represent standard error. cAverage of three independent 
trials; values in parenthesis represent standard error. dF obtained for solution 
(CH3CN) CO release via illumination using 419 nm lamps and potassium 
ferrioxalate actinometer. eF obtained for solution (CH3CN) CO release via 
illumination with white light lamps equipped with 546 nm cut off filters and 
potassium reineckate actinometer. fPowdered compound in the presence of O2. 
CO quantification performed by GC after illumination with 419 nm light (5) or 
white light lamps equipped with 546 nm cut off filters (6, 7, 8) for 48 h. Average 
CO release of two independent samples; values in parentheses represent 
standard error. 
Compounds 6 and 8 have molar absorptivity values at >500 nm that 
exceed all organic photoCORMs20-23, including recently reported BODIPY 
derivatives.20 Illumination into the lowest energy absorption band of 5-8 produces 




and C-19). The sulfur-containing 7 and 8 exhibit smaller Stokes shifts relative to 
the oxygen analogs.   
 
Photoinduced O2 reactivity of 5-8 in CH3CN 
Illumination of CH3CN solutions of 5-8 with visible light results in the 
release of one equivalent of CO and the clean formation of a single zinc 
carboxylate compound (9-12; Scheme 4-2) as determined by 1H NMR, IR, and 
ESI-MS. The1H NMR spectra of 9-12 again exhibit features for the benzylic 
hydrogens consistent with Cs symmetry (Figures C-21, C-25, C-28, C-31). 






Scheme 4-2 Visible light induced CO release reactivity of 5-8 in CH3CN or the 




of mononuclear carboxylate compounds that have resulted from dioxygenase-
type reactivity and CO-release (IR: Figures C-22, C-26, C-29, C-32; ESI/APCI: 
Figures C-23, C-27, C-30, C-33). The incorporation of two oxygen atoms from O2 
into the product is also evidenced by the reaction of 5 in the presence of 18O2, 
which yields 9 containing two labeled oxygen atoms (ESI/APCI MS Figure C-24). 
The reaction quantum yields for CO-release from 9-12 (Table 4-2) in CH3CN 
significantly exceed those exhibited by the neutral flavonols 5-7, metal carbonyl 
photoCORMs12, and all reported neutral organic photoCORMs20-23.  
 
Solid-state photoinduced CO release reactivity of 5-8 
Light induced CO release compounds offer the possibility of control over 
the temporal and spatial release of CO. To date, compounds developed for 
biological and in situ synthetic applications have focused on soluble species. 
However, insoluble solid-state materials or compounds that release CO upon 
introduction of visible light could also be very useful in various applications 
including in implantable systems and for CO release within reaction mixtures. 
Visible and near infra-red light-driven NO-releasing solid-state materials 
(photoNORMs) have been previously developed for biological applications.43-51 A 
current limitation in terms of photoCORM development is the almost complete 
lack of availability of compounds that exhibit solid state CO release reactivity 
upon illumination with visible light. Recently, Mascharak, et al. reported two Mn(I) 




microscope light. However, these compounds were not characterized in terms of 
the amount of CO released or the products remaining following CO release.33  
To our knowledge, solid-state light-induced CO release has not been 
previously reported for flavonol or metal flavonolato complexes.52 Notably, we 
have discovered that exposure of powders of 5-8 to visible light in the presence 
of O2 for 48 h results in quantitative CO release (Table 4-2). Analysis of the 
remaining beige powders following light illumination via 1H NMR in CD3CN 
indicates the clean formation of 9-12. Thus, the same reactivity is observed for 5-
8 both in solution and in the solid state. It is essential to note that the neutral 
flavonols 1-4 are unreactive as solids upon extended illumination (one week) with 
visible light. Both the neutral flavonols (1-4) and the zinc flavonolato derivatives 
(5-8) are also unreactive as solids under anaerobic conditions.  
 
Conclusions 
The dioxygenase-type CO release chemistry of metal complexes of 3-
hydroxy-4-pyrone derivatives (flavonols) has received considerable attention due 
to its relevance to quercetin dioxygenase enzymes.53-60 Our discovery of light-
induced CO release chemistry for divalent metal flavonolato compounds37,38 has 
spurred us to further evaluate the light-induced CO release reactivity of flavonol 
and flavonolato species for applications as photoCORMs. Construction of the 
extended 3-hydroxy-4-pyrone derivatives 1-4 led to the discovery that unlike 
neutral 3-hydroxyflavone52, which undergoes multiple types of reactions upon 




dioxygenase-type visible-light induced CO release in the presence of O2.34 In this 
contribution we have evaluated how stabilizing the flavonolato anion of 1-4 via 
zinc coordination affects the CO release chemistry. Importantly, we have 
discovered that zinc coordination results in a red-shift of the absorption features, 
with 8 exhibiting a large absorption feature that extends into the therapeutic 
window (>650 nm). The reaction quantum yields for CO release are enhanced in 
the flavonolato derivatives relative to the neutral flavonols, in some cases by two 
orders of magnitude. Perhaps most importantly, the flavonolato derivatives 
exhibit CO release both in solution and in the solid state. Overall, these results 
demonstrate that 3-hydroxy-4-pyrone (flavonol) derivatives are tunable using 
both organic and inorganic approaches for the development of light-driven CO-
releasing molecules. The ease with which structural modifications can be made 
positions this family of CO release molecules to contribute to various goals in 
understanding the biological effects of CO. Specifically, the tunability of the 
quantum yield in flavanol/flavonolato derivatives suggests that such compounds 
could be used to deliver various fluxes of CO under site and temporal control. 
The discovery of light-induced solid-state release reactivity in 9-12 also opens up 
the opportunity for the development of metal flavonolato-based solid-state CO-
releasing materials that can be triggered using visible light. Such materials could 
be useful for antibacterial applications61 and well as CO release in synthesis (e.g. 
carbonylation chemistry). We note that replacement of the 6-Ph2TPA ligand with 
other supporting ligands dramatically affects the organic and aqueous solubility 




retained. Studies of applications of various compounds of this class are currently 
in progress in our laboratory.  
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SOLUTION OR SOLID - IT DOESN’T MATTER: VISIBLE-LIGHT INDUCED CO 
RELEASE REACTIVITY OF ZINC FLAVONOLATO COMPLEXES 
 
Abstract 
 Zinc flavonolato complexes, Zn(flavonolato)2, of four extended flavonols 
have been prepared, characterized, and evaluated for visible light-induced CO 
release reactivity. Zinc coordination of each flavonolato anion results in a red-
shift of the lowest energy absorption feature and in some cases enhanced molar 
absorptivity relative to the free flavonol. The zinc-coordinated flavonolato ligands 
undergo visible light-induced CO release producing 2 equivalents of CO per 
equivalent of compound. Most notable is the discovery that zinc flavonolato 
derivatives undergo similar visible light-induced CO release reactivity in solution 
and in the solid state. A solid film of a Zn(flavonolato)2 derivative was evaluated 
as an in situ CO release agent for aerobic oxidative palladium-catalyzed 
alkoxycarbonylation to produce esters in ethanol. The CO release product was 




Delivery of controlled amounts of carbon monoxide (CO) is of 




humans, CO is produced endogenously via the enzyme-catalyzed 
breakdown of heme.1 Studies of the effects of CO have demonstrated its 
potential to produce a variety of beneficial health outcomes including anti-
inflammatory, anti-apoptotic, vasodilation, and anti-bacterial effects.2-3 To 
explore the biology of CO and its possible uses as a therapeutic, CO-
releasing molecules (CORMs) have been developed for the delivery of 
controlled amounts of CO.4 To date, the majority of CORMs investigated 
have been metal carbonyl compounds (MCCs), with the most extensively 
studied being [Ru(CO)3(glycinate)Cl] (CORM-3).5 This compound 
coordinated to histidine residues of proteins and spontaneously releases 
CO via ligand exchange.6-8 Other MCC CORMs release CO via enzyme-
induced reactivity9,10, magnetic heating11, or via visible light-induced 
reactivity (photoCORMs).12-14 CORMs that can be easily controlled in terms 
of their CO release reactivity are especially attractive as they offer the 
opportunity for localized release of CO at specific sites for biological 
studies or therapeutic purposes.  
To address issues of solubility and concerns regarding the use of 
redox-active and heavy metals in MCCs, efforts to encapsulate these 
compounds in micelles, dendrimers, and solid supports have been 
reported.11, 15-19 Efforts to develop metal-free organic photoCORMs have 
also advanced.20-23 The development of organic photoCORMs holds 
significant promise as standard approaches employed in medical chemistry 




CO-releasing molecules are also of significant current interest for 
applications in synthetic organic chemistry. Due to the health hazards of 
handling CO gas, efforts in recent years have focused on the development 
of molecules that release CO on demand for synthetic applications, such 
as palladium-catalyzed carbonylation reactions.27-32 The majority of the CO 
release compounds currently being used in synthetic organic application 
wither are used in an ex situ fashion or are used in situ but require the 
introduction of additional reagents, microwave irradiation, or heating to 
induce CO release. Ex situ approaches require either the use of 
specialized two-chamber glassware to separate the CO-generation process 
from the substrate reaction chamber27-31-, or manual transfer of the gas 
(e.g. via a balloon).32 In situ sources for CO have also been previously 
reported. These include metal carbonyls (e.g. Mo(CO)6), which can serve 
as in situ CO release agents for palladium-catalyzed carbonylations, albeit 
not at a stoichiometric level with respect to CO.33-43 When metal carbonyls 
are used, additional reagents, high temperatures and/or microwave 
assistance are generally needed for CO release. It is also important to note 
that low-valent metal carbonyls typically cannot be used in situ for 
substrates containing functional groups that can be reduced (e.g. –NO2 
derivatives) due to the reducing nature of the low-valent metal complex.34-
40, 44 Two chamber systems can be used to address this issue.45 
Formamides46 (including N-formylsaccharin47,48), formats, and formic 




been recently investigated as in situ CO release agents at near 
stoichiometric levels. However, all of these CO release compounds require 
either significant heat (formamides and formic acids, diethylpyrocarbonate), 
or the presence of additional reagents (e.g. N-formylsaccharin (mild base 
or KF); formats (mild base); formic acid (strongly acidic conditions); CHCl3 
(metal hydroxide) to induce CO release. 
An area that has seen little development is that of solid compounds 
capable of visible light-induced CO release. Such compounds could offer 
the possibility of CO release materials that could have tremendous 
advantages for both biological and synthetic applications. Mascharak 
recently reported two visible light-induced MCC photoCORMs that undergo 
solid-state CO release.54 However, the quantity of CO released and the 
byproducts of this reactivity have not been reported.  
Our laboratory is developing visible light-induced CO release 
compounds based on the 3-hydroxy-4-flavone moiety found in naturally 
occurring flavonols. Prior to our work, metal flavonolato species were well 
known to undergo dioxygenase-type degradation to release CO via either 
enzyme catalysis55 or thermal reactivity56 involving O2 activation. However, 
reports of light-driven CO release reactivity involving O2 activation with 
either free or metal-coordinated flavonols were scarce.57 We recently 






undergo dioxygenase-type visible light-induced quantitative CO release 
when dissolved in organic solvents or organic/aqueous mixtures.58 As 
shown in Table 5-1, this class of compounds can be tuned to undergo 
quantitative CO release under aerobic or anaerobic conditions. These 
flavonol derivatives are fluorescent and therefore trackable in cells. 
Compound 1 has been demonstrated to penetrate cells and then undergo 
quantitative CO release upon exposure to visible light. The structural 
framework in 1-4 also offers the opportunity for chelation to a metal center 
as a means of tuning the reactivity of the CO-releasing moiety. In the 
studies reported herein, we have identified key findings related to zinc 




Table 5-1 Properties of 1-4. 
 
aMost red-shifted absorption feature. bMeasured in acetonitrile in the 
presence of air. c Average of three independent trials; values in parenthesis 
represent standard error. dQuantum yield for CO release not reported due 
to concurrent aerobic and anaerobic CO release reactions. 
 
coordination.  The absorption spectral features of the compounds red shift 
with some being in the therapeutic window (>650 nm) and solid-state CO 
release activity can occur that is identical to the reactivity seen in solution. 
The discovery of light-induced solid-state CO release reactivity is 
particularly significant as it suggests that CO release materials based on a 
zinc flavonolato motif could be developed. Building on this discovery, we 
sought to design zinc flavonolato derivatives that are insoluble in organic 
solvents, which could facilitate their use as in situ light-driven CO release 
agents in synthetic organic processes. Our experience with simple Zn(II) 
bis-flavonolato compounds (Zn(flavonolato)2) suggested that such 






































derivatives of this type using 1-4 were synthesized, characterized, and 
evaluated as solid-state CO release agents. As outlined herein, we have 
found that a member of this family can be used in aerobic oxidative 
palladium-catalyzed carbonylation processes that employ O2 as the sole 
oxidant and are performed under very mild conditions.62 Overall, our results 
suggest that the structural motif in 1-4 is a highly versatile CO release unit 






Chemicals and Reagents 
All chemicals and reagents were obtained from commercial sources 
and used as received unless otherwise noted. The synthesis of the 
extended flavonols 1-4 proceeded as previously reported.58 
 
Physical Methods 
Anaerobic procedures were performed in a Vacuum Atmospheres 
glovebox under N2. Solvents for glovebox use were dried according to 
published methods and distilled under N2.64 UV-vis spectra were recorded 
at room temperature using a Hewlett-Packard 8453A diode array 




Shimadzu RF-530XPC spectrometer in the range of 400-800 nm with the 
excitation wavelength corresponding to the most red-shifted absorption 
maximum of the compound. Infrared spectra were recorded using a 
Shimadzu FTIR-8400 as KBr pellets. 1H NMR spectra (in ppm) are 
referenced to the residual solvent peaks in pyridine-d5 (1H: 7.22 (singlet) 
ppm). J values are given in Hz. Mass spectral data was collected at the 
Mass Spectrometry Facility, University of California, Riverside. Elemental 
analyses were performed by Atlantic Microlab, Inc., Norcross, GA, or by 
Robertson Microlit Laboratories, Ledgewood, NJ. Photochemical 
experiments were performed using a Luzchem photoreactor equipped with 
RPR-4190A, RPR5750A, or Sylvania cool white lamps. Carbon monoxide 
quantification were performed by gas chromatography as previously 
described.61  
General Synthetic Method for Zinc Bis(flavonolato) Compounds. 
A 500 mL round bottom flask, protected from light with aluminium foil, was 
charged with the flavonol (21 mmol), Me4NOH·5H2O (21 mmol), and MeOH 
(50 mL) and the resulting mixture was stirred at room temperature for 2 
hours. Zinc triflate (10.3 mmol) was then transferred to the flask using 
MeOH (15 mL). The mixture was stirred overnight after which time the 
product was collected by filtration, washed with water and dried in vacuo. 
Zn(1-)2·4H2O (5). 88% yield. Orange solid. 1H NMR (pyridine-d5, 300 
MHz)   9.35 (d, J = 7.8 Hz, 4H), 8.86 (s, 2H), 8.07 (s, 2H), 7.89 (d, J = 8.4 




UV-vis (pyridine), nm ( , M-1cm-1) 483 (23,300), 375 (7,600), 306 (25,700). 
LIFDI-MS, m/z (relative intensity) 638.0710, calc. 638.0702 ([M]+, 100%). 
Anal. Calc. C38H22O6Zn·4H2O: C, 64.10; H, 4.25. Found: C, 63.48; H, 4.08. 
The presence and quantity of water present in the solid sample was 
confirmed through integration of the water peak in the 1H NMR spectrum. 
Zn(2-)2·2H2O (6). 86% yield. Red Solid. 1H NMR (pyridine-d5, 300 
MHz)   9.37 (d, J = 8.7 Hz, 4H), 9.03 (s, 2H), 8.10 (s, 2H), 7.91 (d, J = 8.1 
Hz, 2H), 7.88 (d, J = 8.7 Hz, 2H), 7.46 (t, J = 8.7 Hz, 2H), 7.34 (t, J = 8.1 
Hz, 2H), 6.94 (d, J = 8.7 Hz, 4H), 3.30 (q, J = 7.2 Hz, 8H), 1.08 (t, J = 7.2 
Hz, 12H) ppm. UV-vis (pyridine), nm ( , M-1cm-1) 525 (92,500), 402 
(17,600), 305 (47,800). LIFDI-MS, m/z (relative intensity) 780.2163, calc. 
780.2172 ([M+], 100%). Anal. Calc. C46H40N2O6Zn·2H2O: C, 67.52; H, 5.42; 
N, 3.42. Found: C, 67.30; H, 5.29; N, 3.50. The presence and quantity of 
water present in the solid sample was confirmed through integration of the 
water peak in the 1H NMR spectrum. 
Zn(3-)2·2H2O (7). 92% yield. Purple solid. 1H NMR (pyridine-d5, 300 
MHz)   9.48 (d, J = 7.5 Hz, 4H), 9.45 (s, 2H), 8.26 (s, 2H), 8.10 (d, J = 8.7 
Hz, 2H), 8.01 (d, J = 8.4 Hz, 2H), 7.70 (t, J = 7.5 Hz, 4H), 7.56-7.43 (m, 6H) 
ppm. UV-vis (pyridine), nm ( , M-1cm-1) 564 (31,700), 405 (27,500), 306 
(22,800). LIFDI-MS, m/z (relative intensity) 670.0259, calc. 670.0246 ([M+], 
72%). Anal. Calc. C38H22O4S2Zn·2H2O: C, 64.45; H, 3.70. Found: C, 64.21; 




was confirmed through integration of the water peak in the 1H NMR 
spectrum. 
Zn(4-)2·2H2O (8). 91% yield. Blue solid. 1H NMR (pyridine-d5, 300 
MHz)   9.55 (d, J = 9.3 Hz, 4H), 9.44 (s, 2H), 8.16 (s, 2H), 8.05 (d, J = 8.1 
Hz, 2H), 7.95 (d, J = 8.7 Hz, 2H), 7.55-7.37 (m, 4H), 6.91 (d, J = 6.9 Hz, 
4H), 3.33 (q, J = 6.9 Hz, 8H), 1.09 (t, J = 6.9 Hz, 12H) ppm. UV-vis 
(pyridine), nm ( , M-1cm-1) 609 (143,300), 303 (52,200). LIFDI-MS, m/z 
(relative intensity) 812.1711, calc. 812.1715 ([M+], 100%). Anal. Calc. 
C46H40N2O4S2Zn·2H2O: C, 64.97; H, 5.22; N, 3.29. Found: C, 64.75; H, 
5.08; N, 3.27. The presence and quantity of water present in the solid 
sample was confirmed through integration of the water peak in the 1H NMR 
spectrum.  
Photoinduced Reactivity of 5-8 in Pyridine. Solutions of 5-8 
(~0.01 mmol) in pyridine-d5 (~0.7 mL) were placed in NMR tubes under air. 
Each tube was then placed in a Luzchem photoreactor equipped with 419 
nm or white light lamps and illuminated until the reaction was determined to 
be complete by 1H NMR. The solvent was then removed under reduced 
pressure and an FT-IR spectrum was obtained. 
Zinc bis(3-benzoyloxy)-2-naphthoate) (9). Beige solid. 1H NMR 
(pyridine-d5, 300 MHz)   9.14 (s, 2H), 8.48 (d, J = 6.9 Hz, 4H), 1H NMR 
(pyridine-d5, 300 MHz) 7.94-7.82 (m, 6H), 7.56-7.37 (m, 10H) ppm. FT-IR 




Zinc bis(3-((4-(diethylamino)benzoyl)oxy)-2-naphthoate) (10). 
Beige solid. 1H NMR (pyridine-d5, 300 MHz)   9.11 (s, 2H), 8.47 (d, J = 7.2 
Hz, 4H), 8.00-7.75 (m, 6H), 7.51-7.26 (m, 4H), 6.71 (d, J = 7.2 Hz, 4H), 
3.19 (q, J = 6.9 Hz, 8H), 0.99 (t, J = 6.9 Hz, 12H) ppm. FT-IR (KBr, cm-1) 
1714 (nC=O) 
Zinc bis(3-(benzoyloxy)naphthalene-2-carbothiolate (11). Beige 
solid. 1H NMR (pyridine-d5, MHz)   9.14 (s, 2H), 8.36 (d, J = 8.6 Hz, 4H), 
7.97 (d, J = 8.1 Hz, 2H), 7.84 (d, J = 8.1 Hz, 2H), 7.79 (s, 2H), 7.55-7.35 
(m, 10H) ppm. FT-IR (KBr, cm-1) 1739 (nC=O). 
Zinc bis(3-(4-(diethylamino)benzoyl)oxy)naphthalene-2-
carbothiolate (12). Beige solid. 1H NMR (pyridine-d5, 300 MHz)   9.06 (s, 
2H), 8.36 (d, J = 7.5 Hz, 4H), 8.00-7.65 (m, 6H), 7.57-7.29 (m, 4H), 6.73 (d, 
J = 7.5 Hz, 4H), 3.26 (q, J = 6.9 Hz, 8H), 1.04 (t, J = 6.9 Hz, 12H) ppm. FT-
IR (KBr, cm-1) 1713 (nC=O). 
Dark control reactions of 5-8. Solutions of 5-8 (~2 mM) in pyridine-
d5 were prepared in air under minimal red light and each was placed in a 
NMR tube. Each NMR tube was then covered in foil, placed in a 
photoreactor, and illuminated using 419 nm (5 and 6) or white light lamps 
(5-8) for 24 hours. Evaluation of each solution by 1H NMR indicated that no 
reaction had occurred. 
Anaerobic control reaction. Solutions of 5-8 in pyridine-d5 were 




each solution for ~5 minutes. Each NMR tube was then placed in a 
photoreactor and illuminated with 419 nm (5 and 6) or white light lamps (5-
8) for 24 hours. Evaluation of each solution by 1H NMR indicated that no 
reaction had occurred.  
CO release quantification of 5-8 in solution. 50 mL round bottom 
flasks were loaded with 5-8 (ca. 10 mg) dissolved in pyridine (5 mL). Each 
flask was then sealed with a septum, purged with O2 for 45 seconds, and 
illuminated with white light for 24 hours, which resulted in the bleaching of 
each solution to colorless. A sample (10 mL) of headspace gas was then 
analyzed by gas chromatography and the area of the peak associated with 
CO applied to a calibration curve created specifically for reactions 
performed in pyridine. The solvent was then removed under reduced 
pressure and the residual solid was analyzed by 1H NMR for completeness 
of reaction.  
Photoreactivity fo 5-8 as powdered solids. Compounds 5-8 were 
placed in 50 mL round bottom flasks as powdered solids. Each flask was 
then sealed with a septum, gently purged with O2 for 1 minute, and placed 
in a photoreactor with 419 nm (5 and 6) or white light lamps (5-8) for 72 
hours. The headspace gas of the flask was then analyzed by gas 
chromatography for the production of CO. Compounds 5 and 6 as 
powdered solids produced 2 equivalents of CO per equivalent of compound 
when illuminated 419 nm or white light lamps.  Compounds 7 and 8 did not 




the flask was then dissolved in pyridine-d5 and the solution evaluated by 1H 
NMR, indicating 5 and 6 had fully converted to the photoproducts 9 and 10, 
while no reaction occurred for 7 and 8. 
Photoreactivity of 5 as a film deposit. Compound 5 (52.6  mol, 
33.7 mg) was deposited in a round bottom flask and dissolved in pyridine 
(~ 10 mL). The solvent was then removed via rotary evaporator using the 
highest rpm setting to deposit the compound on the vessel walls. The flask 
was sealed with a septum and placed in a photoreactor with 419 nm or 
white light lamps and illuminated for 48 hours. Reactions were determined 
to be complete by 1H NMR.  
CO quantification for solid samples 5 and 6. A GC calibration 
curve for the quantification of CO was created using sodium bicarbonate as 
an inert solid in a 50 mL round bottom flask. Each flask was sealed with a 
septum, evacuated, and varying volumes of O2 and CO were injected. For 
each mixture, GC analysis was performed using  the number of moles of 
CO calculated to be in the flask based on volume.  
Aerobic oxidative palladium-catalyzed carbonylation reactions. 
The general reaction conditions were as follows. Compound 5 was 
deposited as a film in a 50 mL round bottom flask as described above. The 
flask was then loaded with phenyl boronic ester (52.6  mol, 10 mg), 
PdCl2(PPh3)2 (2.63  mol, 1.8 mg), NEt3 (105.2  mol, 15  L) and ethanol 
(5 mL, 190 proof). The flask was then sealed with a septum and placed in 




two CFL blue bulbs set at an average distance of 5 cm from the flask for 24 
hours. The flask was removed from the oil bath and allowed to cool to room 
temperature. The reaction mixture was then passed through a short silica 
plug (~600 mg) 1 L of the filtrate was then analyzed by GC-MS. The 
remaining filtrate from the reactions was then brought to dryness under 
reduced pressure and analyzed by 1H NMR. 
GC-MS parameters. GC-MS spectral data was collected on a 
Shimadzu GCMS-QP5000 equipped with an EC-5 column that is 5% 
phenyl:95% methylpolysiloxane with a fused silica coating. The column is 
30 m in length with a 0.25  m coating and 0.25 mm diameter. The injection 
temperature was 185 °C with an interface temperature of 250 °C. The 
column initial temperature was 70 °C with a final temperature of 250 °C 
and a ramp rate of 12 °C/minute. The column inlet pressure was 43.5 kPa 
with a column flow of 0.8 mL/min and a linear velocity of 32.8 cm/sec for a 
total flow of 35.4 mL/min. Analysis of product mixtures was performed on 1 
 L of EtOH solution. 
Evaluation of CO release reactivity of 5 (film deposit) in the 
presence of ethanol. A film deposit of 5 in a 50 mL round bottom flask 
was generated as outlined above. To this flask was added ethanol (5 mL). 
The flask was then sealed with a septum and placed in an oil bath pre-
heated to 40 °C. The flask was illuminated with two CFL blue bulbs set at 
an average distance of 5 cm from the flask for 24 hours. The flask was then 




ethanol solution was then passed through a short silica plug (~600 mg). 
The filtrate was then analyzed by GC-MS, which revealed the formation of 
ethyl benzoate. The remaining filtrate was then brought to dryness under 
reduced pressure and analyzed by 1H NMR.  
 
Results 
The development of CO-releasing structural motifs that can be easily 
prepared and tuned via multiple strategies (e.g. organic synthesis and/or 
metal coordination) offers advantages toward the generation of compounds 
that can be easily applied in biology and synthesis. Our approach focuses 
on the use of extended 3-hydroxy-4-pyrone based frameworks, which are 
easily structurally modified to modulate spectroscopic and CO release 
properties. The presence of the 3-hydroxy-4-pyrone unit also offers the 
possibility of metal coordination. 
Mixing 1-4 with Zn(OTf)2 in MeOH in the presence of base yielded 
precipitates of the analytical formulation [Zn(flavonolato)2·nH2O (5, n=4; 6-
8, n=2; Scheme 5-1). All exhibit poor solubility in common organic solvents 
except pyridine. Each compound was characterized as a solid using 
elemental analysis and FT-IR. 1H NMR, LIFDI-MS, UV-vis, and 
fluorescence spectra (Figures D-1-D-16) were obtained in pyridine. The 1H 





Scheme 5-1 Synthesis of 5-8. 
 
suggesting possible trans water ligands (Scheme 5-1) in a pseudo-
octahedral structure. As shown in Figure 5-2, the absorption features of 5-8 
in pyridine (Table 5-2) span the visible region from ~400-650 nm. The NEt2-
containing derivatives 6 and 8 have high extinction coefficients, consistent 
with the presence of two flavonolato ligands. 
 
Photoinduced O2 reactivity of 5-8 
When dissolved in pyridine and illuminated with white (5-8) or blue 
light (5 and 6), the Zn(II) bis(flavonolato) compounds exhibit dioxygenase- 
type photoinduced release of two equivalents of CO (Table 5-2). The zinc 
containing products (9-12, Scheme 5-2) are bis-carboxylate derivatives 
based on 1H NMR and IR spectral features (Figures D-17-D-24). Thus, 
5, X = O, R = H 
6, X = O, R = NEt2 
7, X = S, R = H 





Fig 5-2 Absorption spectral features of 5-8. 
 
 
Compounds 5-8 dissolved in pyridine (200 µg/mL) 
5   6       7   8   





Scheme 5-2 Visible light induced CO release reactivity of 5-8 in pyridine. 
 
both flavonolato ligands in 5-8 undergo light-induced CO release when 
dissolved in pyridine. We note than Tran and Cohen previously reported 
light-induced reactivity for a zinc bis(flavonothianoato) complex in CHCl3 
but did not report the nature of the products.63 
 
Solid-state photoinduced CO-release reactivity of 5 and 6 
Light induced CO release compounds offer the possibility of control 
over the temporal and spatial release of CO. To date, compounds 
developed for biological and in situ synthetic applications have focused on 
soluble species. However, solid-state materials or compounds that release 
5, X = O, R = H 
6, X = O, R = NEt2 
7, X = S, R = H 
8, X = S, R = NEt2 
9, X = O, R = H 
10, X = O, R = NEt2 
11, X = S, R = H 




CO upon introduction of visible light could also be very useful in various 
applications, including in implantable systems and for CO release within 
reaction mixtures. Visible and near infra-red light-driven NO-releasing solid-
state materials (photoNORMs) have been previously developed for 
biological applications.64-72 A current limitation in terms of development of 
photoCORM materials is the almost complete lack of availability of 
compounds that exhibit solid state CO release reactivity upon illumination 
compounds that will release CO upon illumination of the crystals with 
microscope light. However, these compounds were not characterized in 
terms of the amount of CO released or the products remaining following 
CO release.54 
To our knowledge, solid state light-induced CO release has not been 
previously reported for flavonol or metal flavonolato complexes. Notably, 
we have discovered that exposure of powders of 5 and 6 to visible light in 
the presence of O2 for 48 h results in quantitative CO release (Table 5-2). 
Analysis of the remaining beige powders following light illumination via 1H 
NMR in pyridine-d5 indicated the clean formation of 9 and 10. Thus the 
same reactivity of observed for 5 and 6 both in solution and in the solid 
state. The solid thiocarbonyl derivatives did not exhibit CO release even 
after extensive periods of illumination (1 week). These results demonstrate 
that there are factors that influence solid-state CO release within this family 
of compounds that remain to be determined. It is important to note that the 




week) with visible light. The zinc bis(flavonolato) complexes (5 and 6) are 
unreactive as solids under anaerobic conditions. 
 
Initial evaluation of 5 as a CO source for oxidative palladium 
catalyzed carbonylation in ethanol 
Building on the discovery of solid-state CO release reactivity for 5, 
we performed initial studies to examine the possibility of using this 
compound as an in situ heterogeneous visible light-induced CO release 
agent for oxidative palladium-catalyzed alkoxycarbonylation processes 
such as the reactions outlined in Scheme 5-3. Liu, et al. have previously 
reported that such reactions can be performed using air:CO (ratio 3:1-5:1) 
to give carbonylated products in >70% yield using various alcohols as the 
solvent.62 To our knowledge, CO-releasing molecules have not been 
previously explored as alternatives to CO gas under this type of low 
temperature, aerobic conditions. Our initial screening reactions focused on 
the use of 5 at near stoichiometric level in terms of available CO in 
reactions with boronic esters of varying electronic substituents (Scheme 
3b). For each reaction, a 50 mL round bottom flask was coated with 1 
equivalent of 5 (up to 2 eq CO) as a film via rotary evaporation of a pyridine 
solution of the complex. The boronic ester, NEt3, and PdCl2(PPh3)2 were 
then added along with ethanol (5 mL). Each reaction mixture was heated 





Scheme 5-3 Aerobic palladium catalyzed alkoxycarbonylation reactions. 
The relative yields of the products generated for R” = -NO2 in b) could not 
be determined due to peak overlap in the GC-MS trace. 
 
bulbs to initiate CO release. After 24 hours of heating and illumination, the 
products of the reactions were evaluated using GC-MS and 1H NMR. In the 
reactions of 13a and 13b, the desired carbonylation ester products are 
generated, along with phenol and biphenyl products (Scheme 5-3, Figures 
D-25 and D-26). Generally similar results were obtained for the nitro 
derivative 13c albeit no biphenyl product was identified (Figure D-27). The 




indicates that the CO flux in the reaction mixture needs to be further 
optimized to limit the formation of these oxidation byproducts. However, 
this was not pursued in these reactions due to the additional identification 
of the formation of ethyl benzoate in each reaction mixture. This ester is 
generated via the breakdown of the flavonol-based CO-release product by 
ester alcoholysis (Scheme 5-4). Compound 5 releases ~1 eq of CO after  
 
 






24 hours of illumination of the deposited film (Figure D-28). Quantification 
(via GC-MS) of the ethyl benzoate generated in reaction mixtures shown in  
Scheme 5-4 after 24 hours indicated that ~60-80% of the expected CO-
release product (1 eq) has undergone ethanolysis to produce ethyl 
benzoate. Overall, these results indicate that while the starting 
heterogeneous zinc bis(flavonolato) complex is a viable source of CO for 
carbonylation reactivity, the CO-release product is reactive with alcohols. 
Minimizing this background alcoholysis reactivity of the CO release agent 
so as to obtain cleaner carbonylation reaction product mixtures is the 
subject of ongoing studies. We believe that such studies are justified by the 
combination of the mild reaction conditions and safe CO-handling present 
in these reactions.  
 
Conclusions 
The dioxygenase-type CO-release chemistry of metal complexes of 
3-hydroxy-4-pyrone derivatives (flavonols) has received considerable 
attention due to its relevance to quercetin dioxygenase enzymes.56,73-79 Our 
discovery of light-induced CO-release chemistry for divalent metal 
flavonolato compounds60,61,67 has spurred us to further evaluate the light-
induced CO release reactivity of flavonols and flavonolato species for 
applications as photoCORMs. Construction of the extended 3-hydroxy-4-
pyrone derivatives 1-4 led to the discovery that unlike neutral 3-




illumination with UV light, the neutral extended flavonols undergo clean 
dioxygenase-type visible-light induced CO release in the presence of O2.58 
In this contribution we have evaluated how stabilizing the flavonolato anion 
of 1-4 via zinc coordination affects the CO release chemistry. Importantly, 
we have discovered that zinc coordination results in a red-shift of the 
absorption features, with 8 exhibiting a large absorption feature that 
extends into the therapeutic window (>650 nm). Perhaps most importantly, 
the flavonolato derivatives exhibit CO release both in solution and in the 
solid state. Overall, these results demonstrate that 3-hydroxy-4-pyrone 
(flavonol) derivatives are tunable using both organic and inorganic 
approaches for the development of light-driven CO-releasing molecules. 
The ease with which structural modifications can be made positions this 
family of CO-releasing molecules to contribute to various current goals in 
the biology and chemistry of carbon monoxide. The discovery of light-
induced solid-state CO release reactivity in 5 and 6 also opens up the 
opportunity for the development of metal flavonolato-based solid-state CO-
releasing materials that can be triggered using visible light. As 
demonstrated herein, solid zinc bis(flavonolato) compounds can be used 
as in situ CO-release compounds in oxidative palladium-catalyzed 
carbonylation reactions albeit with some degradation of the CO release 
product. Further studies of the applications of these solids in carbonylation 
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Supplied in large enough doses, carbon monoxide is toxic. This has been 
known since antiquity. It is only relatively recently that carbon monoxide has 
been recognized as an incredibly useful compound with roles in chemical 
reactions and human health. However, the risk associated with using gaseous 
CO has precluded its wide spread application. In order to overcome this difficulty, 
the research community has been developing compounds that are essentially 
storage devises for carbon monoxide that are safe-to-handle and eliminate the 
safety risk associated with the gas. Great strides have been made in this area, 
with numerous compounds earning the moniker of CO-releasing molecules 
(CORMs) having been reported. These compounds have demonstrated the 
feasibility of storing and releasing CO from a compound. Unfortunately, the 
CORMs reported thus far all exhibit significant drawbacks that have hindered the 
further development of this field. In the Berreau Lab, we are interested in the 
development of novel extended flavonols that act as visible light-induced 
CORMs. These compounds, based on a naturally occurring framework, display 
numerous characteristics desirable in a CORM. Couple these characteristics with 
the ease of synthesis and their unprecedented ability to be modified (Figure 6-1) 
and we have identified a class of compounds that has the potential to 





Figure 6-1. The ease of synthesis and potential for analogs of the extended 
flavonol class of compounds. 
 
outlines the means by which modifications to the core structure of flavonols affect 
the visible light-induced CO-releasing properties of this class of compounds. 
The use of visible light to activate CO-releasing molecules was an 





























light-driven CO release from CORMs is typically easier when performed with UV-
light. However, UV-light is also extremely damaging and lacks penetration depth 
into tissue. Therefore, researchers sought to develop CORMs capable of 
triggered CO release using less damaging visible light that also has better tissue 
penetration. A significant number of compounds have been reported that have 
this capability. However, none of these reported compounds can be tuned in 
terms of the wavelength of visible light utilized for the CO release reaction.  
Through simple modifications to the core flavonol structure, we have developed 
CORMs that have absorption features encompassing almost the entire visible 
spectrum (Figure 6-2). Additionally, neutral extended flavonols display numerous 
 
 
Figure 6-2. Ranges of the lowest energy absorption features for the flavonol 





































features desirable in a CO-releasing molecule. For example, the parent 
compound of the neutral extended flavonols displays low toxicity and, 
importantly, the photoremnant is non-toxic and the fluorescence properties of 
these compounds enable tracking of the localization and the CO-release 
reactivity within cells. The ease with which these compounds can be modified to 
absorb across the visible spectrum means that they have significant potential for 
future commercial development. 
The role of carbon monoxide has been implicated in the regulation of a 
wide range of physiological processes. It therefore seems logical that different 
biological processes would require CO at different rates. For light-triggered 
CORMs, the efficiency of the CO release photoreaction is measured in terms of a 
quantum yield, with compounds typically falling somewhere between 0 and 1. A 
compound with a quantum yield of 1 displays 100% photochemical efficiency. We 
have demonstrated that flavonols can be modified to achieve many different 
quantum yields (Figure 6-3). Not only have we developed photoCORMs with the 
highest quantum yields reported to date, we have compounds that display a 
range of different quantum yields. I believe that the principles used to modulate 
the quantum yields of these compounds will have a significant role in their future 
use and development.  
The usefulness of carbon monoxide goes beyond its potential as a 
therapeutic. It is routinely used in numerous synthetic processes as a carbonyl 





Figure 6-3. Ranges of quantum yields for the differing flavonol compounds. 
 
toxicity of the gas required a significant investment in infrastructure in order to 
ensure the safety of workers. Small-scale chemical companies and academic 
institutions lack the capital to ensure its safe usage. In coordinating the extended 
flavonols to zinc, we discovered that the compounds would undergo 
photoinduced CO-release as solids. The discovery of this type of reactivity has 
the potential to expand the use of photoCORMs into the realm of CO sources for 
synthetic reactions. It was with this in mind that the zinc(bis(flavonolato)) 
compounds were developed. Zn(bis(flavonolato)) compounds are notoriously 
insoluble in almost all solvents and the compounds that we developed are no 
different, the exception being pyridine. These compounds were used as a 


























reactions. The discovery of solid-state photoinduced CO-release in these 
compounds has the potential to develop a new use for photoCORMs. 
The future of this work consists of two distinct pathways: (1) the further 
creation of analogs to enhance the biological properties of the compounds (i.e. 
targeting); and (2) the development of different applications for the solid state 
CO-releasing compounds. The results of these future studies will only serve to 
























































Table A-1. Summary of X-ray data collection and refinement. 
 
 3×CH3CN 4×CHCl3 
empirical formula C35H30ClN5O7Zn C44H50Cl4N6O7Zn 
formula weight 733.46 982.07 
crystal system Monoclinic Triclinic 
space group P21/n P-1 
a (Å) 10.7484(2) 11.8486(3) 
b (Å) 17.7387(3) 12.4945(4) 
x (Å) 17.7291(2) 16.2785(5) 
a (deg) 90 88.8622(12) 
b (deg) 105.7229(10) 75.3891(15) 
g (deg) 90 81.2326(16) 
V (Å3) 3253.80(9) 2304.29(12) 
Z 4 2 
density (calcd), Mg m-3 1.497 1.415 
temp (K) 150(1) 150(1) 
crystal size (mm3) 0.38 x 0.23 x 0.08 0.35 x 0.28 x 0.10 
diffractometer Nonius Kappa CCD Nonius Kappa CCD 
Abs. coeff. (mm-1) 0.896 0.821 
2q max (deg) 54.96 50.68 
Reflections collected 14263 15983 
indep. reflections 7433 8410 
variable parameters 443 588 
R1 / wR2b 0.0405/0.0962 0.0490/0.1235 
goodness-of-fit (F2) 1.037 1.027 
largest diff. (e Å-3) 0.919; -0.530  1.106; -0.664 
CCDC number 1006160 1006159 
 
aRadiation used: Mo Ka (l = 0.71073 Å). bR1 = ∑ | |Fo| - |Fc| | / ∑ |Fo|;  





Table A-2. Selected Bond Distances (Å) and Angles (deg) for 3·CH3CN  
and 4·CHCl3a 
3×CH3CN    
Zn(1)-O(1) 1.9834(17) O(1)-Zn(1)-O(2) 81.57(7) 
Zn(1)-O(2) 2.1373(17) O(1)-Zn(1)-N(3) 103.21(7) 
Zn(1)-N(1) 2.186(2) N(3)-Zn(1)-O(2) 174.39(7) 
Zn(1)-N(2) 2.2116(18) O(1)-Zn(1)-N(4) 108.68(7) 
Zn(1)-N(3) 2.1179(19) N(3)-Zn(1)-N(4) 87.76(7) 
Zn(1)-N(4) 2.171(2) O(2)-Zn(1)-N(4) 87.90(7) 
O(1)-C(19) 1.334(3) O(2)-Zn(1)-N(2) 94.34(6) 
O(2)-C(20) 1.249(3) N(4)-Zn(1)-N(2) 77.13(7) 
C(19)-C(20) 1.439(3) N(1)-Zn(1)-N(2) 76.83(7) 
O(1)-Zn(1)-
N(2) 
172.64(7) O(1)-Zn(1)-N(1) 97.19(7) 
N(3)-Zn(1)-
N(2) 




153.95(8) O(2)-Zn(1)-N(1) 93.04(7) 
    
4×CHCl3    
Zn(1)-O(1) 2.020(2) O(1)-Zn(1)-N(6) 106.46(9) 
Zn(1)-O(2) 2.159(2) O(1)-Zn(1)-N(3) 171.00(10) 
Zn(1)-N(2) 2.200(3) N(6)-Zn(1)-N(3) 82.28(11) 
Zn(1)-N(3) 2.144(3) O(1)-Zn(1)-O(2) 80.24(8) 
Zn(1)-N(4) 2.181(3) N(6)-Zn(1)-O(2) 172.05(9) 
Zn(1)-N(6) 2.124(3) N(3)-Zn(1)-O(2) 91.21(10) 
O(1)-C(29) 1.320(4) N(3)-Zn(1)-N(4) 80.08(10) 
O(2)-C(30) 1.254(4) O(2)-Zn(1)-N(4) 91.51(9) 




95.04(11) O(1)-Zn(1)-N(4) 102.80(9) 
N(3)-Zn(1)-
N(2) 
77.30(10) N(6)-Zn(1)-N(4) 82.91(11) 
N(4)-Zn(1)-
N(2) 
157.35(10) O(2)-Zn(1)-N(4)  91.51(9) 
         
aEstimated standard deviations in the last significant figure are given  






Figure A-1. 1H NMR spectrum of [(6-Ph2TPA)Zn(3-Hfl)]ClO4 (1) in CD3CN at 25 





Figure A-2. 1H NMR spectrum of [(TPA)Zn(3-Hfl)]ClO4 (3) in CD3CN at 25 oC.  
Note: The grouping of resonances at ~8.5-9.0 ppm integrates to 6 H’s. This 
indicates that one of the H’s listed for the other aromatic group is located here. 






















Figure A-4. 1H NMR spectrum of [(bnpapa)Zn(3-Hfl)]ClO4 (4) in CD3CN at 25 oC. 
























































Figure B-1. 1H NMR spectrum of 4 in CDCl3. The * indicates the residual signal 

















Figure B-3. Absorption spectra of 4 in dry CH3CN and 1:1 H2O:DMSO, and 3-
































Figure B-6. 1H NMR spectrum of 5 in CDCl3. The * indicates the residual signal 














Figure B-7. a) 1H NMR spectrum of 4 in CD3CN at ambient temperature. b) 1H 
NMR spectrum obtained after irradiation of the sample at 419 nm for 24 h. The 













Figure B-8. a) 1H NMR spectrum of 4 in CD3OD at ambient temperature. b) 1H 
NMR spectrum obtained after irradiation of the sample at 419 nm for 24 h. The 
results indicate conversion to 5. The * indicates the residual signals of the solvent 

















Figure B-10. Emission spectra of 4 and 5 in CH3CN under N2 generated upon 











Figure B-11. Plots of human leukemia (Jurkat) and non-small cell lung 
carcinoma (A549) cell viability versus complex concentration for 4 and its 
photoinduced reaction product (5). IC50 values were determined using a four-
parameter nonlinear regression for assays wherein at least a 50% reduction in 
cell viability was observed, in this case only for A549 cells treated with compound 
4 (IC50 = 41.5 μM).  Values shown represent the average ± SEM of three 







Figure B-12.  Fluorescence microscopy of human lung cancer (A549) cells 
treated with compound 4 and then exposed to visible light. Detection of 
compound 4 (shown above as green) was performed using Zeiss filter set 38: 
excitation λ of 450-490 nm (BP 470/40 filter) and emission λ of 500-550 nm (BP 
525/50 filter).  Following a 1 hr incubation with compound 4, cells were excited 
with visible light for 30 sec, 3 min and 10 min. For localization of the Hoechst 
dye, a single fluorescence image was acquired at excitation λ at 365 nm; 
emission λ of 420-470nm (BP 445/50 filter), shown in blue above (repeated down 
rows for visual comparison).  Overlay images indicated that compound 4 was cell 
permeable, was present in most cells in the field of view, and was localized 
primarily to the cytoplasm.  The apparent loss of fluorescence with increasing 





Figure B-13. 1H NMR spectrum of 6 in CDCl3. The * indicates the residual signal 





















Figure B-16. 1H NMR spectrum of 7 in CDCl3. The * indicates the residual signal 





















Figure B-19. 1H NMR spectrum of 8 in CDCl3. The * indicates the residual signal 






















Figure B-22. 1H NMR spectrum of 9 in CDCl3. The * indicates the residual signal 



















Figure B-24. 1H NMR spectrum of 10 in CDCl3. The * indicates the residual 








Figure B-25. ESI/APCI-MS of 10. The results provide evidence for the oxidized 





Figure B-26. Proposed structure of oxidized disulfide form of 10.  
 
Figure B-27. 1H NMR spectra of 8 demonstrating anaerobic 
photoreactivity. a) Aromatic region of the 1H NMR spectrum of 8 in CD3CN. 
b) 1H NMR spectrum after 24 h of irradiation ( l max > 546 nm) of 8 in 
CD3CN under anaerobic conditions. c) 1H NMR spectrum after 24 h of 








Figure B-28. ESI/APCI-MS of the reaction mixture produced upon irradiation of 8 
in CH3CN  (lmax > 546 nm) under anaerobic conditions. The observed ions 
suggest an isomerization pathway leading to CO release. Under aerobic 






















Figure C-1. 1H NMR of 5 in CD3CN.     
 

























Figure C-3. Absorption spectrum of 5 in acetonitrile. 
 
Figure C-4. Overlay of the lowest energy absorption feature of 5 with the 



































Figure C-6. 1H NMR spectrum of 6 in CD3CN. (* denotes residual solvent) 
 






























Figure C-8. Absorption spectrum of 6 in acetonitrile. 
 
 
Figure C-9. Overlay of the lowest energy absorption feature of 6 with the 





























































Figure C-11. 1H NMR of 7 in CD3CN. 
 


























Figure C-13. Absorption spectrum of 7 in acetonitrile 
Figure C-14. Overlay of the lowest energy absorption feature of 7 with the 































































Figure C-16. 1H NMR of 8 in CD3CN. (* denotes residual solvent) 
 



























Figure C-18. Absorption spectrum of 8 in acetonitrile.
 
Figure C-19. Overlay of the lowest energy absorption feature of 8 with the 




































Figure C-21. 1H NMR of 9 in CD3CN. 
 









































Figure C-25. 1H NMR of 10 in CD3CN. (* denotes residual solvent) 
 








































Figure C-28. 1H NMR of 11 in CD3CN. 
 

































Figure C-31. 1H NMR of 12 in CD3CN. (* denotes residual solvent) 
 






































Figure D-1. 1H NMR of 5 in pyridine-d5 (* indicates solvent peaks).  
 
































Figure D-5. 1H NMR of 6 in pyridine-d5 (* denotes residual solvent peaks). 
 





























Figure D-9. 1H NMR of 7 in pyridine-d5 (* denotes residual solvent peaks). 
 




































Figure D-13. 1H NMR of 8 in pyridine-d5 (* denotes residual solvent peaks). 
 
Figure D-14. FTIR spectrum of 8. 






















































Figure D-17. 1H NMR spectrum of 9 in pyridine-d5. (* denotes residual solvent 
peaks) 
 
























Figure D-19. 1H NMR spectrum of 10 in pyridine-d5 (* denotes residual solvent 
peaks). 
 





















Figure D-21. 1H NMR spectrum of 11 in pyridine-d5 (* denotes residual solvent). 
 


























Figure D-23. 1H NMR spectrum of 12 in pyridine-d5. (* denotes residual solvent) 
 


























Figure D-25. GC-MS results for the carbonylation reaction of 13a using a film of 




Figure D-26. GC-MS results for the carbonylation reaction of 13b using a film of 







Figure D-27. GC-MS results for the carbonylation reaction of 13c using a film of 











Figure D-28. 1H NMR spectrum of 5 in pyridine-d5 (top). 1H NMR spectrum of 
remaining solid following illumination of 5 (film) with two blue CFL bulbs for 24 
hours (middle). 1H NMR spectrum of 9 in pyridine-d5 (bottom) (* denotes residual 
solvent). 
  
5  (in d5-py) 
9 (film) + blue light (24 h) (in d5-py) 
 
5 (film) + blue light (24 h) (in d5-py) 



















Our Ref: DE/GCOO/P7000 
  
07 April 2016 
  
Dear Stacey Anderson, 
Thank you for your correspondence requesting permission to reproduce the 
following article published in our journal in your printed thesis and to be posted in 
your university’s repository. 
Stacey N. Anderson, Mark Noble, Katarzyna Grubel, Brooks Marshall, Atta 
M. Arif & Lisa M. Berreau (2014) Influence of supporting ligand 
microenvironment on the aqueous stability and visible light-induced CO-
release reactivity of zinc flavonolato species, Journal of Coordination 
Chemistry, 67:23-24, 4061-4075, 
We will be pleased to grant permission on the sole condition that you 
acknowledge the original source of publication and insert a reference to the 
article on the Journals website: 
http://www.tandfonline.com/http://www.tandfonline.com/doi/full/10.1080/0095897
2.2014.977272 
This is the authors accepted manuscript of an article published as the version of 
record in Journal of Coordination Chemistry 14 Nov 2014   
  
Please note that this license does not allow you to post our content on any third 
party websites or repositories. 
  






Debbie East– Permissions & Licence Administrator - Journals. 




JOHN WILEY AND SONS LICENSE 
TERMS AND CONDITIONS 
Apr 03, 2016 
This Agreement between Stacey N Anderson ("You") and John Wiley and Sons 
("John Wiley and Sons") consists of your license details and the terms and 




Mar 14, 2016 
Licensed Content Publisher 
John Wiley and Sons 
Licensed Content Publication 
Chemistry - A European Journal 
Licensed Content Title 
Iron Metal–Organic Frameworks MIL-88B and NH2-MIL-88B for the Loading and 
Delivery of the Gasotransmitter Carbon Monoxide 
Licensed Content Author 
Mingyan Ma,Heshmat Noei,Bernd Mienert,Johanna Niesel,Eckhard Bill,Martin 
Muhler,Roland A. Fischer,Yuemin Wang,Ulrich Schatzschneider,Nils Metzler-
Nolte 
Licensed Content Date 
Mar 27, 2013 
Pages 
6 





Print and electronic 
Portion 
Figure/table 
Number of figures/tables 
1 
Original Wiley figure/table number(s) 
Figure 2 
Will you be translating? 
No 
Title of your thesis / dissertation 
SYNTHESIS, CHARACTERIZATION, AND EVALUATION OF FLAVONOL 
COMPOUNDS AS PHOTOINDUCED CARBON MONOXIDE RELEASING 
MOLECULES 





Expected size (number of pages) 
400 
Requestor Location 
Stacey N Anderson 
780 E. 275 N. Apt. #3 
None 
None 
LOGAN, UT 84321 
United States 




Stacey N Anderson 
780 E. 275 N. Apt. #3 
None 
None 
LOGAN, UT 84321 
United States 
Attn: Stacey N Anderson 
Total 
0.00 USD 
Terms and Conditions 
TERMS AND CONDITIONS 
This copyrighted material is owned by or exclusively licensed to John Wiley & 
Sons, Inc. or one of its group companies (each a"Wiley Company") or handled on 
behalf of a society with which a Wiley Company has exclusive publishing rights in 
relation to a particular work (collectively "WILEY"). By clicking "accept" in 
connection with completing this licensing transaction, you agree that the following 
terms and conditions apply to this transaction (along with the billing and payment 
terms and conditions established by the Copyright Clearance Center Inc., 
("CCC's Billing and Payment terms and conditions"), at the time that you opened 
your RightsLink account (these are available at any time at 
http://myaccount.copyright.com). 
 
Terms and Conditions 
The materials you have requested permission to reproduce or reuse (the "Wiley 
Materials") are protected by copyright.  
 
You are hereby granted a personal, non-exclusive, non-sub licensable (on a 
stand-alone basis), non-transferable, worldwide, limited license to reproduce the 
Wiley Materials for the purpose specified in the licensing process. This license, 
and any CONTENT (PDF or image file) purchased as part of your order, is for a 
one-time use only and limited to any maximum distribution number specified in 




must be completed within two years of the date of the grant of this license 
(although copies prepared before the end date may be distributed thereafter). 
The Wiley Materials shall not be used in any other manner or for any other 
purpose, beyond what is granted in the license. Permission is granted subject to 
an appropriate acknowledgement given to the author, title of the 
material/book/journal and the publisher. You shall also duplicate the copyright 
notice that appears in the Wiley publication in your use of the Wiley Material. 
Permission is also granted on the understanding that nowhere in the text is a 
previously published source acknowledged for all or part of this Wiley Material. 
Any third party content is expressly excluded from this permission. 
 
With respect to the Wiley Materials, all rights are reserved. Except as expressly 
granted by the terms of the license, no part of the Wiley Materials may be copied, 
modified, adapted (except for minor reformatting required by the new 
Publication), translated, reproduced, transferred or distributed, in any form or by 
any means, and no derivative works may be made based on the Wiley Materials 
without the prior permission of the respective copyright owner.For STM Signatory 
Publishers clearing permission under the terms of the STM Permissions 
Guidelines only, the terms of the license are extended to include subsequent 
editions and for editions in other languages, provided such editions are for the 
work as a whole in situ and does not involve the separate exploitation of the 
permitted figures or extracts, You may not alter, remove or suppress in any 
manner any copyright, trademark or other notices displayed by the Wiley 
Materials. You may not license, rent, sell, loan, lease, pledge, offer as security, 
transfer or assign the Wiley Materials on a stand-alone basis, or any of the rights 
granted to you hereunder to any other person. 
 
The Wiley Materials and all of the intellectual property rights therein shall at all 
times remain the exclusive property of John Wiley & Sons Inc, the Wiley 
Companies, or their respective licensors, and your interest therein is only that of 
having possession of and the right to reproduce the Wiley Materials pursuant to 
Section 2 herein during the continuance of this Agreement. You agree that you 
own no right, title or interest in or to the Wiley Materials or any of the intellectual 
property rights therein. You shall have no rights hereunder other than the license 
as provided for above in Section 2. No right, license or interest to any trademark, 
trade name, service mark or other branding ("Marks") of WILEY or its licensors is 
granted hereunder, and you agree that you shall not assert any such right, 
license or interest with respect thereto 
 
NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR 
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY, 
EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS 
OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE 
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY 




FOR A PARTICULAR PURPOSE, USABILITY, INTEGRATION OR NON-
INFRINGEMENT AND ALL SUCH WARRANTIES ARE HEREBY EXCLUDED 
BY WILEY AND ITS LICENSORS AND WAIVED BY YOU.  
 
WILEY shall have the right to terminate this Agreement immediately upon breach 
of this Agreement by you. 
 
You shall indemnify, defend and hold harmless WILEY, its Licensors and their 
respective directors, officers, agents and employees, from and against any actual 
or threatened claims, demands, causes of action or proceedings arising from any 
breach of this Agreement by you. 
 
IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR 
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY 
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR 
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN 
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR 
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION, 
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT, 
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT 
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE, 
BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND 
WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY 
OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING 
ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY 
PROVIDED HEREIN.  
 
Should any provision of this Agreement be held by a court of competent 
jurisdiction to be illegal, invalid, or unenforceable, that provision shall be deemed 
amended to achieve as nearly as possible the same economic effect as the 
original provision, and the legality, validity and enforceability of the remaining 
provisions of this Agreement shall not be affected or impaired thereby.  
 
The failure of either party to enforce any term or condition of this Agreement shall 
not constitute a waiver of either party's right to enforce each and every term and 
condition of this Agreement. No breach under this agreement shall be deemed 
waived or excused by either party unless such waiver or consent is in writing 
signed by the party granting such waiver or consent. The waiver by or consent of 
a party to a breach of any provision of this Agreement shall not operate or be 
construed as a waiver of or consent to any other or subsequent breach by such 
other party.  
 
This Agreement may not be assigned (including by operation of law or otherwise) 





Any fee required for this permission shall be non-refundable after thirty (30) days 
from receipt by the CCC. 
 
These terms and conditions together with CCC's Billing and Payment terms and 
conditions (which are incorporated herein) form the entire agreement between 
you and WILEY concerning this licensing transaction and (in the absence of 
fraud) supersedes all prior agreements and representations of the parties, oral or 
written. This Agreement may not be amended except in writing signed by both 
parties. This Agreement shall be binding upon and inure to the benefit of the 
parties' successors, legal representatives, and authorized assigns.  
 
In the event of any conflict between your obligations established by these terms 
and conditions and those established by CCC's Billing and Payment terms and 
conditions, these terms and conditions shall prevail. 
 
WILEY expressly reserves all rights not specifically granted in the combination of 
(i) the license details provided by you and accepted in the course of this licensing 
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment 
terms and conditions. 
 
This Agreement will be void if the Type of Use, Format, Circulation, or Requestor 
Type was misrepresented during the licensing process. 
 
This Agreement shall be governed by and construed in accordance with the laws 
of the State of New York, USA, without regards to such state's conflict of law 
rules. Any legal action, suit or proceeding arising out of or relating to these Terms 
and Conditions or the breach thereof shall be instituted in a court of competent 
jurisdiction in New York County in the State of New York in the United States of 
America and each party hereby consents and submits to the personal jurisdiction 
of such court, waives any objection to venue in such court and consents to 
service of process by registered or certified mail, return receipt requested, at the 
last known address of such party. 
 
WILEY OPEN ACCESS TERMS AND CONDITIONS 
Wiley Publishes Open Access Articles in fully Open Access Journals and in 
Subscription journals offering Online Open. Although most of the fully Open 
Access journals publish open access articles under the terms of the Creative 
Commons Attribution (CC BY) License only, the subscription journals and a few 
of the Open Access Journals offer a choice of Creative Commons Licenses. The 
license type is clearly identified on the article. 
The Creative Commons Attribution License 
The Creative Commons Attribution License (CC-BY) allows users to copy, 
distribute and transmit an article, adapt the article and make commercial use of 
the article. The CC-BY license permits commercial and non- 




The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits 
use, distribution and reproduction in any medium, provided the original work is 
properly cited and is not used for commercial purposes.(see below) 
 
Creative Commons Attribution-Non-Commercial-NoDerivs License 
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-
NC-ND) permits use, distribution and reproduction in any medium, provided the 
original work is properly cited, is not used for commercial purposes and no 
modifications or adaptations are made. (see below) 
Use by commercial "for-profit" organizations 
Use of Wiley Open Access articles for commercial, promotional, or marketing 
purposes requires further explicit permission from Wiley and will be subject to a 
fee. 








v1.10 Last updated September 2015 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the 






ROYAL SOCIETY OF CHEMISTRY LICENSE 
TERMS AND CONDITIONS 
 
Apr 03, 2016 
 
This Agreement between Stacey N Anderson ("You") and Royal Society of 
Chemistry ("Royal Society of Chemistry") consists of your license details and the 





Mar 14, 2016 
Licensed Content Publisher 
Royal Society of Chemistry 
Licensed Content Publication 
Chemical Communications (Cambridge) 
Licensed Content Title 
A photoCORM nanocarrier for CO release using NIR light 
Licensed Content Author 
Agustin E. Pierri,Po-Ju Huang,John V. Garcia,James G. Stanfill,Megan 
Chui,Guang Wu,Nanfeng Zheng,Peter C. Ford 
Licensed Content Date 
Dec 16, 2014 
Licensed Content Volume Number 
51 
Licensed Content Issue Number 
11 






Number of figures/tables/images 
1 
Format 
print and electronic 
Distribution quantity 
100 
Will you be translating? 
no 





Title of the thesis/dissertation 
SYNTHESIS, CHARACTERIZATION, AND EVALUATION OF FLAVONOL 
COMPOUNDS AS PHOTOINDUCED CARBON MONOXIDE RELEASING 
MOLECULES 





Stacey N Anderson 
780 E. 275 N. Apt. #3 
None 
None 
LOGAN, UT 84321 
United States 




Stacey N Anderson 
780 E. 275 N. Apt. #3 
None 
None 
LOGAN, UT 84321 
United States 
Attn: Stacey N Anderson 
Total 
0.00 USD 
Terms and Conditions 
This License Agreement is between {Requestor Name} (“You”) and The Royal 
Society of Chemistry (“RSC”) provided by the Copyright Clearance Center 
(“CCC”). The license consists of your order details, the terms and conditions 
provided by the Royal Society of Chemistry, and the payment terms and 
conditions. 
RSC / TERMS AND CONDITIONS 
INTRODUCTION 
The publisher for this copyrighted material is The Royal Society of Chemistry. By 
clicking “accept” in connection with completing this licensing transaction, you 
agree that the following terms and conditions apply to this transaction (along with 
the Billing and Payment terms and conditions established by CCC, at the time 
that you opened your RightsLink account and that are available at any time at . 
LICENSE GRANTED 
The RSC hereby grants you a non-exclusive license to use the aforementioned 




herein. Reproduction of the material is confined to the purpose and/or media for 
which permission is hereby given. 
RESERVATION OF RIGHTS  
The RSC reserves all rights not specifically granted in the combination of (i) the 
license details provided by your and accepted in the course of this licensing 
transaction; (ii) these terms and conditions; and (iii) CCC’s Billing and Payment 
terms and conditions. 
REVOCATION 
The RSC reserves the right to revoke this license for any reason, including, but 
not limited to, advertising and promotional uses of RSC content, third party 
usage, and incorrect source figure attribution. 
THIRD-PARTY MATERIAL DISCLAIMER 
If part of the material to be used (for example, a figure) has appeared in the RSC 
publication with credit to another source, permission must also be sought from 
that source. If the other source is another RSC publication these details should 
be included in your RightsLink request. If the other source is a third party, 
permission must be obtained from the third party. The RSC disclaims any 
responsibility for the reproduction you make of items owned by a third party. 
PAYMENT OF FEE 
If the permission fee for the requested material is waived in this instance, please 
be advised that any future requests for the reproduction of RSC materials may 
attract a fee. 
ACKNOWLEDGEMENT 
The reproduction of the licensed material must be accompanied by the following 
acknowledgement: 
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with 
permission of The Royal Society of Chemistry. 
If the licensed material is being reproduced from New Journal of Chemistry 
(NJC), Photochemical & Photobiological Sciences (PPS) or Physical Chemistry 
Chemical Physics (PCCP) you must include one of the following 
acknowledgements: 
For figures originally published in NJC: 
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with 
permission of The Royal Society of Chemistry (RSC) on behalf of the European 
Society for Photobiology, the European Photochemistry Association and the 
RSC. 
For figures originally published in PPS: 
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with 
permission of The Royal Society of Chemistry (RSC) on behalf of the Centre 
National de la Recherche Scientifique (CNRS) and the RSC. 
For figures originally published in PCCP: 
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with 





With any material which is being reproduced in electronic form, you must include 
a hypertext link to the original RSC article on the RSC’s website. The 
recommended form for the hyperlink is http://dx.doi.org/10.1039/DOI suffix, for 
example in the link http://dx.doi.org/10.1039/b110420a the DOI suffix is 
‘b110420a’. To find the relevant DOI suffix for the RSC article in question, go to 
the Journals section of the website and locate the article in the list of papers for 
the volume and issue of your specific journal. You will find the DOI suffix quoted 
there. 
LICENSE CONTINGENT ON PAYMENT 
While you may exercise the rights licensed immediately upon issuance of the 
license at the end of the licensing process for the transaction, provided that you 
have disclosed complete and accurate details of your proposed use, no license is 
finally effective unless and until full payment is received from you (by CCC) as 
provided in CCC's Billing and Payment terms and conditions. If full payment is 
not received on a timely basis, then any license preliminarily granted shall be 
deemed automatically revoked and shall be void as if never granted. Further, in 
the event that you breach any of these terms and conditions or any of CCC's 
Billing and Payment terms and conditions, the license is automatically revoked 
and shall be void as if never granted. Use of materials as described in a revoked 
license, as well as any use of the materials beyond the scope of an unrevoked 
license, may constitute copyright infringement and the RSC reserves the right to 
take any and all action to protect its copyright in the materials. 
WARRANTIES 
The RSC makes no representations or warranties with respect to the licensed 
material. 
INDEMNITY 
You hereby indemnify and agree to hold harmless the RSC and the CCC, and 
their respective officers, directors, trustees, employees and agents, from and 
against any and all claims arising out of your use of the licensed material other 
than as specifically authorized pursuant to this licence. 
NO TRANSFER OF LICENSE 
This license is personal to you or your publisher and may not be sublicensed, 
assigned, or transferred by you to any other person without the RSC's written 
permission. 
NO AMENDMENT EXCEPT IN WRITING  
This license may not be amended except in a writing signed by both parties (or, 
in the case of “Other Conditions, v1.2”, by CCC on the RSC's behalf). 
OBJECTION TO CONTRARY TERMS  
You hereby acknowledge and agree that these terms and conditions, together 
with CCC's Billing and Payment terms and conditions (which are incorporated 
herein), comprise the entire agreement between you and the RSC (and CCC) 
concerning this licensing transaction, to the exclusion of all other terms and 
conditions, written or verbal, express or implied (including any terms contained in 
any purchase order, acknowledgment, check endorsement or other writing 




established by these terms and conditions and those established by CCC's 
Billing and Payment terms and conditions, these terms and conditions shall 
control. 
JURISDICTION  
This license transaction shall be governed by and construed in accordance with 
the laws of the District of Columbia. You hereby agree to submit to the 
jurisdiction of the courts located in the District of Columbia for purposes of 
resolving any disputes that may arise in connection with this licensing 
transaction. 
LIMITED LICENSE 
The following terms and conditions apply to specific license types: 
Translation 
This permission is granted for non-exclusive world English rights only unless your 
license was granted for translation rights. If you licensed translation rights you 
may only translate this content into the languages you requested. A professional 
translator must perform all translations and reproduce the content word for word 
preserving the integrity of the article. 
Intranet 
If the licensed material is being posted on an Intranet, the Intranet is to be 
password-protected and made available only to bona fide students or employees 
only. All content posted to the Intranet must maintain the copyright information 
line on the bottom of each image. You must also fully reference the material and 
include a hypertext link as specified above. 
Copies of Whole Articles 
All copies of whole articles must maintain, if available, the copyright information 
line on the bottom of each page. 
Other Conditions  
v1.2 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this 
printable license for your reference. No payment is required. 
If you would like to pay for this license now, please remit this license along with 
yourpayment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise 
you will be invoiced within 48 hours of the license date. Payment should be in the 
form of a check or money order referencing your account number and this 
invoice number {Invoice Number}. 
Once you receive your invoice for this order, you may pay your invoice by credit 
card. 
Please follow instructions provided at that time. 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 




For suggestions or comments regarding this order, contact Rightslink Customer 
Support: customercare@copyright.com or +1-855-239-3415 (toll free in the US) 
or +1-978-646-2777. 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the 




JOHN WILEY AND SONS LICENSE 
TERMS AND CONDITIONS 
 
Apr 03, 2016 
 
This Agreement between Stacey N Anderson ("You") and John Wiley and Sons 
("John Wiley and Sons") consists of your license details and the terms and 




Feb 27, 2016 
Licensed Content Publisher 
John Wiley and Sons 
Licensed Content Publication 
British Journal of Pharmacology 
Licensed Content Title 
Novel lead structures and activation mechanisms for CO-releasing molecules 
(CORMs) 
Licensed Content Author 
U Schatzschneider 
Licensed Content Date 
Jul 2, 2014 
Pages 
13 





Print and electronic 
Portion 
Figure/table 
Number of figures/tables 
1 
Original Wiley figure/table number(s) 
Figure 3 
Will you be translating? 
No 
Title of your thesis / dissertation 
SYNTHESIS, CHARACTERIZATION, AND EVALUATION OF FLAVONOL 
COMPOUNDS AS PHOTOINDUCED CARBON MONOXIDE RELEASING 
MOLECULES 





Expected size (number of pages) 
400 
Requestor Location 
Stacey N Anderson 
780 E. 275 N. Apt. #3 
None 
None 
LOGAN, UT 84321 
United States 




Stacey N Anderson 
780 E. 275 N. Apt. #3 
None 
None 
LOGAN, UT 84321 
United States 
Attn: Stacey N Anderson 
Total 
0.00 USD 
Terms and Conditions 
TERMS AND CONDITIONS 
This copyrighted material is owned by or exclusively licensed to John Wiley & 
Sons, Inc. or one of its group companies (each a"Wiley Company") or handled on 
behalf of a society with which a Wiley Company has exclusive publishing rights in 
relation to a particular work (collectively "WILEY"). By clicking "accept" in 
connection with completing this licensing transaction, you agree that the following 
terms and conditions apply to this transaction (along with the billing and payment 
terms and conditions established by the Copyright Clearance Center Inc., 
("CCC's Billing and Payment terms and conditions"), at the time that you opened 
your RightsLink account (these are available at any time at 
http://myaccount.copyright.com). 
 
Terms and Conditions 
The materials you have requested permission to reproduce or reuse (the "Wiley 
Materials") are protected by copyright.  
 
You are hereby granted a personal, non-exclusive, non-sub licensable (on a 
stand-alone basis), non-transferable, worldwide, limited license to reproduce the 
Wiley Materials for the purpose specified in the licensing process. This license, 
and any CONTENT (PDF or image file) purchased as part of your order, is for a 
one-time use only and limited to any maximum distribution number specified in 




must be completed within two years of the date of the grant of this license 
(although copies prepared before the end date may be distributed thereafter). 
The Wiley Materials shall not be used in any other manner or for any other 
purpose, beyond what is granted in the license. Permission is granted subject to 
an appropriate acknowledgement given to the author, title of the 
material/book/journal and the publisher. You shall also duplicate the copyright 
notice that appears in the Wiley publication in your use of the Wiley Material. 
Permission is also granted on the understanding that nowhere in the text is a 
previously published source acknowledged for all or part of this Wiley Material. 
Any third party content is expressly excluded from this permission. 
 
With respect to the Wiley Materials, all rights are reserved. Except as expressly 
granted by the terms of the license, no part of the Wiley Materials may be copied, 
modified, adapted (except for minor reformatting required by the new 
Publication), translated, reproduced, transferred or distributed, in any form or by 
any means, and no derivative works may be made based on the Wiley Materials 
without the prior permission of the respective copyright owner.For STM Signatory 
Publishers clearing permission under the terms of the STM Permissions 
Guidelines only, the terms of the license are extended to include subsequent 
editions and for editions in other languages, provided such editions are for the 
work as a whole in situ and does not involve the separate exploitation of the 
permitted figures or extracts, You may not alter, remove or suppress in any 
manner any copyright, trademark or other notices displayed by the Wiley 
Materials. You may not license, rent, sell, loan, lease, pledge, offer as security, 
transfer or assign the Wiley Materials on a stand-alone basis, or any of the rights 
granted to you hereunder to any other person. 
 
The Wiley Materials and all of the intellectual property rights therein shall at all 
times remain the exclusive property of John Wiley & Sons Inc, the Wiley 
Companies, or their respective licensors, and your interest therein is only that of 
having possession of and the right to reproduce the Wiley Materials pursuant to 
Section 2 herein during the continuance of this Agreement. You agree that you 
own no right, title or interest in or to the Wiley Materials or any of the intellectual 
property rights therein. You shall have no rights hereunder other than the license 
as provided for above in Section 2. No right, license or interest to any trademark, 
trade name, service mark or other branding ("Marks") of WILEY or its licensors is 
granted hereunder, and you agree that you shall not assert any such right, 
license or interest with respect thereto 
 
NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR 
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY, 
EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS 
OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE 
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY 




FOR A PARTICULAR PURPOSE, USABILITY, INTEGRATION OR NON-
INFRINGEMENT AND ALL SUCH WARRANTIES ARE HEREBY EXCLUDED 
BY WILEY AND ITS LICENSORS AND WAIVED BY YOU.  
 
WILEY shall have the right to terminate this Agreement immediately upon breach 
of this Agreement by you. 
 
You shall indemnify, defend and hold harmless WILEY, its Licensors and their 
respective directors, officers, agents and employees, from and against any actual 
or threatened claims, demands, causes of action or proceedings arising from any 
breach of this Agreement by you. 
 
IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR 
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY 
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR 
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN 
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR 
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION, 
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT, 
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT 
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE, 
BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND 
WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY 
OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING 
ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY 
PROVIDED HEREIN.  
 
Should any provision of this Agreement be held by a court of competent 
jurisdiction to be illegal, invalid, or unenforceable, that provision shall be deemed 
amended to achieve as nearly as possible the same economic effect as the 
original provision, and the legality, validity and enforceability of the remaining 
provisions of this Agreement shall not be affected or impaired thereby.  
 
The failure of either party to enforce any term or condition of this Agreement shall 
not constitute a waiver of either party's right to enforce each and every term and 
condition of this Agreement. No breach under this agreement shall be deemed 
waived or excused by either party unless such waiver or consent is in writing 
signed by the party granting such waiver or consent. The waiver by or consent of 
a party to a breach of any provision of this Agreement shall not operate or be 
construed as a waiver of or consent to any other or subsequent breach by such 
other party.  
 
This Agreement may not be assigned (including by operation of law or otherwise) 





Any fee required for this permission shall be non-refundable after thirty (30) days 
from receipt by the CCC. 
 
These terms and conditions together with CCC's Billing and Payment terms and 
conditions (which are incorporated herein) form the entire agreement between 
you and WILEY concerning this licensing transaction and (in the absence of 
fraud) supersedes all prior agreements and representations of the parties, oral or 
written. This Agreement may not be amended except in writing signed by both 
parties. This Agreement shall be binding upon and inure to the benefit of the 
parties' successors, legal representatives, and authorized assigns.  
 
In the event of any conflict between your obligations established by these terms 
and conditions and those established by CCC's Billing and Payment terms and 
conditions, these terms and conditions shall prevail. 
 
WILEY expressly reserves all rights not specifically granted in the combination of 
(i) the license details provided by you and accepted in the course of this licensing 
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment 
terms and conditions. 
 
This Agreement will be void if the Type of Use, Format, Circulation, or Requestor 
Type was misrepresented during the licensing process. 
 
This Agreement shall be governed by and construed in accordance with the laws 
of the State of New York, USA, without regards to such state's conflict of law 
rules. Any legal action, suit or proceeding arising out of or relating to these Terms 
and Conditions or the breach thereof shall be instituted in a court of competent 
jurisdiction in New York County in the State of New York in the United States of 
America and each party hereby consents and submits to the personal jurisdiction 
of such court, waives any objection to venue in such court and consents to 
service of process by registered or certified mail, return receipt requested, at the 
last known address of such party. 
 
WILEY OPEN ACCESS TERMS AND CONDITIONS 
Wiley Publishes Open Access Articles in fully Open Access Journals and in 
Subscription journals offering Online Open. Although most of the fully Open 
Access journals publish open access articles under the terms of the Creative 
Commons Attribution (CC BY) License only, the subscription journals and a few 
of the Open Access Journals offer a choice of Creative Commons Licenses. The 
license type is clearly identified on the article. 
The Creative Commons Attribution License 
The Creative Commons Attribution License (CC-BY) allows users to copy, 
distribute and transmit an article, adapt the article and make commercial use of 
the article. The CC-BY license permits commercial and non- 




The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits 
use, distribution and reproduction in any medium, provided the original work is 
properly cited and is not used for commercial purposes.(see below) 
 
Creative Commons Attribution-Non-Commercial-NoDerivs License 
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-
NC-ND) permits use, distribution and reproduction in any medium, provided the 
original work is properly cited, is not used for commercial purposes and no 
modifications or adaptations are made. (see below) 
Use by commercial "for-profit" organizations 
Use of Wiley Open Access articles for commercial, promotional, or marketing 
purposes requires further explicit permission from Wiley and will be subject to a 
fee. 








v1.10 Last updated September 2015 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the 






NATURE PUBLISHING GROUP LICENSE 
TERMS AND CONDITIONS 
 
Apr 03, 2016 
This is an Agreement between Stacey N Anderson ("You") and Nature Publishing 
Group ("Nature Publishing Group"). It consists of your order details, the terms 
and conditions provided by Nature Publishing Group, and the payment terms and 
conditions. 
All payments must be made in full to CCC. For payment instructions, please see 




Feb 27, 2016 
Licensed Content Publisher 
Nature Publishing Group 
Licensed Content Publication 
Nature Reviews Drug Discovery 
Licensed Content Title 
The therapeutic potential of carbon monoxide 
Licensed Content Author 
Roberto Motterlini and Leo E. Otterbein 
Licensed Content Date 





Type of Use 




print and electronic 
Portion 
figures/tables/illustrations 











Your reference number 
None 
Title of your thesis / dissertation 
SYNTHESIS, CHARACTERIZATION, AND EVALUATION OF FLAVONOL 
COMPOUNDS AS PHOTOINDUCED CARBON MONOXIDE RELEASING 
MOLECULES 
Expected completion date 
Apr 2016 




Terms and Conditions 
Terms and Conditions for Permissions 
Nature Publishing Group hereby grants you a non-exclusive license to reproduce 
this material for this purpose, and for no other use,subject to the conditions 
below: 
NPG warrants that it has, to the best of its knowledge, the rights to license reuse 
of this material. However, you should ensure that the material you are requesting 
is original to Nature Publishing Group and does not carry the copyright of another 
entity (as credited in the published version). If the credit line on any part of the 
material you have requested indicates that it was reprinted or adapted by NPG 
with permission from another source, then you should also seek permission from 
that source to reuse the material. 
  
Permission granted free of charge for material in print is also usually granted for 
any electronic version of that work, provided that the material is incidental to the 
work as a whole and that the electronic version is essentially equivalent to, or 
substitutes for, the print version.Where print permission has been granted for a 
fee, separate permission must be obtained for any additional, electronic re-use 
(unless, as in the case of a full paper, this has already been accounted for during 
your initial request in the calculation of a print run).NB: In all cases, web-based 
use of full-text articles must be authorized separately through the 'Use on a Web 
Site' option when requesting permission. 
  
Permission granted for a first edition does not apply to second and subsequent 
editions and for editions in other languages (except for signatories to the STM 
Permissions Guidelines, or where the first edition permission was granted for 
free). 
  
Nature Publishing Group's permission must be acknowledged next to the figure, 
table or abstract in print. In electronic form, this acknowledgement must be 
visible at the same time as the figure/table/abstract, and must be hyperlinked to 






The credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME], 
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL 
ACRONYM].XXXXX) 
 
Note: For republication from the British Journal of Cancer, the following credit 
lines apply. 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication)For AOP papers, the credit line should read: 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME], advance online publication, day month year 
(doi: 10.1038/sj.[JOURNAL ACRONYM].XXXXX)  
 
  
Adaptations of single figures do not require NPG approval. However, the 
adaptation should be credited as follows: 
 
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication) 
 
Note: For adaptation from the British Journal of Cancer, the following credit line 
applies. 
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer 
Research UK: [JOURNAL NAME] (reference citation), copyright (year of 
publication) 
  
Translations of 401 words up to a whole article require NPG approval. Please 
visit http://www.macmillanmedicalcommunications.com for more 
information.Translations of up to a 400 words do not require NPG approval. The 
translation should be credited as follows: 
 
Translated by permission from Macmillan Publishers Ltd: [JOURNAL NAME] 
(reference citation), copyright (year of publication). 
 
Note: For translation from the British Journal of Cancer, the following credit line 
applies. 
Translated by permission from Macmillan Publishers Ltd on behalf of Cancer 





We are certain that all parties will benefit from this agreement and wish you the 
best in the use of this material. Thank you. 
Special Terms: 
v1.1 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the 






ROYAL SOCIETY OF CHEMISTRY LICENSE 
TERMS AND CONDITIONS 
 
Apr 03, 2016 
 
This Agreement between Stacey N Anderson ("You") and Royal Society of 
Chemistry ("Royal Society of Chemistry") consists of your license details and the 





Feb 27, 2016 
Licensed Content Publisher 
Royal Society of Chemistry 
Licensed Content Publication 
Natural Product Reports 
Licensed Content Title 
Structure and catalytic mechanism of heme oxygenase 
Licensed Content Author 
Masaki Unno,Toshitaka Matsui,Masao Ikeda-Saito 
Licensed Content Date 
Mar 8, 2007 
Licensed Content Volume Number 
24 
Licensed Content Issue Number 
3 






Number of figures/tables/images 
1 
Format 
print and electronic 
Distribution quantity 
100 
Will you be translating? 
no 





Title of the thesis/dissertation 
SYNTHESIS, CHARACTERIZATION, AND EVALUATION OF FLAVONOL 
COMPOUNDS AS PHOTOINDUCED CARBON MONOXIDE RELEASING 
MOLECULES 





Stacey N Anderson 
780 E. 275 N. Apt. #3 
None 
None 
LOGAN, UT 84321 
United States 




Stacey N Anderson 
780 E. 275 N. Apt. #3 
None 
None 
LOGAN, UT 84321 
United States 
Attn: Stacey N Anderson 
Total 
0.00 USD 
Terms and Conditions 
This License Agreement is between {Requestor Name} (“You”) and The Royal 
Society of Chemistry (“RSC”) provided by the Copyright Clearance Center 
(“CCC”). The license consists of your order details, the terms and conditions 
provided by the Royal Society of Chemistry, and the payment terms and 
conditions. 
RSC / TERMS AND CONDITIONS 
INTRODUCTION 
The publisher for this copyrighted material is The Royal Society of Chemistry. By 
clicking “accept” in connection with completing this licensing transaction, you 
agree that the following terms and conditions apply to this transaction (along with 
the Billing and Payment terms and conditions established by CCC, at the time 
that you opened your RightsLink account and that are available at any time at . 
LICENSE GRANTED 
The RSC hereby grants you a non-exclusive license to use the aforementioned 




herein. Reproduction of the material is confined to the purpose and/or media for 
which permission is hereby given. 
RESERVATION OF RIGHTS  
The RSC reserves all rights not specifically granted in the combination of (i) the 
license details provided by your and accepted in the course of this licensing 
transaction; (ii) these terms and conditions; and (iii) CCC’s Billing and Payment 
terms and conditions. 
REVOCATION 
The RSC reserves the right to revoke this license for any reason, including, but 
not limited to, advertising and promotional uses of RSC content, third party 
usage, and incorrect source figure attribution. 
THIRD-PARTY MATERIAL DISCLAIMER 
If part of the material to be used (for example, a figure) has appeared in the RSC 
publication with credit to another source, permission must also be sought from 
that source. If the other source is another RSC publication these details should 
be included in your RightsLink request. If the other source is a third party, 
permission must be obtained from the third party. The RSC disclaims any 
responsibility for the reproduction you make of items owned by a third party. 
PAYMENT OF FEE 
If the permission fee for the requested material is waived in this instance, please 
be advised that any future requests for the reproduction of RSC materials may 
attract a fee. 
ACKNOWLEDGEMENT 
The reproduction of the licensed material must be accompanied by the following 
acknowledgement: 
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with 
permission of The Royal Society of Chemistry. 
If the licensed material is being reproduced from New Journal of Chemistry 
(NJC), Photochemical & Photobiological Sciences (PPS) or Physical Chemistry 
Chemical Physics (PCCP) you must include one of the following 
acknowledgements: 
For figures originally published in NJC: 
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with 
permission of The Royal Society of Chemistry (RSC) on behalf of the European 
Society for Photobiology, the European Photochemistry Association and the 
RSC. 
For figures originally published in PPS: 
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with 
permission of The Royal Society of Chemistry (RSC) on behalf of the Centre 
National de la Recherche Scientifique (CNRS) and the RSC. 
For figures originally published in PCCP: 
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with 





With any material which is being reproduced in electronic form, you must include 
a hypertext link to the original RSC article on the RSC’s website. The 
recommended form for the hyperlink is http://dx.doi.org/10.1039/DOI suffix, for 
example in the link http://dx.doi.org/10.1039/b110420a the DOI suffix is 
‘b110420a’. To find the relevant DOI suffix for the RSC article in question, go to 
the Journals section of the website and locate the article in the list of papers for 
the volume and issue of your specific journal. You will find the DOI suffix quoted 
there. 
LICENSE CONTINGENT ON PAYMENT 
While you may exercise the rights licensed immediately upon issuance of the 
license at the end of the licensing process for the transaction, provided that you 
have disclosed complete and accurate details of your proposed use, no license is 
finally effective unless and until full payment is received from you (by CCC) as 
provided in CCC's Billing and Payment terms and conditions. If full payment is 
not received on a timely basis, then any license preliminarily granted shall be 
deemed automatically revoked and shall be void as if never granted. Further, in 
the event that you breach any of these terms and conditions or any of CCC's 
Billing and Payment terms and conditions, the license is automatically revoked 
and shall be void as if never granted. Use of materials as described in a revoked 
license, as well as any use of the materials beyond the scope of an unrevoked 
license, may constitute copyright infringement and the RSC reserves the right to 
take any and all action to protect its copyright in the materials. 
WARRANTIES 
The RSC makes no representations or warranties with respect to the licensed 
material. 
INDEMNITY 
You hereby indemnify and agree to hold harmless the RSC and the CCC, and 
their respective officers, directors, trustees, employees and agents, from and 
against any and all claims arising out of your use of the licensed material other 
than as specifically authorized pursuant to this licence. 
NO TRANSFER OF LICENSE 
This license is personal to you or your publisher and may not be sublicensed, 
assigned, or transferred by you to any other person without the RSC's written 
permission. 
NO AMENDMENT EXCEPT IN WRITING  
This license may not be amended except in a writing signed by both parties (or, 
in the case of “Other Conditions, v1.2”, by CCC on the RSC's behalf). 
OBJECTION TO CONTRARY TERMS  
You hereby acknowledge and agree that these terms and conditions, together 
with CCC's Billing and Payment terms and conditions (which are incorporated 
herein), comprise the entire agreement between you and the RSC (and CCC) 
concerning this licensing transaction, to the exclusion of all other terms and 
conditions, written or verbal, express or implied (including any terms contained in 
any purchase order, acknowledgment, check endorsement or other writing 




established by these terms and conditions and those established by CCC's 
Billing and Payment terms and conditions, these terms and conditions shall 
control. 
JURISDICTION  
This license transaction shall be governed by and construed in accordance with 
the laws of the District of Columbia. You hereby agree to submit to the 
jurisdiction of the courts located in the District of Columbia for purposes of 
resolving any disputes that may arise in connection with this licensing 
transaction. 
LIMITED LICENSE 
The following terms and conditions apply to specific license types: 
Translation 
This permission is granted for non-exclusive world English rights only unless your 
license was granted for translation rights. If you licensed translation rights you 
may only translate this content into the languages you requested. A professional 
translator must perform all translations and reproduce the content word for word 
preserving the integrity of the article. 
Intranet 
If the licensed material is being posted on an Intranet, the Intranet is to be 
password-protected and made available only to bona fide students or employees 
only. All content posted to the Intranet must maintain the copyright information 
line on the bottom of each image. You must also fully reference the material and 
include a hypertext link as specified above. 
Copies of Whole Articles 
All copies of whole articles must maintain, if available, the copyright information 
line on the bottom of each page. 
Other Conditions  
v1.2 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this 
printable license for your reference. No payment is required. 
If you would like to pay for this license now, please remit this license along with 
yourpayment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise 
you will be invoiced within 48 hours of the license date. Payment should be in the 
form of a check or money order referencing your account number and this 
invoice number {Invoice Number}. 
Once you receive your invoice for this order, you may pay your invoice by credit 
card. 
Please follow instructions provided at that time. 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 




For suggestions or comments regarding this order, contact Rightslink Customer 
Support: customercare@copyright.com or +1-855-239-3415 (toll free in the US) 
or +1-978-646-2777. 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the 




ROYAL SOCIETY OF CHEMISTRY LICENSE 
TERMS AND CONDITIONS 
 
Apr 03, 2016 
 
This Agreement between Stacey N Anderson ("You") and Royal Society of 
Chemistry ("Royal Society of Chemistry") consists of your license details and the 





Feb 25, 2016 
Licensed Content Publisher 
Royal Society of Chemistry 
Licensed Content Publication 
Dalton Transactions 
Licensed Content Title 
Metal carbonyls as pharmaceuticals? [Ru(CO)3Cl(glycinate)], a CO-releasing 
molecule with an extensive aqueous solution chemistry 
Licensed Content Author 
Tony R. Johnson,Brian E. Mann,Ian P. Teasdale,Harry Adams,Roberta 
Foresti,Colin J. Green,Roberto Motterlini 
Licensed Content Date 
Mar 8, 2007 
Licensed Content Issue Number 
15 






Number of figures/tables/images 
1 
Format 
print and electronic 
Distribution quantity 
7 
Will you be translating? 
no 
Order reference number 
None 




SYNTHESIS, CHARACTERIZATION, AND EVALUATION OF FLAVONOL 
COMPOUNDS AS PHOTOINDUCED CARBON MONOXIDE RELEASING 
MOLECULES 





Stacey N Anderson 
780 E. 275 N. Apt. #3 
None 
None 
LOGAN, UT 84321 
United States 




Stacey N Anderson 
780 E. 275 N. Apt. #3 
None 
None 
LOGAN, UT 84321 
United States 
Attn: Stacey N Anderson 
Total 
0.00 USD 
Terms and Conditions 
This License Agreement is between {Requestor Name} (“You”) and The Royal 
Society of Chemistry (“RSC”) provided by the Copyright Clearance Center 
(“CCC”). The license consists of your order details, the terms and conditions 
provided by the Royal Society of Chemistry, and the payment terms and 
conditions. 
RSC / TERMS AND CONDITIONS 
INTRODUCTION 
The publisher for this copyrighted material is The Royal Society of Chemistry. By 
clicking “accept” in connection with completing this licensing transaction, you 
agree that the following terms and conditions apply to this transaction (along with 
the Billing and Payment terms and conditions established by CCC, at the time 
that you opened your RightsLink account and that are available at any time at . 
LICENSE GRANTED 
The RSC hereby grants you a non-exclusive license to use the aforementioned 
material anywhere in the world subject to the terms and conditions indicated 
herein. Reproduction of the material is confined to the purpose and/or media for 




RESERVATION OF RIGHTS  
The RSC reserves all rights not specifically granted in the combination of (i) the 
license details provided by your and accepted in the course of this licensing 
transaction; (ii) these terms and conditions; and (iii) CCC’s Billing and Payment 
terms and conditions. 
REVOCATION 
The RSC reserves the right to revoke this license for any reason, including, but 
not limited to, advertising and promotional uses of RSC content, third party 
usage, and incorrect source figure attribution. 
THIRD-PARTY MATERIAL DISCLAIMER 
If part of the material to be used (for example, a figure) has appeared in the RSC 
publication with credit to another source, permission must also be sought from 
that source. If the other source is another RSC publication these details should 
be included in your RightsLink request. If the other source is a third party, 
permission must be obtained from the third party. The RSC disclaims any 
responsibility for the reproduction you make of items owned by a third party. 
PAYMENT OF FEE 
If the permission fee for the requested material is waived in this instance, please 
be advised that any future requests for the reproduction of RSC materials may 
attract a fee. 
ACKNOWLEDGEMENT 
The reproduction of the licensed material must be accompanied by the following 
acknowledgement: 
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with 
permission of The Royal Society of Chemistry. 
If the licensed material is being reproduced from New Journal of Chemistry 
(NJC), Photochemical & Photobiological Sciences (PPS) or Physical Chemistry 
Chemical Physics (PCCP) you must include one of the following 
acknowledgements: 
For figures originally published in NJC: 
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with 
permission of The Royal Society of Chemistry (RSC) on behalf of the European 
Society for Photobiology, the European Photochemistry Association and the 
RSC. 
For figures originally published in PPS: 
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with 
permission of The Royal Society of Chemistry (RSC) on behalf of the Centre 
National de la Recherche Scientifique (CNRS) and the RSC. 
For figures originally published in PCCP: 
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with 
permission of the PCCP Owner Societies. 
HYPERTEXT LINKS 
With any material which is being reproduced in electronic form, you must include 
a hypertext link to the original RSC article on the RSC’s website. The 




example in the link http://dx.doi.org/10.1039/b110420a the DOI suffix is 
‘b110420a’. To find the relevant DOI suffix for the RSC article in question, go to 
the Journals section of the website and locate the article in the list of papers for 
the volume and issue of your specific journal. You will find the DOI suffix quoted 
there. 
LICENSE CONTINGENT ON PAYMENT 
While you may exercise the rights licensed immediately upon issuance of the 
license at the end of the licensing process for the transaction, provided that you 
have disclosed complete and accurate details of your proposed use, no license is 
finally effective unless and until full payment is received from you (by CCC) as 
provided in CCC's Billing and Payment terms and conditions. If full payment is 
not received on a timely basis, then any license preliminarily granted shall be 
deemed automatically revoked and shall be void as if never granted. Further, in 
the event that you breach any of these terms and conditions or any of CCC's 
Billing and Payment terms and conditions, the license is automatically revoked 
and shall be void as if never granted. Use of materials as described in a revoked 
license, as well as any use of the materials beyond the scope of an unrevoked 
license, may constitute copyright infringement and the RSC reserves the right to 
take any and all action to protect its copyright in the materials. 
WARRANTIES 
The RSC makes no representations or warranties with respect to the licensed 
material. 
INDEMNITY 
You hereby indemnify and agree to hold harmless the RSC and the CCC, and 
their respective officers, directors, trustees, employees and agents, from and 
against any and all claims arising out of your use of the licensed material other 
than as specifically authorized pursuant to this licence. 
NO TRANSFER OF LICENSE 
This license is personal to you or your publisher and may not be sublicensed, 
assigned, or transferred by you to any other person without the RSC's written 
permission. 
NO AMENDMENT EXCEPT IN WRITING  
This license may not be amended except in a writing signed by both parties (or, 
in the case of “Other Conditions, v1.2”, by CCC on the RSC's behalf). 
OBJECTION TO CONTRARY TERMS  
You hereby acknowledge and agree that these terms and conditions, together 
with CCC's Billing and Payment terms and conditions (which are incorporated 
herein), comprise the entire agreement between you and the RSC (and CCC) 
concerning this licensing transaction, to the exclusion of all other terms and 
conditions, written or verbal, express or implied (including any terms contained in 
any purchase order, acknowledgment, check endorsement or other writing 
prepared by you). In the event of any conflict between your obligations 
established by these terms and conditions and those established by CCC's 






This license transaction shall be governed by and construed in accordance with 
the laws of the District of Columbia. You hereby agree to submit to the 
jurisdiction of the courts located in the District of Columbia for purposes of 
resolving any disputes that may arise in connection with this licensing 
transaction. 
LIMITED LICENSE 
The following terms and conditions apply to specific license types: 
Translation 
This permission is granted for non-exclusive world English rights only unless your 
license was granted for translation rights. If you licensed translation rights you 
may only translate this content into the languages you requested. A professional 
translator must perform all translations and reproduce the content word for word 
preserving the integrity of the article. 
Intranet 
If the licensed material is being posted on an Intranet, the Intranet is to be 
password-protected and made available only to bona fide students or employees 
only. All content posted to the Intranet must maintain the copyright information 
line on the bottom of each image. You must also fully reference the material and 
include a hypertext link as specified above. 
Copies of Whole Articles 
All copies of whole articles must maintain, if available, the copyright information 
line on the bottom of each page. 
Other Conditions  
v1.2 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this 
printable license for your reference. No payment is required. 
If you would like to pay for this license now, please remit this license along with 
yourpayment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise 
you will be invoiced within 48 hours of the license date. Payment should be in the 
form of a check or money order referencing your account number and this 
invoice number {Invoice Number}. 
Once you receive your invoice for this order, you may pay your invoice by credit 
card. 
Please follow instructions provided at that time. 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
Boston, MA 02284-3006 
For suggestions or comments regarding this order, contact Rightslink Customer 
Support: customercare@copyright.com or +1-855-239-3415 (toll free in the US) 
or +1-978-646-2777. 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the 





ROYAL SOCIETY OF CHEMISTRY LICENSE 
TERMS AND CONDITIONS 
 
Apr 03, 2016 
 
This Agreement between Stacey N Anderson ("You") and Royal Society of 
Chemistry ("Royal Society of Chemistry") consists of your license details and the 





Feb 25, 2016 
Licensed Content Publisher 
Royal Society of Chemistry 
Licensed Content Publication 
Dalton Transactions 
Licensed Content Title 
Metal carbonyls as pharmaceuticals? [Ru(CO)3Cl(glycinate)], a CO-releasing 
molecule with an extensive aqueous solution chemistry 
Licensed Content Author 
Tony R. Johnson,Brian E. Mann,Ian P. Teasdale,Harry Adams,Roberta 
Foresti,Colin J. Green,Roberto Motterlini 
Licensed Content Date 
Mar 8, 2007 
Licensed Content Issue Number 
15 






Number of figures/tables/images 
1 
Format 
print and electronic 
Distribution quantity 
7 
Will you be translating? 
no 
Order reference number 
None 




SYNTHESIS, CHARACTERIZATION, AND EVALUATION OF FLAVONOL 
COMPOUNDS AS PHOTOINDUCED CARBON MONOXIDE RELEASING 
MOLECULES 





Stacey N Anderson 
780 E. 275 N. Apt. #3 
None 
None 
LOGAN, UT 84321 
United States 




Stacey N Anderson 
780 E. 275 N. Apt. #3 
None 
None 
LOGAN, UT 84321 
United States 
Attn: Stacey N Anderson 
Total 
0.00 USD 
Terms and Conditions 
This License Agreement is between {Requestor Name} (“You”) and The Royal 
Society of Chemistry (“RSC”) provided by the Copyright Clearance Center 
(“CCC”). The license consists of your order details, the terms and conditions 
provided by the Royal Society of Chemistry, and the payment terms and 
conditions. 
RSC / TERMS AND CONDITIONS 
INTRODUCTION 
The publisher for this copyrighted material is The Royal Society of Chemistry. By 
clicking “accept” in connection with completing this licensing transaction, you 
agree that the following terms and conditions apply to this transaction (along with 
the Billing and Payment terms and conditions established by CCC, at the time 
that you opened your RightsLink account and that are available at any time at . 
LICENSE GRANTED 
The RSC hereby grants you a non-exclusive license to use the aforementioned 
material anywhere in the world subject to the terms and conditions indicated 
herein. Reproduction of the material is confined to the purpose and/or media for 




RESERVATION OF RIGHTS  
The RSC reserves all rights not specifically granted in the combination of (i) the 
license details provided by your and accepted in the course of this licensing 
transaction; (ii) these terms and conditions; and (iii) CCC’s Billing and Payment 
terms and conditions. 
REVOCATION 
The RSC reserves the right to revoke this license for any reason, including, but 
not limited to, advertising and promotional uses of RSC content, third party 
usage, and incorrect source figure attribution. 
THIRD-PARTY MATERIAL DISCLAIMER 
If part of the material to be used (for example, a figure) has appeared in the RSC 
publication with credit to another source, permission must also be sought from 
that source. If the other source is another RSC publication these details should 
be included in your RightsLink request. If the other source is a third party, 
permission must be obtained from the third party. The RSC disclaims any 
responsibility for the reproduction you make of items owned by a third party. 
PAYMENT OF FEE 
If the permission fee for the requested material is waived in this instance, please 
be advised that any future requests for the reproduction of RSC materials may 
attract a fee. 
ACKNOWLEDGEMENT 
The reproduction of the licensed material must be accompanied by the following 
acknowledgement: 
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with 
permission of The Royal Society of Chemistry. 
If the licensed material is being reproduced from New Journal of Chemistry 
(NJC), Photochemical & Photobiological Sciences (PPS) or Physical Chemistry 
Chemical Physics (PCCP) you must include one of the following 
acknowledgements: 
For figures originally published in NJC: 
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with 
permission of The Royal Society of Chemistry (RSC) on behalf of the European 
Society for Photobiology, the European Photochemistry Association and the 
RSC. 
For figures originally published in PPS: 
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with 
permission of The Royal Society of Chemistry (RSC) on behalf of the Centre 
National de la Recherche Scientifique (CNRS) and the RSC. 
For figures originally published in PCCP: 
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with 
permission of the PCCP Owner Societies. 
HYPERTEXT LINKS 
With any material which is being reproduced in electronic form, you must include 
a hypertext link to the original RSC article on the RSC’s website. The 




example in the link http://dx.doi.org/10.1039/b110420a the DOI suffix is 
‘b110420a’. To find the relevant DOI suffix for the RSC article in question, go to 
the Journals section of the website and locate the article in the list of papers for 
the volume and issue of your specific journal. You will find the DOI suffix quoted 
there. 
LICENSE CONTINGENT ON PAYMENT 
While you may exercise the rights licensed immediately upon issuance of the 
license at the end of the licensing process for the transaction, provided that you 
have disclosed complete and accurate details of your proposed use, no license is 
finally effective unless and until full payment is received from you (by CCC) as 
provided in CCC's Billing and Payment terms and conditions. If full payment is 
not received on a timely basis, then any license preliminarily granted shall be 
deemed automatically revoked and shall be void as if never granted. Further, in 
the event that you breach any of these terms and conditions or any of CCC's 
Billing and Payment terms and conditions, the license is automatically revoked 
and shall be void as if never granted. Use of materials as described in a revoked 
license, as well as any use of the materials beyond the scope of an unrevoked 
license, may constitute copyright infringement and the RSC reserves the right to 
take any and all action to protect its copyright in the materials. 
WARRANTIES 
The RSC makes no representations or warranties with respect to the licensed 
material. 
INDEMNITY 
You hereby indemnify and agree to hold harmless the RSC and the CCC, and 
their respective officers, directors, trustees, employees and agents, from and 
against any and all claims arising out of your use of the licensed material other 
than as specifically authorized pursuant to this licence. 
NO TRANSFER OF LICENSE 
This license is personal to you or your publisher and may not be sublicensed, 
assigned, or transferred by you to any other person without the RSC's written 
permission. 
NO AMENDMENT EXCEPT IN WRITING  
This license may not be amended except in a writing signed by both parties (or, 
in the case of “Other Conditions, v1.2”, by CCC on the RSC's behalf). 
OBJECTION TO CONTRARY TERMS  
You hereby acknowledge and agree that these terms and conditions, together 
with CCC's Billing and Payment terms and conditions (which are incorporated 
herein), comprise the entire agreement between you and the RSC (and CCC) 
concerning this licensing transaction, to the exclusion of all other terms and 
conditions, written or verbal, express or implied (including any terms contained in 
any purchase order, acknowledgment, check endorsement or other writing 
prepared by you). In the event of any conflict between your obligations 
established by these terms and conditions and those established by CCC's 






This license transaction shall be governed by and construed in accordance with 
the laws of the District of Columbia. You hereby agree to submit to the 
jurisdiction of the courts located in the District of Columbia for purposes of 
resolving any disputes that may arise in connection with this licensing 
transaction. 
LIMITED LICENSE 
The following terms and conditions apply to specific license types: 
Translation 
This permission is granted for non-exclusive world English rights only unless your 
license was granted for translation rights. If you licensed translation rights you 
may only translate this content into the languages you requested. A professional 
translator must perform all translations and reproduce the content word for word 
preserving the integrity of the article. 
Intranet 
If the licensed material is being posted on an Intranet, the Intranet is to be 
password-protected and made available only to bona fide students or employees 
only. All content posted to the Intranet must maintain the copyright information 
line on the bottom of each image. You must also fully reference the material and 
include a hypertext link as specified above. 
Copies of Whole Articles 
All copies of whole articles must maintain, if available, the copyright information 
line on the bottom of each page. 
Other Conditions  
v1.2 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this 
printable license for your reference. No payment is required. 
If you would like to pay for this license now, please remit this license along with 
yourpayment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise 
you will be invoiced within 48 hours of the license date. Payment should be in the 
form of a check or money order referencing your account number and this 
invoice number {Invoice Number}. 
Once you receive your invoice for this order, you may pay your invoice by credit 
card. 
Please follow instructions provided at that time. 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
Boston, MA 02284-3006 
For suggestions or comments regarding this order, contact Rightslink Customer 
Support: customercare@copyright.com or +1-855-239-3415 (toll free in the US) 
or +1-978-646-2777. 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the 













 Utah State University 
Department of Chemistry & Biochemistry; Logan, UT 
PhD program in Inorganic Chemistry 
Advisor: Lisa M. Berreau 
Dissertation Title: “CO Release on Demand: Light-Induced 
CO Release of Flavonols.” 
Columbia College 
BA Chemistry, minor concentration in Biology 
 Advisor: Alan James 
Permanent Address: 
780 E. 275 N. Apt. #3 
Logan, UT 84321 
Tel: (573)239-8711 
Campus Address: 
Utah State University 
Department of Chemistry & Biochemistry 
0300 Old Main Hill 








1. S. N. Anderson, M. T. Larson, and L. M. Berreau, “Solution or solid – it
doesn’t matter: visible light-induced CO release reactivity of zinc flavonolato
complexes,” Dalton Trans. 2016, 45, 14570-14580.
2. S. N. Anderson, J. M. Richards, H. J. Esquer, A. D. Benninghoff, A. M. Arif,
and L. M. Berreau, “A structurally-tunable organic motif for carbon monoxide-
releasing molecules (CORMs),” ChemistryOpen, 2015, 4, 590-594.
3. S. N. Anderson, M. Noble, K. Grubel, B. Marshall, A. M. Arif, and L. M.
Berreau, “Influence of supporting ligand microenvironment on the aqueous
stability and visible light-induced CO-release reactivity of zinc flavonolato
species,” J. Coord. Chem. 2014, 67, 4061-4075.
4. K. Grubel, A. M. Marts, S. M. Greer, D. L. Tierney, C. J. Allpress, S. N.
Anderson, B. J. Laughlin, R. C. Smith, A. M. Arif, and L. M. Berreau,
“Photoinitiated dioxygenase-type reactivity of open-shell 3d divalent metal
flavonolato complexes,” Eur. J. Inorg. Chem. 2012, 4750-4757.
5. K. Grubel, S. L. Saraf, S. N. Anderson, B. J. Laughlin, R. C. Smith, A. M. Arif,
and L. M. Berreau, “Synthesis, characterization, and photoinduced CO-




• L. M. Berreau and S. N. Anderson, “Carbon monoxide releasing molecules
and associated methods,” Patent US 9,840,488; Dec 12,2017
Presentations 
• S. N. Anderson, R. Zhang, J. M. Richards, M. Noble, A. M. Arif, and L. M.
Berreau, “A new family of flavonols: tunable photoinduced carbon
monoxide releasing agents,” Present at the 248th American Chemical
Society National Meeting and Symposium, San Francisco, CA, August 10-
14, 2014. (Oral presentation)
• S. N. Anderson and L. M. Berreau, “New family of photoCORMs:
photoinduced CO release in zinc 3-hydroxy-4-pyrone complexes,” 245th
American Chemical Society National Conference, New Orleans, LA, April
7-11, 2013. (Poster presentation)
• S. N. Anderson and L. M. Berreau, “New family of photoCORMs:
photoinduced CO release in zinc 3-hydroxy-4-pyrone complexes,” Utah
State University Graduate Research Symposium, Logan, UT, April 12,
2013.
Awards and Honors 
• Seely-Hinkley Scholar (2014-2015)
• Department of Chemistry and Biochemistry Teaching Award (2014)
308 
• Joseph Rueul Harris Scholarship (2014)
Professional Memberships and Other Activities 
• American Chemical Society (2010-present)
• USU Student Safety Committee, Founder and Chair
Teaching Experience 
Previous Work Experience 
August 2010 – 
May 2015 
1210 General Chemistry I Recitation 
1215 General Chemistry I Laboratory 
1220 General Chemistry II Recitation 
2325 Organic Chemistry II Laboratory 
3005 Quantitative Analysis Laboratory 
3520 Inorganic Chemistry Laboratory 
June 2005 – 
July 2010 
July 1999 – 
June 2005 
Inpatient Pharmacy Technician, Columbia Regional Medical 
Hospital, Columbia, MO. 
Manager: Steven Lee 
Inpatient Pharmacy Technician, University of Missouri 
Hospital, Columbia, MO. 
Manager: Steven Calloway 
